

An Independent Licensee of the Blue Cross and Blue Shield Association.

Investigational Services and Procedures Corporate Medical Policy

File Name: Investigational Services and Procedures

File Code: 10.01.VT204
Origination: 09/2016
Last Review: 10/17/2025
Next Review: 01/01/2026
Effective Date: 01/01/2026

Description

Attachment (I) outlines current services and/or procedure(s) considered to be investigational by Blue Cross Blue Shield of Vermont (Blue Cross VT).

Definition of Investigational

"Experimental or Investigational Services" means health care items or services that are either not generally accepted by informed health care providers in the United States as effective in treating a condition, illness, or diagnosis for which their use is proposed, or are not proven by medical or scientific evidence to be effective in treating a condition, illness, or diagnosis.

Technologies are assessed using the following criteria. Any technology that fails to meet ALL the following criteria is considered to be "Investigational":

- 1. The technology must have final approval from the appropriate governmental regulatory bodies.
 - This criterion applies to drugs, biological products, devices and any other product or procedure that must have final approval to market from the U.S. Food and Drug Administration (FDA) or any other federal governmental body with authority to regulate the use of the technology.
 - Any approval that is granted as an interim step in the U.S. Food and Drug Administration's or any other federal governmental body's regulatory process is not sufficient.
 - The indications for which the technology is approved need not be the same as those which the (Blue Cross VT) Medical Policy Committee is evaluating.

Page 1 of 101

Medical Policy Number: 10.01.VT204

Effective Date: 01/01/2026

- The scientific evidence must permit conclusions concerning the effect of the technology on health outcomes.
 - The evidence should consist of well-designed and well-conducted investigations published in peer- reviewed journals. The quality of the body of studies and the consistency of the results are considered in evaluating the evidence.
 - The evidence should demonstrate that the technology can measure or alter the
 physiological changes related to a disease, injury, illness, or condition. In
 addition, there should be evidence, or a convincing argument based on
 established medical facts that such measurement or alteration affects health
 outcomes.
- 3. The technology must improve the net health outcome.
 - The technology's beneficial effects on health outcomes should outweigh any harmful effects on health outcomes.
- 4. The technology must be as beneficial as any established alternatives.
 - The technology should improve the net health outcome as much as, or more than, established alternatives.
- 5. The improvement must be attainable outside the investigational settings.
 - When used under the usual conditions of medical practice, the technology should be reasonably expected to satisfy Criteria #3 and #4.

In reviewing the above criteria, the Blue Cross VT Medical Policy Committee will consider physician specialty society recommendations, the view of prudent medical practitioners practicing in relevant clinical areas and any other relevant factors.

Policy

The following is a list of current services and/or procedure(s) which are considered investigational.

Coding Information

Attachment I

Policy Implementation/Update information

		Policy new Format
ĺ	10/2020	Coding Updates effective 10/01/2020 Medical Policy: Added codes: 0097U,
		0107U, 82239, 82272, 82274, 82542, 82656, 82710, 82715, 82725, 83520,
		83630, 83986, 83993, 84311, 87045, 87046, 87075, 87102, 87177, 87209,
		87328, 87329, 87336, 89160, 89161, 89240 ARE CONSIDERED
		INVESTIGATIONAL WITH THE FOLLOWING DIAGNOSES CODES: A04.8, A04.9,

Page 2 of 101

Medical Policy Number: 10.01.VT204

Effective Date: 01/01/2026

	K58.0, K58.1, K58.2, K58.8, K58.9, K59.8, K63.9, K90.89.
	Coding Updates effective 10/01/2020 via Adaptive Maintenance Cycle:
	Added codes: 0016M, 0203U, 0204U, 0205U, 0206U, 0207U, 0208U,
	0209U, 0211U, 0216Ú, 0217Ú, 0218Ú, 0219Ú, 0220Ú, 0225Ú, K1006,
	K1007, K1010, K1011, K1012, Q4249, Q4250, Q4254, Q4255.
01/2021	Coding Updates effective 01/01/2021 Adaptive Maintenance Cycle:
01/2021	Changed effective date to 01/01/2021
	Removed Codes 38230, 83993, 90694
	Updated Codes 82172 & 84181 to Investigational for All diagnoses
	Updated Codes 64910, 64911, 64912, 64913 as Investigational with dx
	codes C61, N52.0-N52.9
	Added codes 0227U, 0228U, 0229U, 0620T, 0621T, 0622T, 0623T, 0624T,
	0625T, 0626T, 0627T, 0628T, 0629T, 0630T, 0631T, 0632T, 0633T, 0634T,
	0635T 0636T 0637T 0638T 0639T 22869 22870 30468 55880 57465
	0635T, 0636T, 0637T,0638T, 0639T, 22869,22870 30468, 55880, 57465, 81514, 92229, C1825, C9771, C9772, C9773, C9774, C9775
	Deleted codes 0400T, 0401T
	Removed codes 38206, 38230, 38241 codes require PA
04/2021	Coding Updates effective 04/01/2021 Adaptive Maintenance Cycle:
0-7, 2021	Added codes: C9776, C9777, J3490, K1016, K1017, K1018, K1019,
	K1020, S1091, 0242U, 0243U, 0244U, 0247U. Removed codes: K1010,
	K1011, K1012, 64451, 78803, 78830, 78831, 78832, 78835
05/2021	Coding Update effective 05/01/2021: Added codes 81518, 0045U,
03, 2021	0153U.
07/2021	Coding Updates effective 07/01/2021: 0248U, 0249U, 0250U, 0251U,
0772021	0252U, 0253U, 0640T, 0641T, 0642T, 0643T, 0645T, 0646T, 0647T,
	0648T, 0649T, 0652T, 0653T, 0654T, 0655T, 0656T, 0657T, 0658T,
	0659T, 0660T, 0661T, 0664T, 0665T, 0666T, 0667T, 0668T, 0669T,
	0670T, A9593, A9594, G0327, 58674, 90626, 90627, 90671, 90677,
	90758, C1761
08/2021	Coding Updates effective 08/01/2021: Added codes E1700, E1701,
	E1702
09/2021	Coding update effective 09/01/2021: Removed code 53854
10/2021	Coding update effective 10/01/2021: Added Codes 0255U, 0258U,
	0259U 0260U, 0261U, 0262U, 0263U, 0264U, 0266U, 0267U, 0279U,
	0280U, 0281U, 0282U, 0283U, 0284U, 0018M, Deleted code 0139U.
	Revised 0051U descriptor. Added HCPCS Codes: C1831, C9780,
	K1023, K1024, K1025, K1026, Q4251, Q4252, Q4253
11/2021	Coding update effective 11/01/2021 (To Align Corporate
	Bioengineered Skin Medical Policy Table): Added codes C9354,
	C9356, C9358, C9360, C9363, C9364, Q4103, Q4104, Q4110, Q4111,
	Q4112, Q4113, Q4115, Q4117, Q4118, Q4121, Q4123, Q4124, Q4125,
	Q4126, Q4127, Q4130, Q4134, Q4135, Q4136, Q4141, Q4142, Q4143,
	Q4146, Q4147, Q4149, Q4152, Q4158, Q4161, Q4164, Q4165, Q4166,
	Q4167, Q4179, Q4182, Q4193, Q4196, Q4200, Q4202, Q4203, Q4222.
	Removed codes: Q4185, Q4189, Q4192, Q4249, Q4250, Q4254,
	Q4255.
12/2021	Coding update effective 12/01/2021: Added code G9143
12/2021	Coding Update Effective 01/01/2022 (Adaptive Maintenance Cycle):
	Deleted the following codes: 0548T, 0549T, 0550T, 0551T, C9752,
	C9753, 95943, 0208U
	Codes Added: 33370, 42975, 43497, 53451, 53452, 53453, 53454,
	61736, 61737, 64628, 64629, 81560, 90759. Added codes PLA: 0285U,
	0288U, 0289U, 0290U, 0291U, 0292U, 0293U, 0294U, 0295U, 0296U,
	0297U, 0298U, 0299U, 0300U, 0303U, 0304U, 0305U. Added codes

Page **3** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

	CAT III: 0672T, 0673T, 0674T, 0675T, 0676T, 0677T, 0678T, 0679T,
	0680T, 0681T, 0682T, 0683T, 0684T, 0685T, 0686T, 0687T, 0688T,
	0689T, 0690T, 0691T, 0693T, 0694T, 0695T, 0696T, 0697T, 0698T,
	0700T, 0701T, 0702T, 0703T, 0704T, 0705T, 0706T, 0707T, 0708T,
	0709T, 0710T, 0711T, 0712T, 0713T. Added the following HCPCS
	Codes: A2001, A2002, A2004, A2005, A2006, A2007, A2008, A2009,
	A2010, C1832, C1833, G0465, Q4199. Removed codes: 0030U, 0032U,
	0033U, 0173U, 0175U, 90677.
04/2022	Coding Update Effective 04/01/2022 (Adaptive Maintenance Cycle):
04/2022	A2003 deleted code never became effective 01/01/2021. (0)097U
	deleted. Added codes: 0306U, 0307U, 0308U, 0309U, 0310U, 0311U,
	0312U, 0313U, 0314U, 0315U, 0316U, 0317U, 0318U, 0319U, 0320U,
	0321U, 0322U. A2013, A9291, C9781, K1028, K1029, K1030, K1031,
	K1032, K1033. Removed code J3490 per Ketamine Medical Policy
	effective 04/01/2022.
05/2022	Coding Update Effective 05/01/2022 (Investigational Medical Policy
	Reconciliation): Codes removed: A4641, A4642, A9500, A9502,
	A9520, A9541, A9568, A9572, A9582 may be eligible for benefit
	approved by AIM or BCBSVT. Codes removed: J9035, 15788, 15789,
	15792, 15793, 17000, 17003, 17004, 30520, 17106, 17107, 17108,
	82656, 83630, 90677 effective: 01/01/2022), 97032 may be eligible
	for services based on current standards of care. Codes removed:
	G0259, L8603*, L8605*, L8606*, L8684, S8080, 0026U, 0097U, 0107U,
	0278T, 15824, 15826, 30130, 30140, 31626, 34701, 34702, 34703,
	34704, 34705, 34706, 34707, 34708, 36012, 37241, 38242, 43201,
	43210, 43212, 43257, 51715, 64590, 64595, 64632, 64640, 64716,
	64722, 64771, 64772, 64910, 64911, 64912, 64913, 76940, 78195,
	78800, 78801, 78802, 78804, 82239, 82272, 82274, 82397, 82542,
	82652, 82710, 82715, 82725, 83520, 83698, 83986, 84311, 86141,
	86304, 87045, 87046, 87075, 87102, 87177, 87209, 87328, 87329,
	87336, 89160, 89240, 92229, 93895, 95812, 95813, 95816, 95819,
	95921, 95922, 95923, 95924, 96904 codes require prior approval.
	Removed codes: E0748, E0749, J3490, L8680, L8681, L8682, L8683,
	L8685, L8686, L8687, L8688, L8689, Q4168, Q4185, Q4189, Q4192,
	\$3852, 0029U, 0156U, 0173U, 0175U, 0278U, 0394T, 15780, 15781,
	15782, 15783, 20974, 20975, 61885, 61886, 64553, 64568, 64569,
	64570, 67900, 75571, 81226, 81291, 81313, 81400, 81401, 81403,
	81406, 81407, 81415, 81416, 81417, 81439, 81490, 81493, 81500,
	81503, 81504, 81535, 81536, 81538, 81540, 81595, 95980, 95981,
	95982 codes always required prior approval. Changed the following
	codes to be investigational for all diagnoses: A9584, E0740, E0761,
	E0769, G0166, G0295, G0329, G9147, S3722, 0003U, 0101T, 0102T,
	0207T,0278T, 0330T, 0332T, 0338T, 0339T, 0397T, 0421T, 0424T,
	0425T, 0426T, 0441T, 0563T, 28890, 33548, 43206, 43252, 43284,
	43285, 43647, 43648, 43881, 43882, 46707, 47371, 47381, 47383,
	62263, 62264, 64505, 77085, 77086, 82523, 83006, 83695, 84080,
	85384, 86352, 88375, 95957, 97610, 98922. Added new codes: C1825,
	C9359, C9362, E0746, G9143, S8130, S8131, 0651T, 64575
	investigational for all diagnoses. Removed codes: G0281, G0282,
	V5095, 90876, 97014 codes are considered non-covered. Removed
	code S2080 code considered not medically necessary. Removed codes
	31627 & 57465 not medically necessary per payment policy CPP_04.
	Added codes to as investigation but have been investigational per
	applicable medical policy: E0762, E0764, M0076, P9020, S8040,
	0232T, 0355T, 41512, 64585, 83937, 91111, 92548, 92145, 92572,
	92576, 93701, 95803, 96000, 96001, 96002, 96003, 96004, 97799.
	72310, 73101, 73003, 70000, 70001, 70002, 70003, 7000 4 , 7/177.

Page 4 of 101 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

	Codes deleted: A9599, C9750, 0355T, 0399T, 0406T, 0407T, 30660, 30661, 61632, 98922.
06/2022	Removed codes 0116U & 0117U Effective: 06/01/2022 Added code P2031 Effective: 06/01/2022, Added COVID-19 Monoclonal Antibodies & Administration codes: M0240, M0241, M0243, M0244, M0245, M0246, Q0240, Q0243, Q0244, Q0245 Effective:01/24/2022. Added COVID-19 Monoclonal Antibodies & Administration codes: M0247, M0248, Q0247 Effective: 04/05/2022.
06/2022	Coding Update Effective 07/01/2022 (Adaptive Maintenance Cycle): Revised code descriptor 0229U. Removed code 83880 off- cycle map as medically necessary. Removed codes 0648T & 0649T from NIV to requiring PA add to PA CAT Code 'MQM' per medical policy changes to be reviewed by AIM 07/01/2022.Removed code 42975, 87426 & C9776 - medically necessary. Removed codes 90626 & 90627 FDA approved covered travel. Removed code 90759 FDA approved - preventive grid. Added codes: 90584, 0714T, 0715T, 0716T, 0717T, 0718T, 0719T,0720T, 0721T, 0722T, 0723T, 0724T, 0725T, 0726T, 0727T, 0728T, 0729T, 0730T, 0731T, 0732T, 0733T, 0734T, 0735T, 0736T, 0737T, 0323U, 0324U, 0325U, 0328U, 0329U, 0330U, 0331U A9601, Q4259, Q4260, Q4261. Re-sequenced code 0330T.
09/2022	Coding Update Effective 10/01/2022 (Adaptive Maintenance Cycle): Added Codes Q1005, S0596, V2787, V2788, added to the Investigational policy the codes are considered investigational per the Vision Corporate Medical Policy. Removed codes 95976, 95977 & 58674 the codes will require prior approval. Removed code 84181 as investigational. Added the following PLA codes: 0332U, 0333U, 0334U, 0335U, 0336U, 0337U, 0338U, 0339U, 0340U, 0341U, 0342U, 0343U, 0344U, 0345U, 0346U, 0347U, 0348U, 0349U, 0350U, 0351U, 0352U as investigational. Added codes: A2014, A2015, A2016, A2017, A2018, A4596, C1834.
11/2022	Effective 11/01/2022: Removed codes: 0037U & 0129U from investigational to requiring prior approval. Removed codes 85384 & 85385 from investigational to medically necessary. Removed codes 0224U & 0225U from investigational to eligible at zero-cost share COVID-19.
12/2022	Effective 01/01/2023 (Adaptive Cycle Maintenance): Deleted Codes: 0312T, 0313T, 0314T, 0315T, 0316T, 0317T, 0514T, 0702T, 0703T. C1841, G2170, G2171.Revised Codes: 0733T, 0734T.Added codes as Investigational: 22860, 30469, 36836, 36837, 43290, 43291,77089, 77090, 77091, 77092, 81418, 81449, 81451, 81456, 90678, 98978, 0738T, 0739T, 0740T, 0741T, 0742T, 0743T, 0744T, 0745T, 0746T, 0747T, 0748T, 0749T, 0750T, 0751T, 0752T, 0753T, 0754T, 0755T, 0756T, 0757T, 0758T, 0759T, 0760T, 0761T, 0762T, 0763T, 0764T, 0765T, 0766T, 0767T, 0768T, 0769T, 0770T, 0771T, 0772T, 0773T, 0774T, 0775T, 0776T, 0777T, 0778T, 0779T, 0780T, 0781T, 0782T, 0783T, 0355U, 0356U, 0357U, 0358U, 0359U, 0360U, 0361U, 0362U, 0363U,C1747, C1826, C1827, C7501, C7502, Q4262, Q4263, Q4264. Removed code as Investigational: 0421T.
01/2023	Policy reviewed removed codes 0202U & 0223U from investigational to eligible at zero cost share COVID-19 effective 11/01/2022.
02/2023	Policy reviewed removed code 81518 from investigational to requiring prior approval effective 03/01/2023.
03/2023	Effective 04/01/2023 (Adaptive Maintenance Cycle): C1834, 0324U, 0325U codes deleted. Code 0095U descriptor revised. Removed codes 0449T, 0450T, 90758 from investigational to medically necessary.

Page **5** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

	Added codes: 0364U, 0365U, 0366U, 0367U, 0369U, 0370U, 0371U,
	0372U, 0374U, 0375Ü, 0376Ü, 0377Ü, 0378Ü, 0379Ü, 0380Ü, 0384Ü,
	0385U, 0386U, A2019, A2020, A2021, A4341, A4342, A4560, A6590,
	A6591, A7049, E0677, E0711, E1905, L8678, Q4265, Q4266, Q4267,
00.40000	Q4268, Q4269, Q4270, Q4271 as investigational to the coding table
03/2023	Effective 06/01/2023 Medical Policy Review- Added codes: E1806,
	E1811, E1816, E1818, E1821, E1831, E1841
06/2023	Effective 07/01/2023 (Adaptive Maintenance Cycle): Removed codes:
	83721, 90671. Deleted Code: 0053U.
	Added Codes: 0387U, 0389U, 0390U, 0391U, 0392U, 0393U, 0394U,
	0395U, 0398U, 0399Ú, 0400Ú, 0401Ú, 0791Ť, 0792Ť, 0793Ť, 0794Ť,
	0795T, 0796T, 0797T, 0798T, 0799T, 0800T, 0801T, 0802T, 0803T,
	0804T, 0805T, 0806T, 0807T, 0808T, 0809T, C9150, C9784, C9785,
	C9786, C9787, Q4272, Q4273, Q4274, Q4275, Q4276, Q4277, Q4278,
	Q4280, Q4281, Q4282, Q4283, Q4284.
	Added Codes (COVID-19): Refer to dates in table: 91300, 91301, 91303, 91305, 91306, 91307, 91308, 91309, 91311, 0001A, 0002A,
	0003A, 0004A, 0011A, 0012A, 0013A, 0031A, 0034A, 0051A, 0052A,
	0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0034A, 0031A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A,
	0083A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, M0220, M0221,
	M0222, M0223, M0240, M0241, M0243, M0244, M0245, M0246, M0247,
	M0248, Q0220, Q0221, Q0222, Q0240, Q0243, Q0244, Q0245, Q0247.
09/2023	
09/2023	0389U, 0401U, K1004, K1028. Deleted: 0357U, 0386U.Removed:
	90678 code medically necessary. Added: 0019M, 0071T, 0072T,
	0403U, 0404U, 0405U, 0406U, 0407U, 0408U, 0410U, 0411U, 0412U,
	0413U, 0414U, 0415U, 0416U, 0417U, 0418U, 0419U, A2022, A2023,
	A2024, A2025, A9268, A9269, A9292, A9573, A9603, A9697, C9788,
	C9790, C9791, C9792, E0490, E0491, K1036, Q4285, Q4286.
10/2023	
12/2023	Adaptive Maintenance Effective 01/01/2024: Removed code 0404T from
	investigational to requiring prior approval.
	Added codes: 22836,, 22837, 22838, 31242, 31243, 33276, 33277, 33278,
	33279, 33280, 33281, 33287, 33288, 52284, 90589, 90683, 92972, 93150,
	93151, 93152, 93153, A6566, A6567,A7023, A9609,C1600, E0492, E0493,
	E0530, E0732, E0733, E0734, E2001, Q4279, Q4287, Q4288, Q4289, Q4290,
	Q4291, Q4292, Q4293, Q4294, Q4295, Q4296, Q4297, Q4298, Q4299, Q4300,
	Q4301, Q4302, Q4303, Q4304, 0420U, 0421U, 0422U, 0423U, 0424U, 0427U,
	0429U, 0430U, 0431U, 0432U, 0433U, 0434U, 0435U, 0436U, 0437U,
	0438U,0790T, 0811T, 0812T, 0813T, 0814T, 0815T, 0820T, 0821T, 0827T,
1	0828T, 0829T, 0830T, 0831T, 0832T, 0833T, 0834T, 0835T, 0836T, 0837T,
	0838T, 0839T, 0840T, 0841T, 0842T, 0843T, 0844T, 0845T, 0846T, 0847T,
	0848T, 0849T, 0850T, 0851T, 0858T.
	0852T, 0853T, 0854T, 0855T, 0856T, 0857T, 0859T, 0860T, 0861T, 0862T,
	0863T, 0864T, 0865T, 0866T
	Dovised Codes, 944E4 944E4 0E47T 0E49T 0E40T 0E20T 0E97T 0E97T
	Revised Codes: 81451, 81456, 0517T, 0518T, 0519T, 0520T, 0587T, 0588T,
	0589T, 0590T, 0640T, 0656T, 0657T, 0766T, 0767T. 0095U, 0351U, 0356U,

Page 6 of 101 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

Deleted Codes: 0404T, 0424T, 0425T, 0426T, 0427T, 0428T, 0429T, 0430T, 0431T, 0432T, 0433T, 0434T, 0435T, 0436T, 0508T, 0533T, 0534T, 0533T, 0535T, 0536T, 0715T, 0768T, 0769T, 0775T, 0809T, 0014M, K1001, K1002, C9771, C9788, K1006, K1016, K1017, K1018, K1019, K1020, K1023, K1024, K1025, K1026, K1028, K1029, K1031, K1032, K1033, Removed code C2596 from investigational to medically necessary. 04/2024 Adaptive Maintenance Effective 04/01/2024: Added Codes: 27278, 0439U, 0440U, 0441U, 0442U, 0443U, 0444U, 0445U, 0446U, 0447U, 0449U, A2026, A4438, A4593, A4594, E0468, E0736, E0738, E0739, K1037, Q4305, Q4306, Q4307, Q4308, Q4309, Q4310, S4988, S9002 as investigational to coding table. Added Codes: C9796 & C9797 retroactive to 01/01/2024 Adaptive Maintenance Cycle as investigational to coding table. Removed Code: 0242U from investigational from coding table now requires PA. Deleted Code: 0416U from coding table. Revised Code: E2001 in coding table. 07/2024 Adaptive Maintenance Effective 07/01/2024: Added Codes: 0020M, 0867T, 0868T, 0870T, 0871T, 0872T, 0873T, 0874T, 0875T, 0876T, 0877T, 0878T, 0879T, 0880T, 0881T, 0882T, 0883T, 0884T, 0885T, 0886T, 0887T, 0888T, 0889T, 0890T, 0891T, 0892T, 0893T, 0894T, 0895T, 0896T, 0897T, 0898T, 0899T, 0900T,0450U, 0451U, 0452U, 0453U, 0456U, 0457U, 0458U, 0460U, 0461U, 0462U, 0463U, 0464U, 0465U, 0466U, 0467U, 0468U, 0469U, 0470U, 0472U, 0474U, 0475U, 90637, 90638, Q4311, Q4312, Q4313, Q4314, Q4315, Q4316, Q4317, Q4318, Q4319, Q4320, Q4321, Q4322, Q4323, Q4324, Q4325, Q4326, Q4327, Q4328, Q4329, Q4330, Q4331, Q4332, Q4333 as investigational to coding table. Removed Codes: 0279U, 0280U, 0281U, 0282U, 0283U, 0284U, C9359, 90589, 90683 from coding table. Deleted Codes: 0204U, C9787, C9790, Q4277 from coding table. Revised Codes: 0741T in coding table. 07/2024 Removed CPT® code 33274 from investigational coding table, code will require prior approval. Effective 10/01/2024. 10/2024 Adaptive Maintenance Effective 10/01/2024-Remove codes: 90637, 90638, 86352 (effective 07/01/2024) from investigational codes considered medically necessary. Removed codes: A9586, A9593, A9594, A9601, Q9982,

Page 7 of 101

Medical Policy Number: 10.01.VT204

Effective Date: 01/01/2026

Q9983, 0031U codes require prior approval and were not removed from investigational coding table. Removed codes: 0364U, 0720T from investigational codes require prior approval. Added codes: 90624, 0476U, 0477U, 0479U, 0482U, 0483U, 0484U, 0485U, 0486U, 0487U, 0488U, 0489U, 0490U, 0491U, 0492U, 0493U, 0494U, 0495U, 0496U, 0497U, 0498U, 0499U, 0500U, 0501U, 0502U, 0503U, 0504U, 0505U, 0506U, 0507U, 0508U, 0509U, 0510U, 0511U, 0512U, 0513U, 0514U, 0515U, 0516U, 0517U, 0518U, 0519U, 0520U, A4540, A2027, A2028, A2029, A4543, A4544, A4545, A7021, A9610, C8000, E0469, E0683, E0715, E0716, E0721, E0737, E0743, E0767, E3200, L8720, L8721, P9027, Q4334, Q4335, Q4336, Q4337, Q4338, Q4339, Q4340, Q4341, Q4342, Q4343, Q4344, Q4345 as investigational to coding table. Deleted code: C9150 from coding table. Revised Code Descriptors: 0248U, 0403U, A2024, E0739. 10/2024 Removed Code: Q4121 from coding table requires prior approval effective 11/01/2024. 11/2024 Coding table reviewed removed codes 0889T, 0890T, 0891T, 0892T as investigational effective 01/01/2025. 12/2024 Removed code 0047U as investigational effective 12/01/2024. 12/2024 Adaptive Maintenance Effective 01/01/2025 -Codes Deleted from coding table: 96003, 0553T, 0380U, 0346U, 0456U, C9786. Codes Revised in coding table: 0615T, 0365U, 0095U.Codes Added as investigational to coding table: C1735, C1736, C1737, C1738, C8001, C8002, C8003, G0555, Q4346, Q4347, Q4348, Q4349, Q4350, Q4351, Q4352, Q4353, S4988, 0524U, 0525U, 0526U, 0901T, 0902T, 0903T, 0904T, 0905T, 0906T, 0907T, 0908T, 0909T, 0910T, 0911T, 0912T, 0913T, 0914T, 0915T, 0916T, 0917T, 0918T, 0919T, 0920T, 0921T, 0922T, 0923T, 0924T, 0925T, 0926T, 0927T, 0928T, 0929T, 0930T, 0931T, 0932T, 0933T, 0934T, 0935T, 0936T, 0937T, 0938T, 0939T, 0940T, 0941T, 0942T, 0943T, 0944T, 0945T, 0946T, 0947T,15011, 15012, 15013, 15014, 15015, 15016, 15017, 15018, 51721, 53865, 53866, 55881, 55882, 60660, 60661, 61715, 66683, 81195, 81515, 81558, 82233, 82234, 83884, 84393, 84394. Codes removed: 64585, 0334U.

Medical Policy Number: 10.01.VT204

Effective Date: 01/01/2026

03/2025	Adaptive Maintenance Effective 04/01/2025: Codes Deleted COVID-19 Codes from coding table: M0220, M0221, M0222, M0223, M0240, M0241, M0243, M0244, M0247, Q0220, Q0221, Q0222, Q0240, Q0243, Q0244, Q0245, Q0247 effective 12/12/2024.
	Codes Deleted COVID-19 Codes from coding table: M0245, M0246 effective 12/13/2024.
	Codes Revised in codes: 0228U, 0308U, 0309U, 0310U, E1801, E1811, E1816, E1818, E1841.
	Codes Added as investigational to coding table: 0537U, 0538U, 0539U, 0541U, 0542U, 0544U, 0546U, 0547U, 0548U, 0549U, 0550U, 0551U, A2030, A2031, A2032, A2033, A2034, A2035, A9611, C8004, C8005, C9300, E0201, G0183, G0566, Q4354, Q4355, Q4356, Q4357, Q4358, Q4359, Q4360, Q4361, Q4362, Q4363, Q4364, Q4365, Q4366, Q4367, S4024.
03/2025	Effective 06/01/2025 Added codes A4541, A4542 to table as investigational.
04/2025	Effective 07/01/2025: Removed codes 0889T, 0890T, 0891T, 0892T as requiring prior approval to investigational. Removed code 81514 from investigational to medically necessary.
05/2025	Effective 08/01/2025 Code 0464U removed from the investigational coding table.
	Adaptive Maintenance Effective 07/01/2025: Added the following codes 0948T, 0949T, 0950T, 0951T, 0952T, 0953T, 0954T, 0955T, 0956T, 0957T, 0958T, 0959T, 0960T, 0961T, 0962T, 0963T, 0964T, 0965T, 0966T, 0967T, 0968T, 0969T, 0970T, 0971T, 0972T, 0973T, 0974T, 0975T, 0976T, 0977T, 0978T, 0979T, 0980T, 0981T, 0982T, 0983T, 0984T, 0985T, 0986T, 0987T, 0558U, 0559U, 0562U, 0566U, 0567U, 0568U, 0569U, 0570U, 0572U, 0573U, 0574U, Q4368, Q4369, Q4370, Q4371, Q4372, Q4373, Q4375, Q4376, Q4377, Q4378, Q4379, Q4380, Q4382, 90382, 90612, 90613, 90631, 91323 to the coding table as investigational. Deleted codes 0369U, 0370U, 0374U from coding table.
	Effective 10/01/2025: Removed codes 81515 & A9697 as investigational from coding table to medically necessary.
09/2025	Adaptive Maintenance Effective 10/01/2025: Adaptive Maintenance Effective 10/01/2025: Added the following codes to the coding table as investigational: 0575U, 0576U, 0577U, 0578U, 0579U, 0580U, 0581U, 0586U, 0587U, 0588U, 0589U, 0590U, 0591U, 0592U, 0593U, 0594U, 0597U, 0598U, 0599U, A2036, A2037, A2038, A2039, E0658, E0659, L1007, Q4383, Q4384, Q4385, Q4386, Q4387, Q4388, Q4389, Q4390, Q4391, Q4392, Q4393, Q4394, Q4395, Q4396, Q4397 Removed the following deleted Codes: 0450U, 0451U

Page **9** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

	Effective 12/01/2025: Removed the following code C1747 from the coding table from investigational the code will be considered medically necessary if
	criteria are met.
10/2025	Effective 01/01/2026: Removed code 55706 from coding table the code will require prior approval if criteria are met. Removed code 82610 from the coding table from investigational, the code will be considered medically necessary if criteria are met. Added codes 0422T, E0936, Q4236 to coding table.

Eligible Providers

Qualified healthcare professionals practicing within the scope of their license(s).

Approved by Blue Cross VT Medical Directors

Tom Weigel, MD, MBA Vice President and Chief Medical Officer

Tammaji P. Kulkarni, MD Senior Medical Director

Page 10 of 101

Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

Attachment I

The following codes will be considered investigational when applicable criteria have been met.	
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose
0003U	Oncology (ovarian) biochemical assays of five proteins (apolipoprotein A-1, CA 125 II, follicle stimulating hormone, human epididymis protein 4, transferrin), utilizing serum, algorithm reported as a likelihood score
0004A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose
0004M	Scoliosis, DNA analysis of 53 single nucleotide polymorphisms (SNPs), using saliva, prognostic algorithm reported as a risk score
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose
0011M	Oncology, prostate cancer, mRNA expression assay of 12 genes (10 content and 2 housekeeping), RT-PCR test utilizing blood plasma and urine, algorithms to predict high-grade prostate cancer risk
0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose
0016M	Oncology (bladder), mRNA, microarray gene expression profiling of 209 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as molecular subtype (luminal, luminal infiltrated, basal, basal claudin-low, neuroendocrine-like)
0018M	Transplantation medicine (allograft rejection, renal), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score

Page 11 of 101 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0019M	Cardiovascular disease, plasma, analysis of protein biomarkers by aptamer-based microarray and algorithm reported as 4-year likelihood of coronary event in high-risk populations
0020M	Oncology (central nervous system), analysis of 30000 DNA methylation loci by methylation array, utilizing DNA extracted from tumor tissue, diagnostic algorithm reported as probability of matching a reference tumor subclass
0024U	Glycosylated acute phase proteins (GlycA), nuclear magnetic resonance spectroscopy, quantitative
0025U	Tenofovir, by liquid chromatography with tandem mass spectrometry (LC-MS/MS), urine, quantitative
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage; single dose
0034A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage; booster dose
0034U	TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15) (eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; NUDT15 *3, *4, *5)
0035U	Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative
0038U	Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative
0039U	Deoxyribonucleic acid (DNA) antibody, double stranded, high avidity
0041U	Borrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, IgM
0042U	Borrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, IgG
0043U	Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgM
0044U	Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgG
0045U	Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score
0048U	Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)
0050U	Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements

Page 12 of 101 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following codes will be considered investigational when applicable criteria have been met.	
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0051A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease
20744	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose
0051U	Prescription drug monitoring, evaluation of drugs present by liquid chromatography tandem mass spectrommetry (LC-MS/MS), urine or blood, 31 drug panel, reported as quantitative results, detected or not detected, per date of service
0052A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose
0052U	Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation
0053A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose
0054A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose
0054U	Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service
0055U	Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma
0058U	Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative
0059U	Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative
0060U	Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood
0061U	Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis
0062U	Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score

Page 13 of 101 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0064A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose
0067U	Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer protein [HEC1]), formalin-fixed paraffin-embedded precancerous breast tissue, algorithm reported as carcinoma risk score
0069U	Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score
0071A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose
0071T	Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume less than 200 cc of tissue
0072A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose
0072T	Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume greater or equal to 200 cc of tissue
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose
0074A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose
0075T	Transcatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; initial vessel
0076T	Transcatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; each additional vessel (List separately in addition to code for primary procedure)
0078U	Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positive or negative risk of opioid-use disorder

Page 14 of 101 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	The following codes will be considered investigational when applicable criteria have been met.	
CPT®/HCPCS Code	CPT®/HCPCS Code Description	
0080U	Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy	
0081A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	
0082A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	
0082U	Drug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive, any number of drug classes, by instrument chemistry analyzer (utilizing immunoassay), urine, report of presence or absence of each drug, drug metabolite or substance with description and severity of significant interactions per date of service	
0083A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	
0083U	Oncology, response to chemotherapy drugs using motility contrast tomography, fresh or frozen tissue, reported as likelihood of sensitivity or resistance to drugs or drug combinations	
0084U	Red blood cell antigen typing, DNA, genotyping of 10 blood groups with phenotype prediction of 37 red blood cell antigens	
0087U	Cardiology (heart transplant), mRNA gene expression profiling by microarray of 1283 genes, transplant biopsy tissue, allograft rejection and injury algorithm reported as a probability score	
0088U	Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of 1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection	
0089U	Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es)	
0090U	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)	
0091A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose, when administered to individuals 6 through 11 years	

Page 15 of 101 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0091U	Oncology (colorectal) screening, cell enumeration of circulating tumor cells, utilizing whole blood, algorithm, for the presence of adenoma or cancer, reported as a positive or negative result
0092A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; second dose, when administered to individuals 6 through 11 years
0092U	Oncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor technology, plasma, algorithm reported as risk score for likelihood of malignancy
0093A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; third dose, when administered to individuals 6 through 11 years
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; booster dose, when administered to individuals 18 years and overEosinophilic esophagitis (Eotaxin-3 [CCL26 {C-C motif chemokine ligand 26}] and major basic protein [PRG2 {proteoglycan 2, pro eosinophil major basic protein}]), enzyme-linked immunosorbent assays (ELISA), specimen obtained by esophageal string test device, algorithm reported as probability of active or inactive eosinophilic esophagitis
0095U	Eosinophilic esophagitis, 2 protein biomarkers (Eotaxin-3 [CCL26 {C-C motif chemokine ligand 26}] and Major Basic Protein [PRG2 {proteoglycan 2, pro eosinophil major basic protein}]-1), enzymelinked immunosorbent assays (ELISA), specimen obtained by esophageal string test device, algorithm reported as probability of active or inactive eosinophilic esophagitis
0100T	Placement of a subconjunctival retinal prosthesis receiver and pulse generator, and implantation of intra-ocular retinal electrode array, with vitrectomy
0101T	Extracorporeal shock wave involving musculoskeletal system, not otherwise specified
0101U	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (15 genes [sequencing and deletion/duplication], EPCAM and GREM1 [deletion/duplication only])
0102T	Extracorporeal shock wave performed by a physician, requiring anesthesia other than local, and involving the lateral humeral epicondyle

Page 16 of 101 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0102U	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (17 genes [sequencing and deletion/duplication])
0103U	Hereditary ovarian cancer (eg, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (24 genes [sequencing and deletion/duplication], EPCAM [deletion/duplication only])
0105U	Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD)
0106T	Quantitative sensory testing (QST), testing and interpretation per extremity; using touch pressure stimuli to assess large diameter sensation
0106U	Gastric emptying, serial collection of 7 timed breath specimens, non- radioisotope carbon-13 (13C) spirulina substrate, analysis of each specimen by gas isotope ratio mass spectrometry, reported as rate of 13CO2 excretion
0107T	Quantitative sensory testing (QST), testing and interpretation per extremity; using vibration stimuli to assess large diameter fiber sensation
0108T	Quantitative sensory testing (QST), testing and interpretation per extremity; using cooling stimuli to assess small nerve fiber sensation and hyperalgesia
0108U	Gastroenterology (Barrett's esophagus), whole slide-digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer
0109T	Quantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia
0110T	Quantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensation
0110U	Prescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detected

Page 17 of 101 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0111A	Immunization administration by intramuscular injection of severe
OTTIA	acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative
	free, 100 mcg/0.5mL dosage; first dose
0112A	Immunization administration by intramuscular injection of severe
OTTER	acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative
	free, 25 mcg/0.25 mL dosage; second dose
0113U	Oncology (prostate), measurement of PCA3 and TMPRSS2-ERG in urine
	and PSA in serum following prostatic massage, by RNA amplification
	and fluorescence-based detection, algorithm reported as risk score
0114U	Gastroenterology (Barrett's esophagus), VIM and CCNA1 methylation
	analysis, esophageal cells, algorithm reported as likelihood for Barrett's
	esophagus
0118U	Transplantation medicine, quantification of donor-derived cell-free DNA
	using whole genome next-generation sequencing, plasma, reported as
	percentage of donor-derived cell-free DNA in the total cell-free DNA
0119U	Cardiology, ceramides by liquid chromatography-tandem mass
	spectrometry, plasma, quantitative report with risk score for major
	cardiovascular events
0120U	Oncology (B-cell lymphoma classification), mRNA, gene expression
	profiling by fluorescent probe hybridization of 58 genes (45 content
	and 13 housekeeping genes), formalin-fixed paraffin-embedded tissue,
	algorithm reported as likelihood for primary mediastinal B-cell
	lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) with
	cell of origin subtyping in the latter
0121U	Sickle cell disease, microfluidic flow adhesion (VCAM-1), whole blood
0122U	Sickle cell disease, microfluidic flow adhesion (P-Selectin), whole
	blood
0123U	Mechanical fragility, RBC, shear stress and spectral analysis profiling
0130U	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma
	syndrome, Cowden syndrome, familial adenomatosis polyposis), targeted
	mRNA sequence analysis panel (APC, CDH1, CHEK2, MLH1, MSH2, MSH6,
	MUTYH, PMS2, PTEN, and TP53) (List separately in addition to code for
2.12.111	primary procedure)
0131U	Hereditary breast cancer-related disorders (eg, hereditary breast cancer,
	hereditary ovarian cancer, hereditary endometrial cancer), targeted
	mRNA sequence analysis panel (13 genes) (List separately in addition to
043311	code for primary procedure)
0132U	Hereditary ovarian cancer-related disorders (eg, hereditary breast cancer,
	hereditary ovarian cancer, hereditary endometrial cancer), targeted
	mRNA sequence analysis panel (17 genes) (List separately in addition to
042211	code for primary procedure)
0133U	Hereditary prostate cancer-related disorders, targeted mRNA sequence
	analysis panel (11 genes) (List separately in addition to code for primary
	procedure)

Page 18 of 101 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0134U	Hereditary pan cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (18 genes) (List separately in addition to code for primary procedure)
0135U	Hereditary gynecological cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (12 genes) (List separately in addition to code for primary procedure)
0136U	ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia) mRNA sequence analysis (List separately in addition to code for primary procedure)
0137U	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)
0138U	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)
0152U	Infectious disease (bacteria, fungi, parasites, and DNA viruses), microbial cell-free DNA, plasma, untargeted next-generation sequencing, report for significant positive pathogens
0153U	Oncology (breast), mRNA, gene expression profiling by next-generation sequencing of 101 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a triple negative breast cancer clinical subtype(s) with information on immune cell involvement
0163T	Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression), each additional interspace, lumbar (List separately in addition to code for primary procedure)
0163U	Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (ELISA) of 3 plasma or serum proteins (teratocarcinoma derived growth factor-1 [TDGF-1, Cripto-1], carcinoembryonic antigen [CEA], extracellular matrix protein [ECM]), with demographic data (age, gender, CRC-screening compliance) using a proprietary algorithm and reported as likelihood of CRC or advanced adenomas
0164T	Removal of total disc arthroplasty, (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)
0164U	Gastroenterology (irritable bowel syndrome [IBS]), immunoassay for anti- CdtB and anti-vinculin antibodies, utilizing plasma, algorithm for elevated or not elevated qualitative results
0165T	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)
0165U	Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, individual epitope results and probability of peanut allergy

Page 19 of 101 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0166U	Liver disease, 10 biochemical assays (a2-macroglobulin, haptoglobin,
	apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol,
	fasting glucose) and biometric and demographic data, utilizing serum,
	algorithm reported as scores for fibrosis, necroinflammatory activity,
	and steatosis with a summary interpretation
0169U	NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase)
	(eg, drug metabolism) gene analysis, common variants
0170U	Neurology (autism spectrum disorder [ASD]), RNA, next-generation
	sequencing, saliva, algorithmic analysis, and results reported as
0171U	predictive probability of ASD diagnosis
01/10	Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA
	analysis, 23 genes, interrogation for sequence variants,
	rearrangements and minimal residual disease, reported as
	presence/absence
0174U	Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-
	fixed paraffin-embedded tissue, prognostic and predictive algorithm
	reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and
	targeted therapeutic oncology agents
0176U	Cytolethal distending toxin B (CdtB) and vinculin IgG antibodies by
	immunoassay (ie, ELISA)
0178U	Peanut allergen-specific quantitative assessment of multiple epitopes
	using enzyme-linked immunosorbent assay (ELISA), blood, report of
047011	minimum eliciting exposure for a clinical reaction
0179U	Oncology (non-small cell lung cancer), cell-free DNA, targeted
	sequence analysis of 23 genes (single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint,
	copy number variations), with report of significant mutation(s)
0180U	Red cell antigen (ABO blood group) genotyping (ABO), gene analysis
01000	Sanger/chain termination/conventional sequencing, ABO (ABO, alpha 1-
	3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase)
	gene, including subtyping, 7 exons
0181U	Red cell antigen (Colton blood group) genotyping (CO), gene analysis,
	AQP1 (aquaporin 1 [Colton blood group]) exon 1
0182U	Red cell antigen (Cromer blood group) genotyping (CROM), gene
	analysis, CD55 (CD55 molecule [Cromer blood group]) exons 1-10
0183U	Red cell antigen (Diego blood group) genotyping (DI), gene analysis,
040411	SLC4A1 (solute carrier family 4 member 1 [Diego blood group]) exon 19
0184U	Red cell antigen (Dombrock blood group) genotyping (DO), gene
	analysis, ART4 (ADP-ribosyltransferase 4 [Dombrock blood group]) exon 2
0185U	Red cell antigen (H blood group) genotyping (FUT1), gene analysis,
31030	FUT1 (fucosyltransferase 1 [H blood group]) exon 4
0186U	Red cell antigen (H blood group) genotyping (FUT2), gene analysis,
	FUT2 (fucosyltransferase 2) exon 2
0187U	Red cell antigen (Duffy blood group) genotyping (FY), gene analysis,
	ACKR1 (atypical chemokine receptor 1 [Duffy blood group]) exons 1-2
0188U	Red cell antigen (Gerbich blood group) genotyping (GE), gene analysis,
	GYPC (glycophorin C [Gerbich blood group]) exons 1-4

Page **20** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0189U	Red cell antigen (MNS blood group) genotyping (GYPA), gene analysis, GYPA (glycophorin A [MNS blood group]) introns 1, 5, exon 2
0190U	Red cell antigen (MNS blood group) genotyping (GYPB), gene analysis, GYPB (glycophorin B [MNS blood group]) introns 1, 5, pseudoexon 3
0191U	Red cell antigen (Indian blood group) genotyping (IN), gene analysis, CD44 (CD44 molecule [Indian blood group]) exons 2, 3, 6
0192U	Red cell antigen (Kidd blood group) genotyping (JK), gene analysis, SLC14A1 (solute carrier family 14 member 1 [Kidd blood group]) gene promoter, exon 9
0193U	Red cell antigen (JR blood group) genotyping (JR), gene analysis, ABCG2 (ATP binding cassette subfamily G member 2 [Junior blood group]) exons 2-26
0194U	Red cell antigen (Kell blood group) genotyping (KEL), gene analysis, KEL (Kell metallo-endopeptidase [Kell blood group]) exon 8
0195U	KLF1 (Kruppel-like factor 1), targeted sequencing (ie, exon 13)
0196U	Red cell antigen (Lutheran blood group) genotyping (LU), gene analysis, BCAM (basal cell adhesion molecule [Lutheran blood group]) exon 3
0197U	Red cell antigen (Landsteiner-Wiener blood group) genotyping (LW), gene analysis, ICAM4 (intercellular adhesion molecule 4 [Landsteiner-Wiener blood group]) exon 1
0198U	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis Sanger/chain termination/conventional sequencing, RHD (Rh blood group D antigen) exons 1-10 and RHCE (Rh blood group CcEe antigens) exon 5
0199U	Red cell antigen (Scianna blood group) genotyping (SC), gene analysis, ERMAP (erythroblast membrane associated protein [Scianna blood group]) exons 4, 12
0200U	Red cell antigen (Kx blood group) genotyping (XK), gene analysis, XK (X-linked Kx blood group) exons 1-3
0201U	Red cell antigen (Yt blood group) genotyping (YT), gene analysis, ACHE (acetylcholinesterase [Cartwright blood group]) exon 2
0202T	Posterior vertebral joint(s) arthroplasty (eg, facet joint[s] replacement), including facetectomy, laminectomy, foraminotomy, and vertebral column fixation, injection of bone cement, when performed, including fluoroscopy, single level, lumbar spine
0203U	Autoimmune (inflammatory bowel disease), mRNA, gene expression profiling by quantitative RT-PCR, 17 genes (15 target and 2 reference genes), whole blood, reported as a continuous risk score and classification of inflammatory bowel disease aggressiveness
0205U	Ophthalmology (age-related macular degeneration), analysis of 3 gene variants (2 CFH gene, 1 ARMS2 gene), using PCR and MALDI-TOF, buccal swab, reported as positive or negative for neovascular age-related macular-degeneration risk associated with zinc supplements
0206U	Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by ELISA, cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease

Page **21** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0207T	Evacuation of meibomian glands, automated, using heat and intermittent pressure, unilateral
0207U	Neurology (Alzheimer disease); quantitative imaging of phosphorylated ERK1 and ERK2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as a probability index for Alzheimer disease (List separately in addition to code for primary procedure)
0209U	Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities
0211U	Oncology (pan-tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association
0216U	Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants
0217U	Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants
0218U	Neurology (muscular dystrophy), DMD gene sequence analysis, including small sequence changes, deletions, duplications, and variants in non-uniquely mappable regions, blood or saliva, identification and characterization of genetic variants
0219U	Infectious agent (human immunodeficiency virus), targeted viral next- generation sequence analysis (ie, protease [PR], reverse transcriptase [RT], integrase [INT]), algorithm reported as prediction of antiviral drug susceptibility
0220U	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis, next-generation sequencing, RH proximal promoter, exons 1-10, portions of introns 2-3
0227U	Drug assay, presumptive, 30 or more drugs or metabolites, urine, liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, includes sample validation
0228U	Oncology (prostate), multianalyte molecular profile by photometric detection of macromolecules adsorbed on nanosponge array slides with machine learning, utilizing first morning voided urine, algorithm reported as likelihood of prostate cancer
0229U	BCAT1 (Branched chain amino acid transaminase 1) and IKZF1 (IKAROS family zinc finger 1) (eg, colorectal cancer) promoter methylation analysis
0232T	Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed

Page 22 of 101 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0243U	Obstetrics (preeclampsia), biochemical assay of placental-growth factor, time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia
0244U	Oncology (solid organ), DNA, comprehensive genomic profiling, 257 genes, interrogation for single-nucleotide variants, insertions/deletions, copy number alterations, gene rearrangements, tumor-mutational burden and microsatellite instability, utilizing formalin-fixed paraffinembedded tumor tissue
0247U	Obstetrics (preterm birth), insulin-like growth factor-binding protein 4 (IBP4), sex hormone-binding globulin (SHBG), quantitative measurement by LC-MS/MS, utilizing maternal serum, combined with clinical data, reported as predictive-risk stratification for spontaneous preterm birth
0248U	Oncology spheroid cell culture in a 3D microenvironment, 12 drug panel, brain or brain metastasis response prediction for each drug
0249U	Oncology (breast), semiquantitative analysis of 32 phosphoproteins and protein analytes, includes laser capture microdissection, with algorithmic analysis and interpretative report
0250U	Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes, interrogation for somatic alterations (SNVs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden
0251U	Hepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma
0252U	Fetal aneuploidy short tandem-repeat comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploidy
0253T	Insertion of anterior segment aqueous drainage device, without extraocular reservoir, internal approach, into the suprachoroidal space
0253U	Reproductive medicine (endometrial receptivity analysis), RNA gene expression profile, 238 genes by next-generation sequencing, endometrial tissue, predictive algorithm reported as endometrial window of implantation (eg, pre-receptive, receptive, post-receptive)
0255U	Andrology (infertility), sperm-capacitation assessment of ganglioside GM1 distribution patterns, fluorescence microscopy, fresh or frozen specimen, reported as percentage of capacitated sperm and probability of generating a pregnancy score
0258U	Autoimmune (psoriasis), mRNA, next-generation sequencing, gene expression profiling of 50-100 genes, skin-surface collection using adhesive patch, algorithm reported as likelihood of response to psoriasis biologics
0259U	Nephrology (chronic kidney disease), nuclear magnetic resonance spectroscopy measurement of myo-inositol, valine, and creatinine, algorithmically combined with cystatin C (by immunoassay) and demographic data to determine estimated glomerular filtration rate (GFR), serum, quantitative

Page 23 of 101 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following c	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0260U	Rare diseases (constitutional/heritable disorders), identification of copy
	number variations, inversions, insertions, translocations, and other
	structural variants by optical genome mapping
0261U	Oncology (colorectal cancer), image analysis with artificial intelligence
	assessment of 4 histologic and immunohistochemical features (CD3 and
	CD8 within tumor-stroma border and tumor core), tissue, reported as
	immune response and recurrence-risk score
0262U	Oncology (solid tumor), gene expression profiling by real-time RT-PCR of 7
	gene pathways (ER, AR, PI3K, MAPK, HH, TGFB, Notch), formalin-fixed
	paraffin-embedded (FFPE), algorithm reported as gene pathway activity
	score
0263T	Intramuscular autologous bone marrow cell therapy, with preparation of
	harvested cells, multiple injections, one leg, including ultrasound
	guidance, if performed; complete procedure including unilateral or
	bilateral bone marrow harvest
0263U	Neurology (autism spectrum disorder [ASD]), quantitative measurements
	of 16 central carbon metabolites (ie, a-ketoglutarate, alanine, lactate,
	phenylalanine, pyruvate, succinate, carnitine, citrate, fumarate,
	hypoxanthine, inosine, malate, S-sulfocysteine, taurine, urate, and
	xanthine), liquid chromatography tandem mass spectrometry (LC-
	MS/MS), plasma, algorithmic analysis with result reported as negative or
0264T	positive (with metabolic subtypes of ASD)
02641	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound
	guidance, if performed; complete procedure excluding bone marrow
	harvest
0264U	Rare diseases (constitutional/heritable disorders), identification of copy
02010	number variations, inversions, insertions, translocations, and other
	structural variants by optical genome mapping
0265T	Intramuscular autologous bone marrow cell therapy, with preparation of
	harvested cells, multiple injections, one leg, including ultrasound
	guidance, if performed; unilateral or bilateral bone marrow harvest
	only for intramuscular autologous bone marrow cell therapy
0266T	Implantation or replacement of carotid sinus baroreflex activation
	device; total system (includes generator placement, unilateral or
	bilateral lead placement, intra-operative interrogation, programming,
	and repositioning, when performed)
0266U	Unexplained constitutional or other heritable disorders or syndromes,
	tissue-specific gene expression by whole-transcriptome and next-
	generation sequencing, blood, formalin-fixed paraffin-embedded
	(FFPE) tissue or fresh frozen tissue, reported as presence or absence
	of splicing or expression changes
0267T	Implantation or replacement of carotid sinus baroreflex activation
	device; lead only, unilateral (includes intra-operative interrogation,
	programming, and repositioning, when performed)
0267U	Rare constitutional and other heritable disorders, identification of
	copy number variations, inversions, insertions, translocations, and
	other structural variants by optical genome mapping and whole
	genome sequencing

Page **24** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0268T	Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)
0269T	Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)
0270T	Revision or removal of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)
0271T	Revision or removal of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)
0272T	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day);
0273T	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day); with programming
0274T	Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral; cervical or thoracic
0275T	Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral; lumbar
0278T	Transcutaneous electrical modulation pain reprocessing (eg, scrambler therapy), each treatment session (includes placement of electrodes)
0285U	Oncology, response to radiation, cell-free DNA, quantitative branched chain DNA amplification, plasma, reported as a radiation toxicity score
0288U	Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score
0289U	Neurology (Alzheimer disease), mRNA, gene expression profiling by RNA sequencing of 24 genes, whole blood, algorithm reported as predictive risk score

Page **25** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	The following codes will be considered investigational when applicable criteria have been met.	
CPT®/HCPCS Code		
0290U	Pain management, mRNA, gene expression profiling by RNA sequencing of 36 genes, whole blood, algorithm reported as predictive risk score	
0291U	Psychiatry (mood disorders), mRNA, gene expression profiling by RNA sequencing of 144 genes, whole blood, algorithm reported as predictive risk score	
0292U	Psychiatry (stress disorders), mRNA, gene expression profiling by RNA sequencing of 72 genes, whole blood, algorithm reported as predictive risk score	
0293U	Psychiatry (suicidal ideation), mRNA, gene expression profiling by RNA sequencing of 54 genes, whole blood, algorithm reported as predictive risk score	
0294U	Longevity and mortality risk, mRNA, gene expression profiling by RNA sequencing of 18 genes, whole blood, algorithm reported as predictive risk score	
0295U	Oncology (breast ductal carcinoma in situ), protein expression profiling by immunohistochemistry of 7 proteins (COX2, FOXA1, HER2, Ki-67, p16, PR, SIAH2), with 4 clinicopathologic factors (size, age, margin status, palpability), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a recurrence risk score	
0296U	Oncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing at least 20 molecular features (eg, human and/or microbial mRNA), saliva, algorithm reported as positive or negative for signature associated with malignancy	
0297U	Oncology (pan tumor), whole genome sequencing of paired malignant and normal DNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and variant identification	
0298U	Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification	
0299U	Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal DNA specimens, fresh frozen tissue, blood, or bone marrow, comparative structural variant identification	
0300U	Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens, fresh tissue, blood, or bone marrow, comparative sequence analyses and variant identification	
0303U	Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; hypoxic	
0304U	Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; normoxic	

Page **26** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0305U	Hematology, red blood cell (RBC) functionality and deformity as a function of shear stress, whole blood, reported as a maximum elongation index
0306U	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis, cell-free DNA, initial (baseline) assessment to determine a patient specific panel for future comparisons to evaluate for MRD
0307U	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis of a patient-specific panel, cell-free DNA, subsequent assessment with comparison to previously analyzed patient specimens to evaluate for MRD
0308U	Cardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for obstructive CAD
0309U	Cardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 [TIMP-1], and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for major adverse cardiac event
0310U	Pediatrics (vasculitis, Kawasaki disease [KD]), analysis of 3 biomarkers (NT-proBNP, C-reactive protein, and T-uptake), plasma, algorithm reported as a risk score for KD
0311U	Infectious disease (bacterial), quantitative antimicrobial susceptibility reported as phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility for each organisms identified
0312U	Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment
0313U	Oncology (pancreas), DNA and mRNA next-generation sequencing analysis of 74 genes and analysis of CEA (CEACAM5) gene expression, pancreatic cyst fluid, algorithm reported as a categorical result (ie, negative, low probability of neoplasia or positive, high probability of neoplasia)
0314U	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)
0315U	Oncology (cutaneous squamous cell carcinoma), mRNA gene expression profiling by RT-PCR of 40 genes (34 content and 6 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical risk result (ie, Class 1, Class 2A, Class 2B)
0316U	Borrelia burgdorferi (Lyme disease), OspA protein evaluation, urine
0317U	Oncology (lung cancer), four-probe FISH (3q29, 3p22.1, 10q22.3, 10cen) assay, whole blood, predictive algorithm-generated evaluation reported as decreased or increased risk for lung cancer

Page **27** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following c	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0318U	Pediatrics (congenital epigenetic disorders), whole genome
	methylation analysis by microarray for 50 or more genes, blood
0319U	Nephrology (renal transplant), RNA expression by select transcriptome
	sequencing, using pretransplant peripheral blood, algorithm reported
	as a risk score for early acute rejection
0320U	Nephrology (renal transplant), RNA expression by select transcriptome
	sequencing, using posttransplant peripheral blood, algorithm reported
	as a risk score for acute cellular rejection
0321U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary
	pathogens, identification of 20 bacterial and fungal organisms and
	identification of 16 associated antibiotic-resistance genes, multiplex
	amplified probe technique
0322U	Neurology (autism spectrum disorder [ASD]), quantitative
	measurements of 14 acyl carnitines and microbiome-derived
	metabolites, liquid chromatography with tandem mass spectrometry
	(LC-MS/MS), plasma, results reported as negative or positive for risk of
	metabolic subtypes associated with ASD
0323U	Infectious agent detection by nucleic acid (DNA and RNA), central
	nervous system pathogen, metagenomic next-generation sequencing,
	Cerebrospinal fluid (CSF), identification of pathogenic bacteria,
022011	viruses, parasites or fungi
0328U	Drug assay, definitive, 120 or more drugs and metabolites, urine,
	quantitative liquid chromatography with tandem mass spectrometry
	(LC-MS/MS), includes specimen validity and algorithmic analysis
	describing drug or metabolite and presence or absence of risks for a significant patient adverse event, per date of service
0329U	Oncology (neoplasia), exome and transcriptome sequence analysis for
03290	sequence variants, gene copy number amplifications and deletions,
	gene rearrangements, microsatellite instability and tumor mutational
	burden utilizing DNA and RNA from tumor with and DNA from normal
	blood or saliva for subtraction, report of clinically significant
	mutation(s) with therapy associations
0330T	Tear film imaging, unilateral or bilateral, with interpretation and report
0330U	Infectious agent detection by nucleic acid (DNA or RNA), vaginal
	pathogen panel, identification of 27 organisms, amplified probe
	technique, vaginal swab
0331U	Oncology (hematolymphoid neoplasia), optical for copy number
	alterations and gene rearrangements utilizing DNA from blood or bone
	marrow, report of clinically significant alternations
0332T	Myocardial sympathetic innervation imaging, planar qualitative and
	quantitative assessment; with tomographic SPECT
0332U	Oncology (pan-tumor), genetic profiling of 8 DNA-regulatory
	(epigenetic) markers by quantitative polymerase chain reaction
	(qPCR), whole blood, reported as a high or low probability of
	responding to immune checkpoint-inhibitor therapy

Page **28** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have
	been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0333U	Oncology (liver), surveillance for hepatocellular carcinoma (HCC) in highrisk patients, analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement of serum of AFP/AFP-L3 and oncoprotein des-gammacarboxy-prothrombin (DCP), algorithm reported as normal or abnormal result
0335T	Insertion of sinus tarsi implant
0335U	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, fetal sample, identification and categorization of genetic variants
0336U	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent)
0337U	Oncology (plasma cell disorders and myeloma), circulating plasma cell immunologic selection, identification, morphological characterization, and enumeration of plasma cells based on differential CD138, CD38, CD19, and CD45 protein biomarker expression, peripheral blood
0338T	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral
0338U	Oncology (solid tumor), circulating tumor cell selection, identification, morphological characterization, detection and enumeration based on differential EpCAM, cytokeratins 8, 18, and 19, and CD45 protein biomarkers, and quantification of HER2 protein biomarker-expressing cells, peripheral blood
0339T	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral
0339U	Oncology (prostate), mRNA expression profiling of HOXC6 and DLX1, reverse transcription polymerase chain reaction (RT-PCR), first-void urine following digital rectal examination, algorithm reported as probability of high-grade cancer

Page **29** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0340U	Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient's tumor and germline DNA, reported as absence or presence of MRD, with disease-burden correlation, if appropriate
0341U	Fetal aneuploidy DNA sequencing comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploid
0342U	Oncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B, osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent immunoassay (ECLIA) for CA19-9, serum, diagnostic algorithm reported qualitatively as positive, negative, or borderline
0343U	Oncology (prostate), exosome-based analysis of 442 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as molecular evidence of no-, low-, intermediate- or high-risk of prostate cancer
0344U	Hepatology (nonalcoholic fatty liver disease [NAFLD]), semiquantitative evaluation of 28 lipid markers by liquid chromatography with tandem mass spectrometry (LC-MS/MS), serum, reported as at-risk for nonalcoholic steatohepatitis (NASH) or not NASH
0345U	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6
0347U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 16 gene report, with variant analysis and reported phenotypes
0348U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 25 gene report, with variant analysis and reported phenotypes
0349U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis, including reported phenotypes and impacted gene-drug interactions
0350U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis and reported phenotypes
0351U	Infectious disease (bacterial or viral), biochemical assays, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP-10), and C- reactive protein, serum, or venous whole blood, algorithm reported as likelihood of bacterial infection

Page 30 of 101 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0352U	Infectious disease (bacterial vaginosis and vaginitis), multiplex amplified probe technique, for detection of bacterial vaginosis-associated bacteria (BVAB-2, Atopobium vaginae, and Megasphera type 1), algorithm reported as detected or not detected and separate detection of Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata/Candida krusei, and trichomonas vaginalis, vaginal-fluid specimen, each result reported as detected or not detected
0355U	APOL1 (apolipoprotein L1) (eg, chronic kidney disease), risk variants (G1, G2)
0356U	Oncology (oropharyngeal or anal), evaluation of 17 DNA biomarkers using droplet digital PCR (ddPCR), cell-free DNA, algorithm reported as a prognostic risk score for cancer recurrence
0358U	Neurology (mild cognitive impairment), analysis of B-amyloid 1-42 and 1-40, chemiluminescence enzyme immunoassay, cerebral spinal fluid, reported as positive, likely positive, or negative
0359U	Oncology (prostate cancer), analysis of all prostate-specific antigen (PSA) structural isoforms by phase separation and immunoassay, plasma, algorithm reports risk of cancer
0360U	Oncology (lung), enzyme-linked immunosorbent assay (ELISA) of 7 autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, MAGE A4, and HuD), plasma, algorithm reported as a categorical result for risk of malignancy
0361U	Neurofilament light chain, digital immunoassay, plasma, quantitative
0362U	Oncology (papillary thyroid cancer), gene-expression profiling via targeted hybrid capture-enrichment RNA sequencing of 82 content genes fine needle aspiration or formalin-fixed paraffin embedded (FFPE) tissue, algorithm reported as one of three molecular subtypes
0363U	Oncology (urothelial), mRNA, geneexpression profiling by real-time quantitative PCR of 5 genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm incorporates age, sex, smoking history, and macrohematuria frequency, reported as a risk score for having urothelial carcinoma
0365U	Oncology (bladder), 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, diagnostic, algorithm including patient's age, race and gender reported as a probability of harboring urothelial cancer
0366U	Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, algorithm reported as a probability of recurrent bladder cancer
0367U	Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of recurrent or persistent cancer following transurethral resection

Page **31** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0371U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogen, semiquantitative identification, DNA from 16 bacterial organisms and 1 fungal organism, multiplex amplified probe technique via quantitative polymerase chain reaction (qPCR), urine
0372U	Infectious disease (genitourinary pathogens), antibiotic-resistance gene detection, multiplex amplified probe technique, urine, reported as an antimicrobial stewardship risk score
0375U	Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [ie, transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score
0376U	Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [ie, transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score
0377U	Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (NMR) spectrometry with report of a lipoprotein profile (including 23 variables)
0378U	RFC1 (replication factor C subunit 1), repeat expansion variant analysis by traditional and repeat-primed PCR, blood, saliva, or buccal swab
0379U	Targeted genomic sequence analysis panel, solid organ neoplasm, DNA (523 genes) and RNA (55 genes) by next-generation sequencing, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutational burden
0384U	Nephrology (chronic kidney disease), carboxymethyllysine, methylglyoxal hydroimidazolone, and carboxyethyl lysine by liquid chromatography with tandem mass spectrometry (LCMS/MS) and HbA1c and estimated glomerular filtration rate (GFR), with risk score reported for predictive progression to high-stage kidney disease
0385U	Nephrology (chronic kidney disease), apolipoprotein A4 (ApoA4), CD5 antigen-like (CD5L), and insulin-like growth factor binding protein 3 (IGFBP3) by enzyme-linked immunoassay (ELISA), plasma, algorithm combining results with HDL, estimated glomerular filtration rate (GFR) and clinical data reported as a risk score for developing diabetic kidney disease
0387U	Oncology (melanoma), autophagy and beclin 1 regulator 1 (AMBRA1) and loricrin (AMLo) by immunohistochemistry, formalinfixed paraffn-embedded (FFPE) tissue, report for risk of progression
0389U	Pediatric febrile illness (Kawasaki disease [KD]), interferon alphainducible protein 27 (IFI27) and mast cell-expressed membrane protein 1 (MCEMP1), RNA, using quantitative reverse transcription polymerase chain reaction (RT-qPCR), blood, reported as a risk score for KD

Page **32** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0390U	Obstetrics (preeclampsia), kinase insert domain receptor (KDR), Endoglin (ENG), and retinol-binding
	protein 4 (RBP4), by immunoassay, serum, algorithm reported as a risk score
0391U	"Oncology (solid tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded (FFPE) tissue, 437 genes, interpretive report for single nucleotide variants, splicesite variants, insertions/deletions, copy number alterations, gene fusions, tumor mutational burden, and microsatellite instability, with algorithm quantifying immunotherapy response score"
0392U	"Drug metabolism (depression, anxiety, attention deficit hyperactivity disorder [ADHD]), gene-drug interactions, variant analysis of 16 genes, including deletion/duplication analysis of CYP2D6, reported as impact of gene-drug interaction for each drug"
0393U	SYNTap® Biomarker Test by Amprion Clinical Laboratory. The lab, this chemistry test aids in the diagnosis of synucleinopathies (e.g., Parkinson's disease, Lewy body dementia, multiple system atrophy (MSA), Lewy body variant of Alzheimer's disease) and differential diagnosis of other movement and cognitive disorders. A CSF specimen is subjected to qualitative seed amplification assay assessment for detection of misfolded aggregates of α-synuclein protein
0394U	PFAS Testing & PFASureTM, by National Medical Services (NMS Labs). Per the lab, this chemistry quantitative toxicology test, monitors for Perfluoroalkyl Substances, (eg. perfluorooctanoic acid, perfluorooctane sulfonic acid). Plasma or serum is analyzed by HPLC/Tandem Mass Spectrometry (LC-MS/MS) for 16 PFAS compounds and reported with a calculated NASEM Summation value (National Academies of Science, Engineering and Medicine guidance value). The US Department of Defense, Lab Corp (and other large national clinical laboratories) and individual State-Level agencies will order this testing in Serum/Plasma matrix to monitor for exposure to PFAS. NMS Labs anticipates that testing will begin in Q1 2023. Testing will be high volume.
0395U	"Oncology (lung), multi-omics (microbial DNA by shotgun nextgeneration sequencing and carcinoembryonic antigen and osteopontin by immunoassay), plasma, algorithm reported as malignancy risk for lung nodules in early-stage disease"
0397T	Endoscopic retrograde cholangiopancreatography (ERCP), with optical endomicroscopy (List separately in addition to code for primary procedure)
0398U	"Gastroenterology (Barrett esophagus), P16, RUNX3, HPP1, and FBN1 DNA methylation analysis using PCR, formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as risk score for progression to high-grade dysplasia or cancer"

Page **33** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0399U	Neurology (cerebral folate deficiency), serum, detection of anti-human folate receptor IgGbinding antibody and blocking autoantibodies by enzyme-linked immunoassay (ELISA), qualitative, and blocking autoantibodies, using a functional blocking assay for IgG or IgM,
0400U	quantitative, reported as positive or not detected Obstetrics (expanded carrier screening), 145 genes by nextgeneration sequencing, fragment analysis and multiplex ligationdependent probe amplification, DNA, reported as carrier positive or negative
0401U	Cardiology (coronary heart disease [-CHD]), 9 genes (12 variants), targeted variant genotyping, blood, saliva, or buccal swab, algorithm reported as a genetic risk score for a coronary event
0403U	Oncology (prostate), mRNA, gene expression profiling of 18 genes, first-catch urine, algorithm reported as percentage of likelihood of detecting clinically significant prostate cancer
0404U	Oncology (breast), semiquantitative measurement of thymidine kinase activity by immunoassay, serum, results reported as risk of disease progression
0405U	Oncology (pancreatic), 59 methylation haplotype block markers, next- generation sequencing, plasma, reported as cancer signal detected or not detected
0406U	Oncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [4-carboxyphenyl] porphyrin [TCPP], CD206, CD66b, CD3, CD19), algorithm reported as likelihood of lung cancer
0407U	Nephrology (diabetic chronic kidney disease [CKD]), multiplex electrochemiluminescent immunoassay (ECLIA) of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor necrosis receptor 2 (sTNFR2), and kidney injury molecule 1 (KIM-1) combined with clinical data, plasma, algorithm reported as risk for progressive decline in kidney function
0408U	Infectious agent antigen detection by bulk acoustic wave biosensor immunoassay, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])
0410U	Oncology (pancreatic), DNA, whole genome sequencing with 5-hydroxymethylcytosine enrichment, whole blood or plasma, algorithm reported as cancer detected or not detected
0411U	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 (For additional PLA code with identical clinical descriptor, see 0345U. See Appendix O to determine appropriate code assignment)
0412U	Beta amyloid, AB42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoform-specific proteotyping, plasma combined with age, algorithm reported as presence or absence of brain amyloid pathology
0413U	Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements, DNA from blood or bone marrow, report of clinically significant alterations

Page **34** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0414U	Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), and KRAS G12C and PD-L1, if performed, formalin-fixed paraffinembedded (FFPE) tissue, reported as positive or negative for each biomarker
0415U	Cardiovascular disease (acute coronary syndrome [ACS]), IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3 by immunoassay combined with age, sex, family history, and personal history of diabetes, blood, algorithm reported as a 5-year (deleted risk) score for ACS
0417U	Rare diseases (constitutional/heritable disorders), whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclearencoded mitochondrial gene analysis of 335 nuclear genes, including sequence changes, deletions, insertions, and copy number variants analysis, blood or saliva, identification and categorization of mitochondrial disorder-associated genetic variants
0418U	Oncology (breast), augmentative algorithmic analysis of digitized whole slide imaging of 8 histologic and immunohistochemical features, reported as a recurrence score
0419U	Neuropsychiatry (eg, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each gene phenotype
0420U	Oncology (bladder), mRNA expression profiling by real time quantitative PCR of 5 genes (MDK, HOXA13, CDC2, IGFBP5, and CXCR2) in combination with ddPCR analysis of 6 single nucleotide polymorphisms in two genes (TERT and FGFR3) utilizing a midstream voided urine sample, algorithm reported as a risk score of having urothelial carcinoma
0421U	Oncology (colorectal) screening, quantitative real-time target and signal amplification of 8 RNA markers (GAPDH, SMAD4, ACY1, AREG, CDH1, KRAS, TNFRSF10B, and EGLN2) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result
0422T	Tactile breast imaging by computer-aided tactile sensors, unilateral or bilateral
0422U	Oncology (pan-cancer), analysis of DNA biomarker response to anti-cancer therapy using cell-free circulating DNA, biomarker comparison to a previous baseline pretreatment cell-free circulating DNA analysis using next-generation sequencing, algorithm reported as a quantitative change from baseline, including specific alterations, if appropriate
0423U	Gene analysis panel for detection of variants in 26 genes associated with psychiatric and other pharmaceutical treatment (eg, depression, anxiety), genomic analysis panel, variant analysis of 26 genes
0424U	Oncology (prostate) analysis of 53 small noncoding RNAs (sncRNAs), extracted from urinary exosomes, by quantitative real time polymerase chain reaction (rt-qPCR), reported as no molecular evidence, low-, moderate- or elevated-risk of prostate cancer
0427U	Monocyte distribution width, whole blood (list separately in addition to code for primary procedure)

Page **35** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0429U	Infectious disease (viral), real-time PCR testing for 14 high-risk HPV types using oropharyngeal swab
0430U	Gastroenterology, malabsorption evaluation of alpha-1-antitrypsin, calprotectin, pancreatic elastase
	and reducing substances, feces, quantitative
0431U	Glycine Receptor Alpha1 IgG, serum or cerebrospinal fluid (CSF), live Cell-Binding Assay (LCBA), qualitative
0432U	Kelch-Like Protein 11 (KLHL11) Antibody, serum or cerebrospinal fluid (CSF), cell-binding assay, qualitative
0433U	Oncology (prostate) 5 DNA regulatory markers by quantitative PCR, whole blood, algorithm, including prostate-specific antigen, reported as likelihood of cancer.
0434U	Drug metabolism (adverse drug reactions and drug response), genomic analysis panel, variant analysis of 25 genes with reported phenotypes
0435U	Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on cytotoxicity percentage observed, minimum of 14 drugs or drug combinations
0436U	Oncology (lung), plasma analysis of 388 proteins, using aptamer-based proteomics technology, predictive algorithm reported as clinical benefit from immune checkpoint inhibitor therapy.
0437U	Psychiatry (anxiety disorders), mRNA gene expression profiling by RNA sequencing of 15 biomarkers, whole blood, algorithm reported as predictive risk score
0438U	Drug Metabolism (adverse dr4ug reactions and drug response) buccal specimen, gene-drug interactions, variant analysis of 33 genes, including deletion/duplication analysis of CYP2D6, including reported phenotypes and impacted gene-drug interactions
0439U	Cardiology (coronary heart disease [CHD]), DNA, analysis of 5 single-nucleotide polymorphisms (SNPs) (rs11716050 [LOC105376934], rs6560711 [WDR37], rs3735222 [SCIN/LOC107986769], rs6820447 [intergenic], and rs9638144 [ESYT2]) and 3 DNA methylation markers (cg00300879 [transcription start site {TSS200} of CNKSR1], cg09552548 [intergenic], and cg14789911 [body of SPATC1L]), qPCR and digital PCR, whole blood, algorithm reported as a 4-tiered risk score for a 3-year risk of symptomatic CHD
0440U	Cardiology (coronary heart disease [CHD]), DNA, analysis of 10 single-nucleotide polymorphisms (SNPs) (rs710987 [LINC010019], rs1333048 [CDKN2B-AS1], rs12129789 [KCND3], rs942317 [KTN1-AS1], rs1441433 [PPP3CA], rs2869675 [PREX1], rs4639796 [ZBTB41], rs4376434 [LINC00972], rs12714414 [TMEM18], and rs7585056 [TMEM18]) and 6 DNA methylation markers (cg03725309 [SARS1], cg12586707 [CXCL1, cg04988978 [MPO], cg17901584 [DHCR24-DT], cg21161138 [AHRR], and cg12655112 [EHD4]), qPCR and digital PCR, whole blood, algorithm reported as detected or not detected for CHD
0441T	Ablation, percutaneous, cryoablation, includes imaging guidance; lower extremity distal/peripheral nerve

Page **36** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	The following codes will be considered investigational when applicable criteria have been met.	
CPT®/HCPCS Code	CPT®/HCPCS Code Description	
0441U	Infectious disease (bacterial, fungal or viral infection), semiquantitative biomechanical assessment (via deformability cytometry), whole blood, with algorithmic analysis and result reported as an index.	
0442U	Infectious disease (respiratory infection), Myxovirus resistance protein A (MxA) and C-reactive protein (CRP), fingerstick whole blood specimen, each biomarker reported as present or absent	
0443U	Neurofilament light chain (NfL), ultra-sensitive immunoassay , serum or cerebrospinal fluid	
0444U	Oncology (solid organ neoplasia), targeted genomic sequence panel of 361 genes, interrogation for gene fusions, translocations, or other rearrangements, using DNA from formalin-fixed paraffin-embedded (DDPE) tumor tissue, report of clinically significant variant(s)	
0445U	Bamyloid (Abeta42) and Phospho Tau (181P) (pTau181), electrochemiluminescence immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology	
0446U	Autoimmune diseases (systemic lupus erythematosus) [SLE], analysis of 10 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic risk score for current disease activity	
0447U	Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 11 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic prognostic risk score for developing a clinical flare	
0449U	Carrier screening for severe inherited conditions (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemias) regardless of race or self-identified ancestry, genomic sequence analysis of 5 genes (CFTR, SMN1, HBB, HBA1, HBA2)	
0452U	Oncology (bladder), methylated PENK DNA detection by linear target enrichment-quantitative methylation-specific real-time PCR (LTE-qMSP), urine, reported as likelihood of bladder cancer	
0453U	Oncology (colorectal cancer), cell-free DNA (cfDNA), methylation-based quantitative PCR assay (SEPTIN9, IKZF1, BCAT1, Septin9-2, VAV3, BCAN), plasma, reported as presence or absence of circulating tumor DNA (ctDNA)	
0457U	Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 9 PFAS compounds by LC-MS/MS, plasma or serum, quantitative	
0458U	Oncology (breast cancer), \$100A8 and \$100A9, by enzyme-linked immunosorbent assay (ELISA), tear fluid with age, algorithm reported as a risk score	
0460U	Oncology, whole blood or buccal, DNA single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, with variant analysis and reported phenotypes	
0461U	Oncology, pharmacogenomic analysis of single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, whole blood or buccal swab, with variant analysis, including impacted gene-drug interactions and reported phenotypes	

Page **37** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0462U	Melatonin levels test, sleep study, 7 or 9 sample melatonin profile
0.020	(cortisol optional), enzyme-linked immunosorbent assay (ELISA), saliva,
	screening/preliminary
0463U	Oncology (cervix), mRNA gene expression profiling of 14 biomarkers (E6
	and E7 of the highest-risk human papillomavirus [HPV] types 16, 18, 31,
	33, 45, 52, 58), by real-time nucleic acid sequence-based amplification
	(NASBA), exo- or endocervical epithelial cells, algorithm reported as
	positive or negative for increased risk of cervical dysplasia or cancer for
	each biomarker
0465U	Oncology (urothelial carcinoma), DNA, quantitative methylation-specific
	PCR of 2 genes (ONECUT2, VIM), algorithmic analysis reported as positive
	or negative
0466U	Cardiology (coronary artery disease [CAD]), DNA, genome-wide
	association studies (564856 single-nucleotide polymorphisms [SNPs],
	targeted variant genotyping), patient lifestyle and clinical data, buccal
046711	swab, algorithm reported as polygenic risk to acquired heart disease
0467U	Oncology (bladder), DNA, next-generation sequencing (NGS) of 60 genes
	and whole genome aneuploidy, urine, algorithms reported as minimal residual disease (MRD) status positive or negative and quantitative
	disease burden
0468U	Hepatology (nonalcoholic steatohepatitis [NASH]), miR-34a-5p, alpha 2-
04000	macroglobulin, YKL40, HbA1c, serum and whole blood, algorithm
	reported as a single score for NASH activity and fibrosis
0469U	Rare diseases (constitutional/heritable disorders), whole genome
04070	sequence analysis for chromosomal abnormalities, copy number variants,
	duplications/deletions, inversions, unbalanced translocations, regions of
	homozygosity (ROH), inheritance pattern that indicate uniparental
	disomy (UPD), and aneuploidy, fetal sample (amniotic fluid, chorionic
	villus sample, or products of conception), identification and
	categorization of genetic variants, diagnostic report of fetal results
	based on phenotype with maternal sample and paternal sample, if
	performed, as comparators and/or maternal cell contamination
0470U	Oncology (oropharyngeal), detection of minimal residual disease by next-
	generation sequencing (NGS) based quantitative evaluation of 8 DNA
	targets, cell-free HPV 16 and 18 DNA from plasma
0472U	Carbonic anhydrase VI (CA VI), parotid specific/secretory protein (PSP)
	and salivary protein (SP1) IgG, IgM, and IgA antibodies, enzyme-linked
	immunosorbent assay (ELISA), semiqualitative, blood, reported as
0.47.411	predictive evidence of early Sjogren syndrome
0474U	Hereditary pan-cancer (eg, hereditary sarcomas, hereditary endocrine
	tumors, hereditary neuroendocrine tumors, hereditary cutaneous
	melanoma), genomic sequence analysis panel of 88 genes with 20
	duplications/deletions using next-generation sequencing (NGS), Sanger sequencing, blood or saliva, reported as positive or negative for germline
	variants, each gene
	ימוזמווני, כמנוו צבווב

Page **38** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	The following codes will be considered investigational when applicable criteria have been met.	
CPT®/HCPCS Code	·	
0475U	Hereditary prostate cancer-related disorders, genomic sequence analysis panel using next-generation sequencing (NGS), Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA), and array comparative genomic hybridization (CGH), evaluation of 23 genes and duplications/deletions when indicated, pathologic mutations reported with a genetic risk score for prostate cancer	
0476U	Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis and reported phenotypes	
0477U	Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis, including impacted gene-drug interactions and reported phenotypes	
0479U	Tau, phosphorylated, pTau217	
0482U	Obstetrics (preeclampsia), biochemical assay of soluble fms-like tyrosine kinase 1 (sFlT-1) and placental growth factor (PIGF), serum, ratio reported for sFlT-1/PIGF, with risk of progression for preeclampsia with severe features within 2 weeks	
0483U	Infectious disease (Neisseria gonorrhoeae), sensitivity, ciprofloxacin resistance (gyrA S91F point mutation), oral/rectal/vaginal swab, algorithm reported as probability of fluoroquinolone resistance	
0484U	Infectious disease (Mycoplasma genitalium), macrolide sensitivity, (23S rRNA point mutation), oral/rectal/vaginal swab, algorithm reported as probability of macrolide resistance	
0485U	Oncology (solid tumor), cell-free DNA and RNA by next-generation sequencing, interpretative report for germline mutations, clonal hematopoiesis of indeterminate potential, and tumor-derived single nucleotide variants, small insertions/deletions, copy number alterations, fusions, microsatellite instability and tumor mutational burden.	
0486U	Oncology (pan-solid tumor), nextgeneration sequencing analysis of tumor methylation markers present in cell-free circulating tumor DNA, algorithm reported as quantitative measurement of methylation as a correlate of tumor fraction	
0487U	Oncology (solid tumor), cell-free circulating DNA, targeted genomic sequence analysis panel of 84 genes, interrogation for sequence variants, aneuploidycorrected gene copy number amplifications and losses, gene rearrangements, and microsatellite instability	
0488U	Obstetrics (fetal antigen noninvasive prenatal test), cellfree DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized pregnancies, reported as selected antigen(s) detected or not detected	

Page **39** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0489U	Obstetrics (single-gene noninvasive prenatal test), cellfree DNA sequence
	analysis of 1 or more targets (eg, CFTR, SMN1, HBB, HBA1, HBA2) to
	identify paternally inherited pathogenic variants, and relative mutation-
	dosage analysis based on molecular counts to determine fetal
	inheritance of maternal mutation, algorithm reported as a fetal risk
	score for the condition (eg, cystic fibrosis, spinal muscular atrophy, beta
	hemoglobinopathies [including sickle cell disease], alpha thalassemia)
0490U	Oncology (cutaneous or uveal melanoma), circulating tumor cell
	selection, morphological characterization and enumeration based on
	differential CD146, high molecular-weight melanoma associated antigen,
0.40.411	CD34 and CD45 protein biomarkers, peripheral blood
0491U	Oncology (solid tumor), circulating tumor cell selection, morphological
	characterization and enumeration based on differential epithelial cell
	adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of estrogen receptor (ER) protein
	biomarker-expressing cells, peripheral blood
0492U	Oncology (solid tumor), circulating tumor cell selection, morphological
04720	characterization and enumeration based on differential epithelial cell
	adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein
	biomarkers, and quantification of PD-L1 protein biomarker- expressing
	cells, peripheral blood
0493U	Transplantation medicine, quantification of donor-derived cell-free DNA
	(cfDNA) using nextgeneration sequencing, plasma, reported as
	percentage of donor derived cell-free DNA
0494U	Red blood cell antigen (fetal RhD gene analysis), next-generation
	sequencing of circulating cell-free DNA (cfDNA) of blood in pregnant
0.40511	individuals known to be RhD negative, reported as positive or negative
0495U	Oncology (prostate), analysis of circulating plasma proteins (tPSA, fPSA,
	KLK2, PSP94, and GDF15), germline polygenic risk score (60 variants), clinical information (age, family history of prostate cancer, prior
	negative prostate biopsy), algorithm reported as risk of likelihood of
	detecting clinically significant prostate cancer
0496U	Oncology (colorectal), cell-free DNA, 8 genes for mutations, 7 genes for
	methylation by real-time RT-PCR, and 4 proteins by enzyme-linked
	immunosorbent assay, blood, reported positive or negative for colorectal
	cancer or advanced adenoma risk
0497U	Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR
	of 6 genes (FOXM1, MCM3, MTUS1, TTC21B, ALAS1, and PPP2CA), utilizing
	formalin fixed paraffin-embedded (FFPE) tissue, algorithm reported as a
0.40011	risk score for prostate cancer
0498U	Oncology (colorectal), next generation sequencing for mutation
	detection in 43 genes and methylation pattern in 45 genes, blood, and formalin-fixed paraffin-embedded (FFPE) tissue, report of variants and
	methylation pattern with interpretation
0499U	Oncology (colorectal and lung), DNA from formalin-fixed paraffin
07//0	embedded (FFPE) tissue, next generation sequencing of 8 genes (NRAS,
	EGFR, CTNNB1, PIK3CA, APC, BRAF, KRAS, and TP53), mutation detection
	==::, :::::=:, ::::=:; ::::=; :::::=; :::::=; :::::=; :::::=; ::::::=; ::::::::

Page 40 of 101 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0500U	Autoinflammatory disease (VEXAS syndrome), DNA, UBA1 gene
	mutations, targeted variant analysis (M41T, M41V, M41L, c.118-2A>C,
	c.118-1G>C, c.118- 9_118-2del, \$56F, \$621C)
0501U	Oncology (colorectal), blood, cell free DNA (cfDNA)
0502U	Human papillomavirus (HPV), E6/E7 markers for high-risk types (16, 18,
	31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), cervical cells,
	branched-chain capture hybridization, reported as negative or positive
	for high risk for HPV
0503U	Neurology (Alzheimer disease), beta amyloid (AB40, AB42, AB42/40 ratio)
	and tau-protein (ptau217, np-tau217, ptau217/nptau217 ratio), blood,
	immunoprecipitation with quantitation by liquid chromatography with
	tandem mass spectrometry (LC-MS/MS), algorithm score reported as
	likelihood of positive or negative for amyloid plaques
0504U	Infectious disease (urinary tract infection), identification of 17
	pathologic organisms, urine, real-time PCR, reported as positive or
OFOFU	negative for each organism
0505U	Infectious disease (vaginal infection), identification of 32 pathogenic
	organisms, swab, real-time PCR, reported as positive or negative for
0506T	each organism
03061	Macular pigment optical density measurement by heterochromatic flicker
0506U	photometry, unilateral or bilateral, with interpretation and report Gastroenterology (Barrett's esophagus), esophageal cells, DNA
03000	methylation analysis by next-generation sequencing of at least 89
	differentially methylated genomic regions, algorithm reported as
	likelihood for Barrett's esophagus
0507T	Near-infrared dual imaging (ie, simultaneous reflective and trans-
03071	illuminated light) of meibomian glands, unilateral or bilateral, with
	interpretation and report
0507U	Oncology (ovarian), DNA, whole genome sequencing with 5-
	hydroxymethylcytosine (5hmC) enrichment, using whole blood or plasma,
	algorithm reported as cancer detected or not detected
0508U	Transplantation medicine, quantification of donor-derived cell-free DNA
	using 40 single nucleotide polymorphisms (SNPs), plasma, and urine, initia
	evaluation reported as percentage of donor-derived cell free DNA with risk
	for active rejection
0509T	Electroretinography (ERG) with interpretation and report, pattern (PERG)
0509U	Transplantation medicine, quantification of donor-derived cell-free DNA
	using 40 single nucleotide polymorphisms (SNPs), plasma, and urine, initia
	evaluation reported as percentage of donor-derived cell free DNA with risk
	for active rejection
0510T	Removal of sinus tarsi implant
0510U	Oncology (pancreatic cancer), augmentative algorithmic analysis of 16
	genes from previously sequenced RNA whole transcriptome data,
	reported as probability of predicted molecular subtype
0511T	Removal and reinsertion of sinus tarsi implant

Page **41** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0511U	Oncology (solid tumor), tumor cell culture in 3D microenvironment, 36 or more drug panel, reported as tumor-response prediction for each
	drug
0512T	Extracorporeal shock wave for integumentary wound healing, including topical application and dressing care; initial wound
0512U	Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) status, formalin-fixed paraffin embedded (FFPE) tissue, reported as increased or decreased probability of MSI-high (MSI-H)
0513T	Extracorporeal shock wave for integumentary wound healing, including topical application and dressing care; each additional wound (List separately in addition to code for primary procedure)
0513U	Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) and homologous recombination deficiency (HRD) status, formalin fixed paraffin-embedded (FFPE) tissue, reported as increased or decreased probability of each biomarker
0514U	Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of adalimumab (ADL) levels in venous serum in patients undergoing adalimumab therapy, results reported as a numerical value as micrograms per milliliter (µg/mL)
0515T	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery])
0515U	Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of infliximab (IFX) levels in venous serum in patients undergoing infliximab therapy, results reported as a numerical value as micrograms per milliliter (µg/mL)
0516T	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only
0516U	Drug metabolism, whole blood, pharmacogenomic genotyping of 40 genes and CYP2D6 copy number variant analysis, reported as metabolizer status
0517T	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; both components of pulse generator (battery and transmitter) only
0517U	Therapeutic drug monitoring, 80 or more psychoactive drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally and maximally effective dose of prescribed and non-prescribed medications
0518T	Removal of pulse generator for wireless cardiac stimulator for left ventricular pacing; battery component only
0518U	Therapeutic drug monitoring, 90 or more pain and mental health drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications

Page **42** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	The following codes will be considered investigational when applicable criteria have been met.	
CPT®/HCPCS Code	CPT®/HCPCS Code Description	
0519T	Removal and replacement of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; both components (battery and transmitter)	
0519U	Therapeutic drug monitoring, medications specific to pain, depression, and anxiety, LCMS/MS, plasma, 110 or more drugs or substances, qualitative and quantitative therapeutic minimally effective range of prescribed, non-prescribed, and illicit medications in circulation	
0520T	Removal and replacement of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; battery component only	
0520U	Therapeutic drug monitoring, 200 or more drugs or substances, LCMS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications	
0521T	Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing	
0522T	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing	
0523T	Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention (List separately in addition to code for primary procedure)	
0524T	Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring	
0524U	Obstetrics (preeclampsia), sFlt1/PIGF ratio, immunoassay, utilizing serum or plasma, reported as a value	
0525T	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)	
0525U	"Oncology, spheroid cell culture, 11-drug panel (carboplatin, docetaxel, doxorubicin, etoposide, gemcitabine, niraparib, olaparib, paclitaxel, rucaparib, topotecan, veliparib) ovarian, fallopian, or peritoneal response prediction for each drug"	
0526T	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only	
0526U	"Nephrology (renal transplant), quantification of CXCL10 chemokines, flow cytometry, urine, reported as pg/mL creatinine baseline and monitoring over time"	
0527T	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only	

Page **43** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following c	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0528T	Programming device evaluation (in person) of intracardiac ischemia
	monitoring system with iterative adjustment of programmed values, with
	analysis, review, and report
0529T	Interrogation device evaluation (in person) of intracardiac ischemia
	monitoring system with analysis, review, and report
0529U	"Hematology (venous thromboembolism [VTE]), genome-wide single-
	nucleotide
	polymorphism variants, including F2 and F5 gene analysis, and Leiden
	variant, by microarray analysis, saliva, report as risk score for VTE"
0530T	Removal of intracardiac ischemia monitoring system, including all
	imaging supervision and interpretation; complete system (electrode and
	implantable monitor)
0531T	Removal of intracardiac ischemia monitoring system, including all
	imaging supervision and interpretation; electrode only
0531U	Infectious disease (acid-fast bacteria and invasive fungi), DNA (673
	organisms), next-generation sequencing, plasma
0532T	Removal of intracardiac ischemia monitoring system, including all
	imaging supervision and interpretation; implantable monitor only
0533U	Drug metabolism (adverse drug reactions and drug response), genotyping
	of 16 genes (ie, ABCG2, CYP2B6, CYP2C9, CYP2C19, CYP2C, CYP2D6,
	CYP3A5, CYP4F2, DPYD, G6PD, GGCX, NUDT15, SLCO1B1, TPMT, UGT1A1,
	VKORC1), reported as metabolizer status and transporter function
0534U	Oncology (prostate), microRNA, single-nucleotide polymorphisms (SNPs)
	analysis by RT-PCR of 32 variants, using buccal swab, algorithm reported
	as a risk score
0535U	Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid,
	perfluorooctane sulfonic acid), by liquid chromatography with tandem
052711	mass spectrometry (LC-MS/MS), plasma or serum, quantitative
0536U	Red blood cell antigen (fetal RhD), PCR analysis of exon 4 of RHD gene
	and housekeeping control gene GAPDH from whole blood in pregnant individuals at 10+ weeks gestation known to be RhD negative, reported
	as fetal RhD status
0537U	Oncology (colorectal cancer), analysis of cell-free DNA for epigenomic
03370	patterns, next-generation sequencing, >2500 differentially methylated
	regions (DMRs), plasma, algorithm reported as positive or negative
0538U	Oncology (solid tumor), next-generation targeted sequencing analysis,
03300	formalin-fixed paraffin-embedded (FFPE) tumor tissue, DNA analysis of
	600 genes, interrogation for single-nucleotide variants,
	insertions/deletions, gene rearrangements, and copy number alterations,
	microsatellite instability, tumor mutation burden, reported as actionable
	variant
0539U	Oncology (solid tumor), cell-free circulating tumor DNA (ctDNA), 152
	genes, next-generation sequencing, interrogation for single-nucleotide
	variants, insertions/deletions, gene rearrangements, copy number
	alterations, and microsatellite instability, using whole-blood samples,
	mutations with clinical actionability reported as actionable variant

Page 44 of 101 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0541T	Myocardial imaging by magnetocardiography (MCG) for detection of
	cardiac ischemia, by signal acquisition using minimum 36 channel grid,
	generation of magnetic-field time-series images, quantitative analysis of
	magnetic dipoles, machine learning-derived clinical scoring, and
	automated report generation, single study;
0541U	Cardiovascular disease (HDL reverse cholesterol transport), cholesterol
	efflux capacity, LC-MS/MS, quantitative measurement of 5 distinct HDL-
	bound apolipoproteins (apolipoproteins A1, C1, C2, C3, and C4), serum,
0542T	algorithm reported as prediction of coronary artery disease (pCAD) score Myocardial imaging by magnetocardiography (MCG) for detection of
03421	cardiac ischemia, by signal acquisition using minimum 36 channel grid,
	generation of magnetic-field time-series images, quantitative analysis of
	magnetic dipoles, machine learning-derived clinical scoring, and
	automated report generation, single study; interpretation and report
0542U	Nephrology (renal transplant), urine, nuclear magnetic resonance (NMR)
	spectroscopy measurement of 84 urinary metabolites, combined with
	patient data, quantification of BK virus (human polyomavirus 1) using
	real-time PCR and serum creatinine, algorithm reported as a probability
	score for allograft injury status
0543T	Transapical mitral valve repair, including transthoracic
	echocardiography, when performed, with placement of artificial chordae
0.7.4.11	tendineae
0544U	Nephrology (transplant monitoring), 48 variants by digital PCR, using
	cell-free DNA from plasma, donor-derived cell-free DNA, percentage reported as risk for rejection
0545T	Transcatheter tricuspid valve annulus reconstruction with
05451	implantation of adjustable annulus reconstruction device,
	percutaneous approach
0546T	Radiofrequency spectroscopy, real time, intraoperative margin
	assessment, at the time of partial mastectomy, with report
0546U	Low-density lipoprotein receptor-related protein 4 (LRP4), antibody
	identification by immunofluorescence, using live cells, reported as
	positive or negative
0547T	Bone-material quality testing by microindentation(s) of the tibia(s),
05.4511	with results reported as a score
0547U	Neurofilament light chain (NfL), chemiluminescent enzyme
0548U	immunoassay, plasma, quantitative Glial fibrillary acidic protein (GFAP), chemiluminescent enzyme
03460	immunoassay, using plasma
0549U	Oncology (urothelial), DNA, quantitative methylated real-time PCR of
03470	TRNA-Cys, SIM2, and NKX1-1, using urine, diagnostic algorithm
	reported as a probability index for bladder cancer and/or upper tract
	urothelial carcinoma (UTUC)
0550U	Oncology (prostate), enzyme-linked immunosorbent assays (ELISA) for
	total prostate-specific antigen (PSA) and free PSA, serum, combined
	with age, previous negative prostate biopsy status, digital rectal
	examination findings, prostate volume, and image and data reporting
	of the prostate, algorithm reported as a risk score for the presence of
	high-grade prostate cancer

Page **45** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following c	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0551U	Tau, phosphorylated, pTau217, by single-molecule array
	(ultrasensitive digital protein detection), using plasma
0554T	Bone strength and fracture risk using finite element analysis of
	functional data, and bone-mineral density, utilizing data from a
	computed tomography scan; retrieval and transmission of the scan
	data, assessment of bone strength and fracture risk and bone mineral
	density, interpretation and report
0555T	Bone strength and fracture risk using finite element analysis of
	functional data, and bone-mineral density, utilizing data from a
	computed tomography scan; retrieval and transmission of the scan data
0556T	Bone strength and fracture risk using finite element analysis of
	functional data, and bone-mineral density, utilizing data from a
	computed tomography scan; assessment of bone strength and fracture
	risk and bone mineral density
0557T	Bone strength and fracture risk using finite element analysis of
	functional data, and bone-mineral density, utilizing data from a
	computed tomography scan; interpretation and report
0558T	Computed tomography scan taken for the purpose of biomechanical
	computed tomography analysis
0558U	Oncology (colorectal), quantitative enzyme-linked immunoassay (ELISA)
	for secreted colorectal cancer protein marker (BF7 antigen), using
	serum, result reported as indicative of response/no response to therapy
	or disease progression/regression
0559T	Anatomic model 3D-printed from image data set(s); first individually
	prepared and processed component of an anatomic structure
0559U	Oncology (breast), quantitative enzyme-linked immunoassay (ELISA) for
	secreted breast cancer protein marker (BF9 antigen), serum, result
	reported as indicative of response/no response to therapy or disease
OFCOT	progression/regression
0560T	Anatomic model 3D-printed from image data set(s); each additional
	individually prepared and processed component of an anatomic structure
0561T	(List separately in addition to code for primary procedure) Anatomic guide 3D-printed and designed from image data set(s); first
03611	anatomic guide
0562T	Anatomic guide Anatomic guide 3D-printed and designed from image data set(s); each
03021	additional anatomic guide (List separately in addition to code for primary
	procedure)
0562U	Oncology (solid tumor) targeted genomic sequence analysis, 33 genes,
03020	detection of single nucleotide variants (SNVs), insertions and deletions,
	copy number amplifications, and translocations in human genomic
	circulating cell-free DNA, plasma, reported as presence of actionable
	variants
0563T	Evacuation of meibomian glands, using heat delivered through wearable,
	open-eye eyelid treatment devices and manual gland expression,
	bilateral
0564T	Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem
	cells (CSCs), from cultured CSCs and primary tumor cells, categorical
	drug response reported based on percent of cytotoxicity observed, a
	minimum of 14 drugs or drug combinations

Page **46** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0565T	Autologous cellular implant derived from adipose tissue for the
	treatment of osteoarthritis of the knees; tissue harvesting and cellular
	implant creation
0566T	Autologous cellular implant derived from adipose tissue for the
	treatment of osteoarthritis of the knees; injection of cellular implant
	into knee joint including ultrasound guidance, unilateral
0566U	"Oncology (lung), qPCR-based analysis of 13 differentially methylated
	regions (CCDC181, HOXA7,
	LRRC8A, MARCHF11, MIR129-2, NCOR2, PANTR1, PRKCB, SLC9A3,
	TBR1_2, TRAP1, VWC2, ZNF781), pleural fluid, algorithm reported as a
	qualitative result"
0567T	Permanent fallopian tube occlusion with degradable biopolymer implant,
	transcervical approach, including transvaginal ultrasound
0567U	Rare diseases (constitutional/heritable disorders), whole genome
	sequence analysis combination of short and long reads, for single
	nucleotide variants, deletions/insertions and characterized intronic
	variants, copy number variants, duplications/deletions, mobile
	element insertions, runs of homozygosity, aneuploidy and inversions,
	mitochondrial DNA sequence and deletions, short tandem repeat
	genes, methylation status of selected regions, blood, saliva,
	amniocentesis, chorionic villus sample or tissue, identification and
	categorization of genetic variants
0568T	Introduction of mixture of saline and air for sonosalpingography to
	confirm occlusion of fallopian tubes, transcervical approach, including
	transvaginal ultrasound and pelvic ultrasound
0568U	Neurology (dementia), beta amyloid (AB40, AB42, AB42/40 ratio), tau-
	protein phosphorylated at residue (eg, pTau217), neurofilament light
	chain (NfL), and glial fibrillary acidic protein (GFAP), by ultra-high
	sensitivity molecule array detection, plasma, algorithm reported as
	positive, intermediate, or negative for Alzheimer pathology
0569T	Transcatheter tricuspid valve repair, percutaneous approach; initial
	prosthesis
0569U	Oncology (solid tumor) next-generation sequencing analysis of tumor
	methylation markers (>20,000 differentially methylated regions)
	present in cell-free circulating tumor DNA (ctDNA), whole blood,
	algorithm reported as presence or absence of ctDNA with tumor
	fraction, if appropriate
0570T	Transcatheter tricuspid valve repair, percutaneous approach; each
	additional prosthesis during same session (List separately in addition
	to code for primary procedure)
0570U	Neurology (traumatic brain injury), analysis of glial fibrillary acidic
	protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1),
	immunoassay, whole blood or plasma, individual components reported
	with overall result of elevated or not elevated based on threshold
057411	comparison
0571U	Oncology (solid tumor), DNA (80 genes) and RNA (10 genes), by next-
	generation sequencing, plasma, including single nucleotide variants,
	insertions/deletions, copy number alterations, microsatellite instability,
	and fusions, reported as clinically actionable variants

Page **47** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	The following codes will be considered investigational when applicable criteria have been met.	
CPT®/HCPCS Code		
0572U	Oncology (prostate), high-throughput telomere length quantification by FISH, whole blood, diagnostic algorithm reported as risk of prostate cancer	
0573U	Oncology (pancreas), 3 biomarkers (glucose, carcinoembryonic antigen, and gastricsin), pancreatic cyst lesion fluid, algorithm reported as categorical mucinous or non-mucinous	
0574U	Mycobacterium tuberculosis, culture filtrate protein-10-kDa (CFP-10), serum or plasma, liquid chromatography-mass spectrometry (LC-MS)	
0575U	Transplantation medicine (liver allograft rejection), miRNA gene expression profiling by RT-PCR of 4 genes (miR-122, miR-885, miR-23a housekeeping, spike-in control), serum, algorithm reported as risk of liver allograft rejection	
0576U	Transplantation medicine (liver allograft rejection), quantitative donor- derived cell-free DNA (cfDNA) by whole genome next generation sequencing, plasma and mRNA gene expression profiling by multiplex real-time PCR of 56 genes, whole blood, combined algorithm reported as a rejection risk score	
0577U	Oncology (ovarian), serum, analysis of 39 glycoproteins by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in multiple reaction monitoring mode, reported as likelihood of malignancy	
0578U	Oncology (cutaneous melanoma), RNA, gene expression profiling by real- time qPCR of 10 genes (8 content and 2 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reports a binary result, either low-risk or high-risk for sentinel lymph node metastasis and recurrence	
0579U	Nephrology (diabetic chronic kidney disease), enzyme linked immunosorbent assay (ELISA) of apolipoprotein A4 (APOA4), CD5 antigenlike (CD5L) combined with estimated glomerular filtration rate (GFR), age, plasma, algorithm reported as a risk score for kidney function decline	
0580U	Borrelia burgdorferi, antibody detection of 24 recombinant protein groups, by immunoassay, IgG	
0581T	Ablation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral	
0581U	Transplantation medicine, antibody to non-human leukocyte antigens (nonHLA), blood specimen, flow cytometry, single-antigen bead technology, 39 targets, individual positive antibodies reported	
0582T	Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance	
0583T	Tympanostomy (requiring insertion of ventilating tube), using an automated tube delivery system, iontophoresis local anesthesia	
0586U	Oncology, mRNA, gene expression profiling of 216 genes (204 targeted and 12 housekeeping genes), RNA expression analysis, formalin fixed paraffin-embedded (FFPE) tissue, quantitative, reported as log2 ratio per gene	

Page **48** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0587T	Percutaneous implantation or replacement of integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming,
0587U	and imaging guidance when performed, posterior tibial nerve Therapeutic drug monitoring, 60-150 drugs and metabolites, urine, saliva, quantitative liquid chromatography with tandem mass spectrometry (LCMS/MS), specimen validity, and algorithmic analyses for presence or absence of drug or metabolite, risk score predicted for adverse drug effects
0588T	Revision or removal of percutaneously placed integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve
0588U	Infectious disease (bacterial or viral), 32 genes (29 informative and 3 housekeeping), immune response mRNA, gene expression profiling by split well multiplex reverse transcription loop-mediated isothermal amplification (RTLAMP), whole blood, reported as continuous risk scores for likelihood of bacterial and viral infection and likelihood of severe illness within the next 7 days
0589T	Electronic analysis with simple programming of implanted integrated neurostimulation system for bladder dysfunction (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters
0589U	Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 24 PFAS compounds by high-performance liquid chromatography with tandem mass spectrometry (LCMS/MS), plasma or serum, quantitative
0590T	Electronic analysis with complex programming of implanted integrated neurostimulation system for bladder dysfunction (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters
0590U	Infectious disease (bacterial and fungal), DNA of 44 organisms (34 bacteria, 10 fungi), urine, next-generation sequencing, reported as positive or negative for each organism
0591U	Oncology (prostate cancer), biochemical analysis of 3 proteins (total PSA, free PSA, and HE4), plasma, serum, prognostic algorithm incorporating 3 proteins and digital rectal examination, results reported as a probability score for clinically significant prostate cancer

Page **49** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0592U	Infectious disease (genitourinary pathogens), DNA, 46 targets (28
03720	pathogens, 18 resistance genes), RT-PCR amplified probe technique,
	urine, each analyte reported as detected or not detected
0593U	Infectious disease (genitourinary pathogens), DNA, 46 targets (28
33733	pathogens, 18 resistance genes), RT-PCR amplified probe technique,
	urine, each analyte reported as detected or not detected
0594T	Osteotomy, humerus, with insertion of an externally controlled
	intramedullary lengthening device, including intraoperative imaging,
	initial and subsequent alignment assessments, computations of
	adjustment schedules, and management of the intramedullary
	lengthening device
0594U	Infectious disease (sepsis), semiquantitative measurement of pancreatic
	stone protein concentration, whole blood, reported as risk of sepsis
0596T	Temporary female intraurethral valve-pump (ie, voiding prosthesis);
	initial insertion, including urethral measurement
0597T	Temporary female intraurethral valve-pump (ie, voiding prosthesis);
	replacement
0597U	"Oncology (breast), RNA expression profiling of 329 genes by targeted
	next generation sequencing and 20 proteins by multiplex
	immunofluorescence, formalin-fixed paraffin embedded (FFPE) tissue,
	algorithmic analyses to
	determine tumor-recurrence risk score"
0598T	Noncontact real-time fluorescence wound imaging, for bacterial
	presence, location, and load, per session; first anatomic site (eg, lower
	extremity)
0598U	Gastroenterology (irritable bowel syndrome), IgG antibodies to 18
	food items by microarray-based immunoassay, whole blood or serum,
	report as elevated (positive) or normal (negative) antibody levels
0599T	Noncontact real-time fluorescence wound imaging, for bacterial
	presence, location, and load, per session; each additional anatomic
	site (eg, upper extremity) (List separately in addition to code for
OFOOLL	primary procedure)
0599U	Oncology (pancreatic cancer), multiplex immunoassay of ICAM1,
	TIMP1, CTSD, THBS1, and CA 19-9, serum, diagnostic algorithm
0602T	reported as positive or negative Glomerular filtration rate (GFR) measurement(s), transdermal,
00021	including sensor placement and administration of a single dose of
	fluorescent pyrazine agent
0603T	Glomerular filtration rate (GFR) monitoring, transdermal, including
00031	sensor placement and administration of more than one dose of
	fluorescent pyrazine agent, each 24 hours
0604T	Optical coherence tomography (OCT) of retina, remote, patient-initiated
00071	image capture and transmission to a remote surveillance center
	unilateral or bilateral; initial device provision, set-up and patient
	education on use of equipment

Page **50** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	•
0605T	Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; remote surveillance center technical support, data analyses and reports, with a minimum of 8 daily recordings, each 30 days
0606T	Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; review, interpretation and report by the prescribing physician or other qualified health care professional of remote surveillance center data analyses, each 30 days
0607T	Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour attended surveillance center; set-up and patient education on use of equipment
0608T	Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour attended surveillance center; analysis of data received and transmission of reports to the physician or other qualified health care professional
0609T	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); acquisition of single voxel data, per disc, on biomarkers (ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs
0610T	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of biomarker data for software analysis
0611T	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); postprocessing for algorithmic analysis of biomarker data for determination of relative chemical differences between discs
0612T	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); interpretation and report
0613T	Percutaneous transcatheter implantation of interatrial septal shunt device, including right and left heart catheterization, intracardiac echocardiography, and imaging guidance by the proceduralist, when performed
0614T	Removal and replacement of substernal implantable defibrillator pulse generator
0615T	Automated analysis of binocular eye movements without spatial calibration, including disconjugacy, saccades, and pupillary dynamics for the assessment of concussion, with interpretation and report
0619T	Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed

Page **51** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0620T	Endovascular venous arterialization, tibial or peroneal vein, with
	transcatheter placement of intravascular stent graft(s) and closure by any
	method, including percutaneous or open vascular access, ultrasound
	guidance for vascular access when performed, all catheterization(s) and
	intraprocedural roadmapping and imaging guidance necessary to complete
	the intervention, all associated radiological supervision and
	interpretation, when performed
0621T	Trabeculostomy ab interno by laser
0622T	Trabeculostomy ab interno by laser; with use of ophthalmic endoscope
0623T	Automated quantification and characterization of coronary
	atherosclerotic plaque to assess severity of coronary disease, using data
	from coronary computed tomographic angiography; data preparation and
	transmission, computerized analysis of data, with review of
	computerized analysis output to reconcile discordant data,
0.40.47	interpretation and report
0624T	Automated quantification and characterization of coronary
	atherosclerotic plaque to assess severity of coronary disease, using data
	from coronary computed tomographic angiography; data preparation and transmission
0625T	Automated quantification and characterization of coronary
00231	atherosclerotic plaque to assess severity of coronary disease, using data
	from coronary computed tomographic angiography; computerized
	analysis of data from coronary computed tomographic angiography
0626T	Automated quantification and characterization of coronary
	atherosclerotic plaque to assess severity of coronary disease, using data
	from coronary computed tomographic angiography; review of
	computerized analysis output to reconcile discordant data,
	interpretation and report
0627T	Percutaneous injection of allogeneic cellular and/or tissue-based product,
	intervertebral disc, unilateral or bilateral injection, with fluoroscopic
	guidance, lumbar; first level
0628T	Percutaneous injection of allogeneic cellular and/or tissue-based
	product, intervertebral disc, unilateral or bilateral injection, with
	fluoroscopic guidance, lumbar; each additional level (List separately in
0/20T	addition to code for primary procedure)
0629T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance,
	lumbar; first level
0630T	Percutaneous injection of allogeneic cellular and/or tissue-based
00301	product, intervertebral disc, unilateral or bilateral injection, with CT
	guidance, lumbar; each additional level (List separately in addition to
	code for primary procedure)
0631T	Transcutaneous visible light hyperspectral imaging measurement of
	oxyhemoglobin, deoxyhemoglobin, and tissue oxygenation, with
	interpretation and report, per extremity
0632T	Percutaneous transcatheter ultrasound ablation of nerves innervating the
	pulmonary arteries, including right heart catheterization, pulmonary
	artery angiography, and all imaging guidance

Page **52** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0633T	Computed tomography, breast, including 3D rendering, when performed, unilateral; without contrast material
0634T	Computed tomography, breast, including 3D rendering, when performed, unilateral; with contrast material(s)
0635T	Computed tomography, breast, including 3D rendering, when performed, unilateral; without contrast, followed by contrast material(s)
0636T	Computed tomography, breast, including 3D rendering, when performed, bilateral; without contrast material(s)
0637T	Computed tomography, breast, including 3D rendering, when performed, bilateral; with contrast material(s)
0638T	Computed tomography, breast, including 3D rendering, when performed, bilateral; without contrast, followed by contrast material(s)
0639T	Wireless skin sensor thermal anisotropy measurement(s) and assessment of flow in cerebrospinal fluid shunt, including ultrasound guidance, when performed
0640T	Noncontact near-infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), other than for screening for peripheral arterial disease, image acquisition, interpretation, and report; first anatomic site
0643T	Transcatheter left ventricular restoration device implantation including right and left heart catheterization and left ventriculography when performed, arterial approach
0646T	Transcatheter tricuspid valve implantation (TTVI)/replacement with prosthetic valve, percutaneous approach, including right heart catheterization, temporary pacemaker insertion, and selective right ventricular or right atrial angiography, when performed
0647T	Insertion of gastrostomy tube, percutaneous, with magnetic gastropexy, under ultrasound guidance, image documentation and report
0651T	Magnetically controlled capsule endoscopy, esophagus through stomach, including intraprocedural positioning of capsule, with interpretation and report
0652T	Esophagogastroduodenoscopy, flexible, transnasal; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)
0653T	Esophagogastroduodenoscopy, flexible, transnasal; with biopsy, single or multiple
0654T	Esophagogastroduodenoscopy, flexible, transnasal; with insertion of intraluminal tube or catheter
0655T	Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging
0656T	Anterior lumbar or thoracolumbar vertebral body tethering; up to 7 vertebral segments
0657T	Anterior lumbar or thoracolumbar vertebral body tethering; 8 or more vertebral segments
0658T	Electrical impedance spectroscopy of 1 or more skin lesions for automated melanoma risk score

Page **53** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

Deen met. CPT®/HCPCS Code CPT®/HCPCS Code Description Transcatheter intracoronary infusion of supersaturated oxygen in conjunction with percutaneous coronary revascularization during acute myocardial infarction, including catheter placement, imaging guidance (eg, fluoroscopy), angiography, and radiologic supervision and interpretation O660T Implantation of anterior segment intraocular nonbiodegradable drugeluting system, internal approach Removal and reimplantation of anterior segment intraocular
Transcatheter intracoronary infusion of supersaturated oxygen in conjunction with percutaneous coronary revascularization during acute myocardial infarction, including catheter placement, imaging guidance (eg, fluoroscopy), angiography, and radiologic supervision and interpretation O660T Implantation of anterior segment intraocular nonbiodegradable drugeluting system, internal approach
conjunction with percutaneous coronary revascularization during acute myocardial infarction, including catheter placement, imaging guidance (eg, fluoroscopy), angiography, and radiologic supervision and interpretation O660T Implantation of anterior segment intraocular nonbiodegradable drugeluting system, internal approach
acute myocardial infarction, including catheter placement, imaging guidance (eg, fluoroscopy), angiography, and radiologic supervision and interpretation O660T Implantation of anterior segment intraocular nonbiodegradable drugeluting system, internal approach
guidance (eg, fluoroscopy), angiography, and radiologic supervision and interpretation O660T Implantation of anterior segment intraocular nonbiodegradable drugeluting system, internal approach
and interpretation O660T Implantation of anterior segment intraocular nonbiodegradable drug- eluting system, internal approach
O660T Implantation of anterior segment intraocular nonbiodegradable drug- eluting system, internal approach
eluting system, internal approach
The indicated in the second of an antended the second of an antended second in the second of the sec
nonbiodegradable drug-eluting implant
O664T Donor hysterectomy (including cold preservation); open, from cadave
donor
O665T Donor hysterectomy (including cold preservation); open, from living
donor
O666T Donor hysterectomy (including cold preservation); laparoscopic or
robotic, from living donor
O667T Donor hysterectomy (including cold preservation); recipient uterus
allograft transplantation from cadaver or living donor
0668T Backbench standard preparation of cadaver or living donor uterine
allograft prior to transplantation, including dissection and removal of
surrounding soft tissues and preparation of uterine vein(s) and uterine
artery(ies), as necessary
0669T Backbench reconstruction of cadaver or living donor uterus allograft
prior to transplantation; venous anastomosis, each
0670T Backbench reconstruction of cadaver or living donor uterus allograft
prior to transplantation; arterial anastomosis, each
0672T Endovaginal cryogen-cooled, monopolar radiofrequency remodeling of
the tissues surrounding the female bladder neck and proximal urethra
for urinary incontinence
O673T Ablation, benign thyroid nodule(s), percutaneous, laser, including
imaging guidance
0674T Laparoscopic insertion of new or replacement of permanent implantal
synchronized diaphragmatic stimulation system for augmentation of
cardiac function, including an implantable pulse generator and
diaphragmatic lead(s)
0675T Laparoscopic insertion of new or replacement of diaphragmatic
lead(s), permanent implantable synchronized diaphragmatic
stimulation system for augmentation of cardiac function, including
connection to an existing pulse generator; first lead
0676T Laparoscopic insertion of new or replacement of diaphragmatic
lead(s), permanent implantable synchronized diaphragmatic
stimulation system for augmentation of cardiac function, including
connection to an existing pulse generator; each additional lead (List
separately in addition to code for primary procedure)
0677T Laparoscopic repositioning of diaphragmatic lead(s), permanent
implantable synchronized diaphragmatic stimulation system for
augmentation of cardiac function, including connection to an existing
pulse generator; first repositioned lead

Page **54** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0678T	Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional repositioned lead (List separately in addition to code for primary procedure)
0679T	Laparoscopic removal of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function
0680T	Insertion or replacement of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing lead(s)
0681T	Relocation of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing dual leads
0682T	Relocation of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing dual leads
0683T	Programming device evaluation (in-person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function
0684T	Peri-procedural device evaluation (in-person) and programming of device system parameters before or after a surgery, procedure, or test with analysis, review, and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function
0685T	Interrogation device evaluation (in-person) with analysis, review and report by a physician or other qualified health care professional, including connection, recording and disconnection per patient encounter, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function
0686T	Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of malignant hepatocellular tissue, including image guidance
0687T	Treatment of amblyopia using an online digital program; device supply, educational set-up, and initial session
0688T	Treatment of amblyopia using an online digital program; assessment of patient performance and program data by physician or other qualified health care professional, with report, per calendar month
0689T	Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained without diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure)

Page **55** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following coo	des will be considered investigational when applicable criteria have
CPT®/HCPCS Code	been met. CPT®/HCPCS Code Description
	Quantitative ultrasound tissue characterization (non-elastographic),
	including interpretation and report, obtained with diagnostic
	ultrasound examination of the same anatomy (eg, organ, gland,
	tissue, target structure) (List separately in addition to code for
	primary procedure)
	Automated analysis of an existing computed tomography study for
	vertebral fracture(s), including assessment of bone density when
	performed, data preparation, interpretation, and report
	Comprehensive full body computer-based markerless 3D kinematic and
	kinetic motion analysis and report
0694T	3-dimensional volumetric imaging and reconstruction of breast or
	axillary lymph node tissue, each excised specimen, 3-dimensional
	automatic specimen reorientation, interpretation and report, real-
	time intraoperative
0695T	Body surface-activation mapping of pacemaker or pacing cardioverter-
	defibrillator lead(s) to optimize electrical synchrony, cardiac
	resynchronization therapy device, including connection, recording,
	disconnection, review, and report; at time of implant or replacement
	Body surface-activation mapping of pacemaker or pacing cardioverter-
	defibrillator lead(s) to optimize electrical synchrony, cardiac
	resynchronization therapy device, including connection, recording,
	disconnection, review, and report; at time of follow-up interrogation
	or programming device evaluation
	Quantitative magnetic resonance for analysis of tissue composition
	(eg, fat, iron, water content), including multiparametric data
	acquisition, data preparation and transmission, interpretation and
	report, obtained without diagnostic MRI examination of the same
	anatomy (eg, organ, gland, tissue, target structure) during the same
	session; multiple organs Quantitative magnetic resonance for analysis of tissue composition
	(eg, fat, iron, water content), including multiparametric data
	acquisition, data preparation and transmission, interpretation and
	report, obtained with diagnostic MRI examination of the same
	anatomy (eg, organ, gland, tissue, target structure); multiple organs
	(List separately in addition to code for primary procedure)
	Molecular fluorescent imaging of suspicious nevus; first lesion
	Molecular fluorescent imaging of suspicious nevus; each additional
	lesion (List separately in addition to code for primary procedure)
	Remote treatment of amblyopia using an eye tracking device; device
	supply with initial set-up and patient education on use of equipment
	Remote treatment of amblyopia using an eye tracking device;
	surveillance center technical support including data transmission with
	analysis, with a minimum of 18 training hours, each 30 days
	Remote treatment of amblyopia using an eye tracking device;
	interpretation and report by physician or other qualified health care
	professional, per calendar month

Page **56** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0707T	Injection(s), bone substitute material (eg, calcium phosphate) into
	subchondral bone defect (ie, bone marrow lesion, bone bruise, stress
	injury, microtrabecular fracture), including imaging guidance and
	arthroscopic assistance for joint visualization
0708T	Intradermal cancer immunotherapy; preparation and initial injection
0709T	Intradermal cancer immunotherapy; each additional injection (List separately in addition to code for primary procedure)
0710T	Noninvasive arterial plaque analysis using software processing of data
07101	from non-coronary computerized tomography angiography; including
	data preparation and transmission, quantification of the structure and
	composition of the vessel wall and assessment for lipid-rich necrotic core
	plaque to assess atherosclerotic plaque stability, data review,
	interpretation and report
0711T	Noninvasive arterial plaque analysis using software processing of data
	from non-coronary computerized tomography angiography; data
	preparation and transmission
0712T	Noninvasive arterial plaque analysis using software processing of data
	from non-coronary computerized tomography angiography; quantification
	of the structure and composition of the vessel wall and assessment for
	lipid-rich necrotic core plaque to assess atherosclerotic plaque stability
0713T	Noninvasive arterial plaque analysis using software processing of data
	from non-coronary computerized tomography angiography; data review,
	interpretation and report
0714T	Transperineal laser ablation of benign prostatic hyperplasia, including
	imaging guidance; prostate volume less than 50 mL
0716T	Cardiac acoustic waveform recording with automated analysis and
	generation of coronary artery disease risk score
0717T	"Autologous adipose-derived regenerative cell (ADRC) therapy for
	partial thickness rotator cuff tear; adipose tissue harvesting, isolation
	and preparation of harvested cells, including incubation with cell
07407	dissociation enzymes, filtration, washing and concentration of ADRCs
0718T	Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; injection into supraspinatus tendon
	including ultrasound guidance, unilateral
0719T	Posterior vertebral joint replacement, including bilateral
0/171	facetectomy, laminectomy, and radical discectomy, including imaging
	guidance, lumbar spine, single segment
0721T	Quantitative computed tomography (CT) tissue characterization,
0,211	including interpretation and report, obtained without concurrent CT
	examination of any structure contained in previously acquired
	diagnostic imaging
0722T	Quantitative computed tomography (CT) tissue characterization,
	including
	interpretation and report, obtained with concurrent CT examination
	of any
	structure contained in the concurrently acquired diagnostic imaging
	dataset (List
	separately in addition to code for primary procedure)

Page **57** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0723T	Quantitative magnetic resonance cholangiopancreatography (QMRCP) including data preparation and transmission, interpretation and report, obtained without diagnostic magnetic resonance imaging (MRI) examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session
0724T	Quantitative magnetic resonance cholangiopancreatography (QMRCP) including data preparation and transmission, interpretation and report, obtained with diagnostic magnetic resonance imaging (MRI) examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code for primary procedure)
0725T	Vestibular device implantation, unilateral
0726T	Removal of implanted vestibular device, unilateral
0727T	Removal and replacement of implanted vestibular device, unilateral
0728T	Diagnostic analysis of vestibular implant, unilateral; with initial programming
0729T	with subsequent programming (For initial and subsequent diagnostic analysis and programming of cochlear implant
0730T	Trabeculotomy by laser, including optical coherence tomography (OCT) guidance
0731T	Augmentative AI-based facial phenotype analysis with report
0732T	Immunotherapy administration with electroporation, intramuscular
0733T	Remote therapy ordered by a physician or other qualified health care professional; supply and technical support, per 30 days
0734T	Remote body and limb kinematic measurement-based therapy ordered by a physician or other qualified health care professional; supply and technical support, per 30 days; treatment management services by a physician or other qualified health care professional, per calendar month"
0735T	"Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with primary craniotomy (List separately in addition to code for primary procedure)
0736T	Colonic lavage, 35 or more liters of water, gravity-fed, with induced defecation, including insertion of rectal catheter
0737T	Xenograft implantation into the articular surface
0738T	Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination
0739T	Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation

Page **58** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0740T	Remote autonomous algorithm-based recommendation system for insulin dose calculation and titration; initial set-up and patient education
0741T	Remote autonomous algorithm-based recommendation system for insulin dose calculation and titration; initial set-up and patient education; provision of software, data collection, transmission, and storage, each 30 days
0742T	Absolute quantitation of myocardial blood flow (AQMBF), single- photon emission computed tomography (SPECT), with exercise or pharmacologic stress, and at rest, when performed (List separately in addition to code for primary procedure)
0743T	Bone strength and fracture risk usig finite element analysis of functional data and bone-mineral density, with concurrent vertebral fracture assessment, utilizing data from a computed tomography scan, retrieval and transmission of the scan data, measurement of bone strength and bone mineral density and classification of any vertebral fractures, with overall fracture risk assessment, interpretation and report
0744T	Insertion of bioprosthetic valve, open, femoral vein, including duplex ultrasound imaging guidance, when performed, including autogenous or nonautogenous patch graft (eg, polyester, ePTFE, bovine pericardium), when performed
0745T	Cardiac focal ablation utilizing radiation therapy for arrhythmia; noninvasive arrhythmia localization and mapping of arrhythmia site (nidus), derived from anatomical image data (eg, CT, MRI, or myocardial perfusion scan) and electrical data (eg, 12-lead ECG data), and identification of areas of avoidance
0746T	Cardiac focal ablation utilizing radiation therapy for arrhythmia; conversion of arrhythmia localization and mapping of arrhythmia site (nidus) into a multidimensional radiation treatment plan
0747T	Cardiac focal ablation utilizing radiation therapy for arrhythmia; delivery of radiation therapy, arrhythmia
0748T	Injections of stem cell product into perianal perifistular soft tissue, including fistula preparation (eg, removal of setons, fistula curettage, closure of internal openings)
0749Т	Bone strength and fracture-risk assessment using digital X-ray radiogrammetrybone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone strength and fracture-risk and BMD, interpretation and report
0750T	Bone strength and fracture-risk assessment using digital X-ray radiogrammetrybone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone strength and fracture-risk and BMD, interpretation and report; with single-view digital X-ray examination of the hand taken for the purpose of DXR-BMD

Page **59** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have
CPT®/HCPCS Code	been met. CPT®/HCPCS Code Description
0751T	Digitization of glass microscope slides for level II, surgical pathology,
0/311	gross and microscopic examination (List separately in addition to code
	for primary procedure)
0752T	Digitization of glass microscope slides for level III, surgical pathology,
0/321	gross and microscopic examination (List separately in addition to code
	for primary procedure)
0753T	Digitization of glass microscope slides for level IV, surgical pathology,
07331	gross and microscopic examination (List separately in addition to code
	for primary procedure)
0754T	Digitization of glass microscope slides for level V, surgical pathology,
07541	gross and microscopic examination (List separately in addition to code
	for primary procedure)
0755T	Digitization of glass microscope slide for level VI, surgical pathology,
3,331	gross and microscopic examination (List separately in addition to code
	for primary procedure)
0756T	Digitization of glass microscope slides for special stain, including
5,55.	interpretation and report, group I, for microorganisms (eg, acid fast,
	methenamine silver) (List separately in addition to code for primary
	procedure)
0757T	Digitization of glass microscope slides for special stain, including
	interpretation and report, group II, all other (eg, iron, trichrome),
	except stain for microorganisms, stains for enzyme constituents, or
	immunocytochemistry and immunohistochemistry (List separately in
	addition to code for primary procedure)
0758T	Digitization of glass microscope slides for special stain, including
	interpretation and report, histochemical stain on frozen tissue block
	(List separately in addition to code for primary procedure)
0759T	Digitization of glass microscope slides for special stain, including
	interpretation and report, group III, for enzyme constituents (List
	separately in addition to code for primary procedure)
0760T	Digitization of glass microscope slides for immunohistochemistry or
	immunocytochemistry, per specimen, initial single antibody stain
	procedure (List separately in addition to code for primary procedure)
0761T	Digitization of glass microscope slides for immunohistochemistry or
	immunocytochemistry, per specimen, each additional single antibody
	stain procedure (List separately in addition to code for primary
	procedure)
0762T	Digitization of glass microscope slides for immunohistochemistry or
	immunocytochemistry, per specimen, each multiplex antibody stain
	procedure (List separately in addition to code for primary procedure)
0763T	Digitization of glass microscope slides for morphometric analysis,
	tumor immunohistochemistry (eg, Her-2/neu, estrogen
	receptor/progesterone receptor), quantitative or semiquantitative,
	per specimen, each single antibody stain procedure, manual (List
	separately in addition to code for primary procedure)

Page **60** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0764T	Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to concurrently performed electrocardiogram (List separately in addition to code for primary procedure)
0765T	Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to previously performed electrocardiogram
0766T	Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; first nerve
0767T	Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; each additional nerve (List separately in addition to code for primary procedure)
0770T	Virtual reality technology to assist therapy (List separately in addition to code for primary procedure)
0771T	Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older
0772T	Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; each additional 15 minutes intraservice time (List separately in addition to code for primary service)
0773T	Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; initial 15 minutes of intraservice time, patient age 5 years or older

Page **61** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0774T	Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; each additional 15 minutes intraservice time (List separately in
	addition to code for primary service)
0776T	Therapeutic induction of intra-brain hypothermia, including placement of a mechanical temperature-controlled cooling device to the neck over carotids and head, including monitoring (eg, vital signs and sport concussion assessment tool 5 [SCAT5]), 30 minutes of treatment
0777T	Real-time pressure-sensing epidural guidance system (List separately in addition to code for primary procedure)
0778T	Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU) sensors for measurement of multijoint range of motion, posture, gait, and muscle function
0779T	Gastrointestinal myoelectrical activity study, stomach through colon, with interpretation and report
0780T	Instillation of fecal microbiota suspension via rectal enema into lower gastrointestinal tract
0781T	Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; bilateral mainstem bronchi
0782T	Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; unilateral mainstem bronchus
0783T	Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment
0790T	Revision (eg, augmentation, division of tether), replacement, or removal of thoracolumbar or lumbar vertebral body tethering, including thoracoscopy, when performed
0791T	Motor-cognitive, semi-immersive virtual reality-facilitated gait training, each 15 minutes (List separately in addition to code for primary procedure)
0792T	Application of silver diamine fluoride 38%, by a physician or other qualified health care professional
0793T	Percutaneous transcatheter thermal ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance
0794T	Patient-specific, assistive, rules-based algorithm for ranking pharmaco-oncologic treatment options based on the patient's tumor-specific cancer marker information obtained from prior molecular pathology, immunohistochemical, or other pathology results which have been previously interpreted and reported separately

Page **62** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have
CPT®/HCPCS Code	been met. CPT®/HCPCS Code Description
0795T	Transcatheter insertion of permanent dual-chamber leadless
07751	pacemaker, including imaging guidance (e.g., fluoroscopy, venous
	ultrasound, right atrial angiography, right ventriculography, femoral
	venography) and device evaluation (e.g., interrogation or
	programming), when performed; complete system (i.e., right atrial
	and right ventricular pacemaker components)
0796T	Transcatheter insertion of permanent dual-chamber leadless
	pacemaker, including imaging guidance (e.g., fluoroscopy, venous
	ultrasound, right atrial angiography, right ventriculography, femoral
	venography) and device evaluation (e.g., interrogation or
	programming), when performed; right atrial pacemaker component
	(when an existing right ventricular single leadless pacemaker exists to
	create a dual-chamber leadless pacemaker system)
0797T	Transcatheter insertion of permanent dual-chamber leadless
	pacemaker, including imaging guidance (e.g., fluoroscopy, venous
	ultrasound, right atrial angiography, right ventriculography, femoral
	venography) and device evaluation (e.g., interrogation or
	programming), when performed; right ventricular pacemaker
07007	component (when part of a dual-chamber leadless pacemaker system)
0798T	Transcatheter removal of permanent dual-chamber leadless
	pacemaker, including imaging guidance (e.g., fluoroscopy, venous
	ultrasound, right atrial angiography, right ventriculography, femoral
	venography), when performed; complete system (i.e., right atrial and right ventricular pacemaker components)
0799T	Transcatheter removal of permanent dual-chamber leadless
07771	pacemaker, including imaging guidance (e.g., fluoroscopy, venous
	ultrasound, right atrial angiography, right ventriculography, femoral
	venography), when performed; right atrial pacemaker component
0800T	Transcatheter removal of permanent dual-chamber leadless
	pacemaker, including imaging guidance (e.g., fluoroscopy, venous
	ultrasound, right atrial angiography, right ventriculography, femoral
	venography), when performed; right ventricular pacemaker
	component (when part of a dual-chamber leadless pacemaker system)
0801T	Transcatheter removal and replacement of permanent dual-chamber
	leadless pacemaker, including imaging guidance (e.g., fluoroscopy,
	venous ultrasound, right atrial angiography, right ventriculography,
	femoral venography) and device evaluation (e.g., interrogation or
	programming), when performed; dual-chamber system (i.e., right
00037	atrial and right ventricular pacemaker components)
0802T	Transcatheter removal and replacement of permanent dual-chamber
	leadless pacemaker, including imaging guidance (e.g., fluoroscopy,
	venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or
	programming), when performed; right atrial pacemaker component
	programming), when performed, right atrial pacemaker component

Page **63** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	The following codes will be considered investigational when applicable criteria have been met.	
CPT®/HCPCS Code	CPT®/HCPCS Code Description	
0803T	Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)	
0804T	Programming device evaluation (in person) with iterative adjustment of implantable device to test the function of device and to select optimal permanent programmed values, with analysis, review, and report, by a physician or other qualified health care professional, leadless pacemaker system in dual cardiac chambers	
0805T	Transcatheter superior and inferior vena cava prosthetic valve implantation (i.e., caval valve implantation [CAVI]); percutaneous femoral vein approach	
0806T	Transcatheter superior and inferior vena cava prosthetic valve implantation (i.e., caval valve implantation [CAVI]); open femoral vein approach	
080 <i>7</i> T	Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with previously acquired computed tomography (CT) images, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report	
0808T	Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with computed tomography (CT) images taken for the purpose of pulmonary tissue ventilation analysis, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report	
0811T	Remote multi-day complex uroflowmetry (eg, calibrated electronic equipment); setup and patient education on use of equipment	
0812T	Remote multi-day complex uroflowmetry (eg, calibrated electronic equipment); device supply with automated report generation, up to 10 days	
0813T	Esophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon	
0814T	Percutaneous injection of calcium-based biodegradable osteoconductive material, proximal femur, including imaging guidance, unilateral	
0815T	Ultrasound-based radiofrequency echographic multi-spectrometry (REMS), bonedensity study and fracture-risk assessment, 1 or more sites, hips, pelvis or spine	
0820T	Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; first physician or other qualified health care professional, each hour	

Page **64** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0821T	Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication
	therapy; second physician or other qualified health care professional, concurrent with first physician or other qualified health care
	professional, each hour
	(List separately in addition to code for primary procedure)
0822T	Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; clinical staff under the direction of a physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure)
0827T	Digitization of glass microscope slides for cytopathology, fluids,
00271	washings, or brushings, except cervical or vaginal; smears with interpretation (List separately in addition to code for primary procedure) (Use 0827T in conjunction with 88104)
0828T	Digitization of glass microscope slides for cytopathology, fluids, washings, or brushings, except cervical or vaginal; simple filter method with interpretation (List separately in addition to code for primary procedure) (Use 0828T in conjunction with 88106)
0829T	Digitization of glass microscope slides for cytopathology, concentration technique, smears, and interpretation (eg, Saccomanno technique) (List separately in addition to code for primary procedure) (Use 0829T in conjunction with 88108)
0830T	Digitization of glass microscope slides for cytopathology, selective-cellular enhancement technique with interpretation (eg, liquid-based slide preparation method), except cervical or vaginal (List separately in addition to code for primary procedure) (Use 0830T in conjunction with 88112)
0831T	Digitization of glass microscope slides for cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician (List separately in addition to code for primary procedure) (Use 0831T in conjunction with 88141)
0832T	Digitization of glass microscope slides for cytopathology, smears, any other source; screening and interpretation (List separately in addition to code for primary procedure) (Use 0832T in conjunction with 88160)
0833T	Digitization of glass microscope slides for cytopathology, smears, any other source; preparation, screening and interpretation (List separately in addition to code for primary procedure) (Use 0833T in conjunction with 88161)
0834T	Digitization of glass microscope slides for cytopathology, smears, any other source; extended study involving over 5 slides and/or multiple stains (List separately in addition to code for primary procedure) (Use 0834T in conjunction with 88162)

Page **65** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	The following codes will be considered investigational when applicable criteria have been met.	
CPT®/HCPCS Code		
0835T	Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site (List separately in addition to code for primary procedure) (Use 0835T in conjunction with 88172)	
0836T	Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, each separate additional evaluation episode, same site (List separately in addition to code for primary procedure) (Use 0836T in conjunction with 88177)	
0837T	Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; interpretation and report (List separately in addition to code for primary procedure) (Use 0837T in conjunction with 88173)	
0838T	Digitization of glass microscope slides for consultation and report on referred slides prepared elsewhere (List separately in addition to code for primary procedure) (Use 0838T in conjunction with 88321)	
0839T	Digitization of glass microscope slides for consultation and report on referred material requiring preparation of slides (List separately in addition to code for primary procedure) (Use 0839T in conjunction with 88323)	
0840T	Digitization of glass microscope slides for consultation, comprehensive, with review of records and specimens, with report on referred material (List separately in addition to code for primary procedure) (Use 0840T in conjunction with 88325)	
0841T	Digitization of glass microscope slides for pathology consultation during surgery; first tissue block, with frozen section(s), single specimen (List separately in addition to code for primary procedure) (Use 0841T in conjunction with 88331)	
0842T	Digitization of glass microscope slides for pathology consultation during surgery; each additional tissue block with frozen section(s) (List separately in addition to code for primary procedure) (Use 0842T in conjunction with 88332)	
0843T	Digitization of glass microscope slides for pathology consultation during surgery; cytologic examination (eg, touch preparation, squash preparation), initial site (List separately in addition to code for primary procedure) (Use 0843T in conjunction with 88333)	
0844T	Digitization of glass microscope slides for pathology consultation during surgery; cytologic examination (eg, touch preparation, squash preparation), each additional site (List separately in addition to code for primary procedure) (Use 0844T in conjunction with 88334)	
0845T	Digitization of glass microscope slides for immunofluorescence, per specimen; initial single antibody stain procedure (List separately in addition to code for primary procedure) (Use 0845T in conjunction with 88346)	

Page **66** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0846T	Digitization of glass microscope slides for immunofluorescence, per
00101	specimen; each additional single antibody stain procedure (List
	separately in addition to code for primary procedure)
	(Use 0846
	Cystourethroscopy, with urethral mechanical dilation and drug delivery
	by drug-coated balloon catheter
	T in conjunction with 88350)
0847T	Digitization of glass microscope slides for examination and selection of
	retrieved archival (ie, previously diagnosed) tissue(s) for molecular
	analysis (eg, KRAS mutational analysis) (List separately in addition to
	code for primary procedure) (Use 0847T in conjunction with 88363)
0848T	Digitization of glass microscope slides for in situ hybridization (eg,
	FISH), per specimen; initial single probe stain procedure (List
	separately in addition to code for primary procedure) (Use 0848T in
	conjunction with 88365)
0849T	Digitization of glass microscope slides for in situ hybridization (eg,
	FISH), per specimen; each additional single probe stain procedure
	(List separately in addition to code for primary procedure) (Use 0849T
	in conjunction with 88364)
0850T	Digitization of glass microscope slides for in situ hybridization (eg,
	FISH), per specimen; each multiplex probe stain procedure (List
	separately in addition to code for primary procedure)
	(Use 0850T in conjunction with 88366)
0851T	Digitization of glass microscope slides for morphometric analysis, in
	situ hybridization (quantitative or semiquantitative), manual, per
	specimen; initial single probe stain procedure (List separately in
	addition to code for primary procedure) (Use 0851T in conjunction
	with 88368)
0852T	Digitization of glass microscope slides for morphometric analysis, in
	situ hybridization (quantitative or semiquantitative), manual, per
	specimen; each additional single probe stain procedure (List
	separately in addition to
	code for primary procedure)
	(Use 0852T in conjunction with 88369)
0853T	Digitization of glass microscope slides for morphometric analysis, in
	situ hybridization (quantitative or semiquantitative), manual, per
	specimen; each multiplex probe stain procedure (List separately in
	addition to code for primary procedure) (Use 0853T in conjunction
00F 4T	with 88377)
0854T	Digitization of glass microscope slides for blood smear, peripheral,
	interpretation by physician with written report (List separately in
	addition to code for primary procedure)
COEET	(Use 0854T in conjunction with 85060)
0855T	Digitization of glass microscope slides for bone marrow, smear
	interpretation (List separately in addition to code for primary
OOF4T	procedure) (Use 0855T in conjunction with 85097)
0856T	Digitization of glass microscope slides for electron microscopy,
	diagnostic (List separately in addition to code for primary procedure)
	(Use 0856T in conjunction with 88348)

Page **67** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0857T	Opto-acoustic imaging, breast, unilateral, including axilla when performed, realtime with image documentation, augmentative analysis and report (List separately in addition to code for primary procedure) (Use 0857T in conjunction with 76641, 76642)
0858T	Externally applied transcranial magnetic stimulation with concomitant measurement of evoked cortical potentials with automated report (Do not report 0858T in conjunction with 95836, 95957, 95961, 95965, 95966)
0859T	Noncontact near-infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), other than for screening for peripheral arterial disease, image acquisition, interpretation, and report; each additional anatomic site (List separately in addition to code for primary procedure)
0860T	Noncontact near-infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), for screening for peripheral arterial disease, including provocative maneuvers, image acquisition, interpretation, and report, one or both lower extremities
0861T	Removal of pulse generator for wireless cardiac stimulator for left ventricular pacing; both components (battery and transmitter)
0862T	Relocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; battery component only
0863T	Relocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; transmitter component only
0864T	Low-intensity extracorporeal shock wave therapy involving corpus cavernosum, low energy (Do not report 0864T in conjunction with 0101T when treating the same area)
0865T	Quantitative magnetic resonance image (MRI) analysis of the brain with comparison to prior magnetic resonance (MR) study(ies), including lesion identification, characterization, and quantification, with brain volume(s) quantification and/or severity score, when performed, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the brain during the same session (Do not report 0865T in conjunction with 70551, 70552, 70553)
0866T	Quantitative magnetic resonance image (MRI) analysis of the brain with comparison to prior magnetic resonance (MR) study(ies), including lesion detection, characterization, and quantification, with brain volume(s) quantification and/or severity score, when performed, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the brain (List separately in addition to code for primary procedure) (Use 0866T in conjunction with 70551, 70552, 70553)
0867T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50 mL

Page **68** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0868T	High-resolution gastric electrophysiology mapping with simultaneous patient-symptom profiling, with interpretation and report
0870T	Implantation of subcutaneous peritoneal ascites pump system, percutaneous, including pump-pocket creation, insertion of tunneled indwelling bladder and peritoneal catheters with pump connections,
0871T	including all imaging and initial programming, when performed Replacement of a subcutaneous peritoneal ascites pump, including reconnection between pump and indwelling bladder and peritoneal
0872T	catheters, including initial programming and imaging, when performed Replacement of indwelling bladder and peritoneal catheters, including tunneling of catheter(s) and connection with previously implanted peritoneal ascites pump, including imaging and programming, when performed
0873T	Revision of a subcutaneously implanted peritoneal ascites pump system, any component (ascites pump, associated peritoneal catheter, associated bladder catheter), including imaging and programming, when performed
0874T	Removal of a peritoneal ascites pump system, including implanted peritoneal ascites pump and indwelling bladder and peritoneal catheters
0875T	Programming of subcutaneously implanted peritoneal ascites pump system by physician or other qualified health care professional
0876T	Duplex scan of hemodialysis fistula, computer-aided, limited (volume flow, diameter, and depth, including only body of fistula)
0877T	Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging
0878T	Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structure
0879T	Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmission
0880T	Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and report
0881T	Cryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance to treatment, and removal of the oral device
0882T	Intraoperative therapeutic electrical stimulation of peripheral nerve to promote nerve regeneration, including lead placement and removal, upper extremity, minimum of 10 minutes; initial nerve (List separately in addition to code for primary procedure)

Page **69** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0883T	Intraoperative therapeutic electrical stimulation of peripheral nerve
00031	to promote nerve regeneration, including lead placement and
	removal, upper extremity, minimum of 10 minutes; each additional
	nerve (List separately in addition to code for primary procedure)
0884T	Esophagoscopy, flexible, transoral, with initial transendoscopic
00041	mechanical dilation (eg, nondrug-coated balloon) followed by
	therapeutic drug delivery by drug-coated balloon catheter for
	esophageal stricture, including fluoroscopic guidance, when
	performed
0885T	Colonoscopy, flexible, with initial transendoscopic mechanical dilation
00001	(eg, nondrug-coated balloon) followed by therapeutic drug delivery by
	drug-coated balloon catheter for colonic stricture, including
	fluoroscopic guidance, when performed
0886T	Sigmoidoscopy, flexible, with initial transendoscopic mechanical
	dilation (eg, nondrug-coated balloon) followed by therapeutic drug
	delivery by drug-coated balloon catheter for colonic stricture,
	including fluoroscopic guidance, when performed
0887T	End-tidal control of inhaled anesthetic agents and oxygen to assist
	anesthesia care delivery (List separately in addition to code for
	primary procedure)
0888T	Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of
	malignant renal tissue, including imaging guidance
0889T	Personalized target development for accelerated, repetitive high-dose
	functional connectivity MRI-guided theta-burst stimulation derived
	from a structural and resting-state functional MRI, including data
	preparation and transmission, generation of the target, motor
	threshold-starting location, neuronavigation files and target report,
	review and interpretation
0890T	Accelerated, repetitive high-dose functional connectivity MRI-guided
	theta-burst stimulation, including target assessment, initial motor
	threshold determination, neuronavigation, delivery and management,
	initial treatment day
0891T	Accelerated, repetitive high-dose functional connectivity MRI-guided
	theta-burst stimulation, including neuronavigation, delivery and
	management, subsequent treatment day
0892T	Accelerated, repetitive high-dose functional connectivity MRI-guided
	theta-burst stimulation, including neuronavigation, delivery and
	management, subsequent motor threshold redetermination with
	delivery and management, per treatment day
0893T	Noninvasive assessment of blood oxygenation, gas exchange
	efficiency, and cardiorespiratory status, with physician or other
	qualified health care professional interpretation and report
0894T	Cannulation of the liver allograft in preparation for connection to the
	normothermic perfusion device and decannulation of the liver
	allograft following normothermic perfusion

Page **70** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0895T	Connection of liver allograft to normothermic machine perfusion
00751	device, hemostasis control; initial 4 hours of monitoring time,
	including hourly physiological and laboratory assessments (eg,
	perfusate temperature, perfusate pH, hemodynamic parameters, bile
	production, bile pH, bile glucose, biliary bicarbonate, lactate levels,
	macroscopic assessment)
0896T	Connection of liver allograft to normothermic machine perfusion
	device, hemostasis control; each additional hour, including
	physiological and laboratory assessments (eg, perfusate temperature,
	perfusate pH, hemodynamic parameters, bile production, bile pH, bile
	glucose, biliary bicarbonate, lactate levels, macroscopic assessment)
	(List separately in addition to code for primary procedure)
0897T	Noninvasive augmentative arrhythmia analysis derived from
	quantitative computational cardiac arrhythmia simulations, based on
	selected intervals of interest from 12-lead electrocardiogram and
	uploaded clinical parameters, including uploading clinical parameters
	with interpretation and report
0898T	Noninvasive prostate cancer estimation map, derived from
	augmentative analysis of image-guided fusion biopsy and pathology,
	including visualization of margin volume and location, with margin
	determination and physician interpretation and report
0899T	Noninvasive determination of absolute quantitation of myocardial
	blood flow (AQMBF), derived from augmentative algorithmic analysis
	of the dataset acquired via contrast cardiac magnetic resonance
	(CMR), pharmacologic stress, with interpretation and report by a
	physician or other qualified health care professional (List separately in
0000T	addition to code for primary procedure)
0900T	Noninvasive estimate of absolute quantitation of myocardial blood
	flow (AQMBF), derived from assistive algorithmic analysis of the dataset acquired via contrast cardiac magnetic resonance (CMR),
	pharmacologic stress, with interpretation and report by a physician or
	other qualified health care professional (List separately in addition to
	code for primary procedure)
0901T	Placement of bone marrow sampling port, including imaging guidance
0,011	when performed
0902T	QTc interval derived by augmentative algorithmic analysis of input
0,02.	from an external, patient-activated mobile ECG device
0903T	Electrocardiogram, algorithmically generated 12-lead ECG from a
·	reduced-lead ECG; with interpretation and report
0904T	Electrocardiogram, algorithmically generated 12-lead ECG from a
	reduced-lead ECG; tracing only
0905T	Electrocardiogram, algorithmically generated 12-lead ECG from a
	reduced-lead ECG; interpretation and report only
0906T	Concurrent optical and magnetic stimulation (COMS) therapy, wound
	assessment and dressing care; first application, total wound(s) surface
	area less than or equal to 50 sq cm

Page **71** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

	The following codes will be considered investigational when applicable criteria have been met.	
CPT®/HCPCS Code	CPT®/HCPCS Code Description	
0907T	Concurrent optical and magnetic stimulation (COMS) therapy, wound assessment and dressing care; each additional application, total wound(s) surface area less than or equal to 50 sq cm (List separately	
	in addition to code for primary procedure)	
0908T	Open implantation of integrated neurostimulation system, vagus	
0,001	nerve, including analysis and programming, when performed	
0909T	Replacement of integrated neurostimulation system, vagus nerve,	
	including analysis and programming, when performed	
0910T	Removal of integrated neurostimulation system, vagus nerve	
0911T	Electronic analysis of implanted integrated neurostimulation system, vagus nerve; without programming by physician or other qualified health care professional	
0912T	Electronic analysis of implanted integrated neurostimulation system, vagus nerve; with simple programming by physician or other qualified health care professional	
0913T	Percutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon (eg, drug-coated, drug-eluting), including mechanical dilation by nondrug-delivery balloon angioplasty, endoluminal imaging using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) when performed, imaging supervision, interpretation, and report, single major coronary artery or branch	
0914T	Percutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon (eg, drug-coated, drug-eluting) performed on a separate target lesion from the target lesion treated with balloon angioplasty, coronary stent placement or coronary atherectomy, including mechanical dilation by nondrug-delivery balloon angioplasty, endoluminal imaging using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) when performed, imaging supervision, interpretation, and report, single major coronary artery or branch (List separately in addition to code for percutaneous coronary stent or atherectomy intervention)	
0915T	Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; pulse generator and dual transvenous electrodes/leads (pacing and defibrillation)	
0916T	Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; pulse generator only	
0917T	Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; single transvenous lead (pacing or defibrillation) only	
0918T	Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; dual transvenous leads (pacing and defibrillation) only	

Page **72** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0919T	Removal of a permanent cardiac contractility modulation- defibrillation system component(s); pulse generator only
0920T	Removal of a permanent cardiac contractility modulation- defibrillation system component(s); single transvenous pacing lead only
0921T	Removal of a permanent cardiac contractility modulation- defibrillation system component(s); single transvenous defibrillation lead only
0922T	Removal of a permanent cardiac contractility modulation- defibrillation system component(s); dual (pacing and defibrillation) transvenous leads only
0923T	Removal and replacement of permanent cardiac contractility modulation-defibrillation pulse generator only
0924T	Repositioning of previously implanted cardiac contractility modulation-defibrillation transvenous electrode(s)/lead(s), including fluoroscopic guidance and programming of sensing and therapeutic parameters
0925T	Relocation of skin pocket for implanted cardiac contractility modulation-defibrillation pulse generator
0926T	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation-defibrillation system
0927T	Interrogation device evaluation (in person) with analysis, review, and report, including connection, recording, and disconnection, per patient encounter, implantable cardiac contractility modulation-defibrillation system
0928T	Interrogation device evaluation (remote), up to 90 days, cardiac contractility modulation-defibrillation system with interim analysis and report(s) by a physician or other qualified health care professional
0929T	Interrogation device evaluation (remote), up to 90 days, cardiac contractility modulation-defibrillation system, remote data acquisition(s), receipt of transmissions, technician review, technical support, and distribution of results
0930T	Electrophysiologic evaluation of cardiac contractility modulation-defibrillator leads, including defibrillation-threshold evaluation (induction of arrhythmia, evaluation of sensing and therapy for arrhythmia termination), at time of initial implantation or replacement with testing of cardiac contractility modulation-defibrillator pulse generator
0931T	Electrophysiologic evaluation of cardiac contractility modulation-defibrillator leads, including defibrillation-threshold evaluation (induction of arrhythmia, evaluation of sensing and therapy for arrhythmia termination), separate from initial implantation or replacement with testing of cardiac contractility modulation-defibrillator pulse generator

Page **73** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0932T	Noninvasive detection of heart failure derived from augmentative
07321	analysis of an echocardiogram that demonstrated preserved ejection
	fraction, with interpretation and report by a physician or other
	qualified health care professional
0933T	Transcatheter implantation of wireless left atrial pressure sensor for
	long-term left atrial pressure monitoring, including sensor calibration
	and deployment, right heart catheterization, transseptal puncture,
	imaging guidance, and radiological supervision and interpretation
0934T	Remote monitoring of a wireless left atrial pressure sensor for up to
	30 days, including data from daily uploads of left atrial pressure
	recordings, interpretation(s) and trend analysis, with adjustments to
	the diuretics plan, treatment paradigm thresholds, medications or
	lifestyle modifications, when performed, and report(s) by a physician
	or other qualified health care professional
0935T	Cystourethroscopy with renal pelvic sympathetic denervation,
	radiofrequency ablation, retrograde ureteral approach, including
	insertion of guide wire, selective placement of ureteral sheath(s) and
	multiple conformable electrodes, contrast injection(s), and
	fluoroscopy, bilateral
0936T	Photobiomodulation therapy of retina, single session
0937T	External electrocardiographic recording for greater than 15 days up to
	30 days by continuous rhythm recording and storage; including
	recording, scanning analysis with report, review and interpretation by
	a physician or other qualified health care professional
0938T	External electrocardiographic recording for greater than 15 days up to
	30 days by continuous rhythm recording and storage; recording
	(including connection and initial recording)
0939T	External electrocardiographic recording for greater than 15 days up to
	30 days by continuous rhythm recording and storage; scanning analysis
	with report
0940T	External electrocardiographic recording for greater than 15 days up to
	30 days by continuous rhythm recording and storage; review and
	interpretation by a physician or other qualified health care
2211	professional
0941T	Cystourethroscopy, flexible; with insertion and expansion of prostatic
00.42T	urethral scaffold using integrated cystoscopic visualization
0942T	Cystourethroscopy, flexible; with removal and replacement of
00.43T	prostatic urethral scaffold
0943T	Cystourethroscopy, flexible; with removal of prostatic urethral
0044T	scaffold 2D contour simulation of target liver losion(s) and margin(s) for image
0944T	3D contour simulation of target liver lesion(s) and margin(s) for image-
00457	guided percutaneous microwave ablation
0945T	Intraoperative assessment for abnormal (tumor) tissue, in-vivo,
	following partial mastectomy (eg, lumpectomy) using computer-aided
	fluorescence imaging (List separately in addition to code for primary
	procedure)

Page **74** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following c	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0946T	Orthopedic implant movement analysis using paired computed
·	tomography (CT) examination of the target structure, including data
	acquisition, data preparation and transmission, interpretation and
	report (including CT scan of the joint or extremity performed with
	paired views)
0947T	Magnetic resonance image guided low intensity focused ultrasound
	(MRgFUS), stereotactic blood-brain barrier disruption using
	microbubble resonators to increase the concentration of blood-based
	biomarkers of target, intracranial, including stereotactic navigation
	and frame placement, when performed
0948T	"Interrogation device evaluation (remote), up to 90 days, cardiac
	contractility modulation system with interim analysis, review and
	report(s) by a physician or
	other qualified health care professional"
0949T	"Interrogation device evaluation (remote), up to 90 days, cardiac
	contractility modulation system, remote data acquisition(s), receipt of
	transmissions, technician
	review, technical support, and distribution of results"
0950T	Ablation of benign prostate tissue, transrectal, with high intensity-
	focused ultrasound (HIFU), including ultrasound guidance
	► (For ablation of malignant prostate tissue, transrectal, with high
	intensity-focused ultrasound [HIFU], including ultrasound guidance,
	use 55880)
0951T	Totally implantable active middle ear hearing implant; initial
	placement, including mastoidectomy, placement of and attachment to
	sound processor
0952T	Totally implantable active middle ear hearing implant; revision or
	replacement, with mastoidectomy and replacement of sound
	processor
0953T	Totally implantable active middle ear hearing implant; revision or
	replacement, without mastoidectomy and replacement of sound
	processor
0954T	Totally implantable active middle ear hearing implant; replacement of
	sound processor only, with attachment to existing transducers
0955T	Totally implantable active middle ear hearing implant; removal,
	including removal of sound processor and all implant components
0956T	"Partial craniectomy, channel creation, and tunneling of electrode for
	sub-scalp implantation of an electrode array, receiver, and telemetry
	unit for continuous
	bilateral electroencephalography monitoring system, including
	imaging guidance"
0957T	Revision of sub-scalp implanted electrode array, receiver, and
	telemetry unit for electrode, when required, including imaging
	guidance
	(Do not report 0957T in conjunction with 0958T, 0960T)
0958T	Removal of sub-scalp implanted electrode array, receiver, and
	telemetry unit for continuous bilateral electroencephalography
	monitoring system, including imaging guidance
	► (Do not report 0958T in conjunction with 0957T, 0960T)

Page **75** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
0959T	Removal or replacement of magnet from coil assembly that is
	connected to continuous bilateral electroencephalography monitoring
	system, including imaging guidance
0960T	"Replacement of sub-scalp implanted electrode array, receiver, and
	telemetry unit with tunneling of electrode for continuous bilateral
	electroencephalography monitoring system, including imaging
	guidance
00/4T	► (Do not report 0960T in conjunction with 0957T, 0958T)"
0961T	"Shortwave infrared radiation imaging, surgical pathology specimen, to assist gross examination for lymph node localization in fibroadipose
	tissue, per specimen (List separately in addition to code for primary
	procedure)
	► (Use 0961T in conjunction with 88307, 88309)
	► (Do not report more than 1 unit of 0961T for each specimen)"
0962T	Assistive algorithmic analysis of acoustic and electrocardiogram
	recording for detection of cardiac dysfunction (eg, reduced ejection
	fraction, cardiac murmurs, atrial fibrillation), with review and
	interpretation by a physician or other qualified health care
2012	professional
0963T	Anoscopy with directed submucosal injection of bulking agent into
	anal canal ▶ (Do not report 0963T in conjunction with 46600) ◀
0964T	Impression and custom preparation of jaw expansion oral prosthesis
07041	for obstructive sleep apnea, including initial adjustment; single arch,
	without mandibular advancement mechanism
0965T	Impression and custom preparation of jaw expansion oral prosthesis
	for obstructive sleep apnea, including initial adjustment; dual arch,
	with additional mandibular advancement, non-fixed hinge mechanism
0966T	Impression and custom preparation of jaw expansion oral prosthesis
	for obstructive sleep apnea, including initial adjustment; dual arch,
2247	with additional mandibular advancement, fixed hinge mechanism
0967T	Transanal insertion of endoluminal temporary colorectal anastomosis
	protection device, including vacuum anchoring component and flexible sheath connected to external vacuum source and monitoring
	system
0968T	"Insertion or replacement of epicranial neurostimulator system,
	including electrode array and pulse generator, with connection to
	electrode array
	► (For insertion of cranial neurostimulator pulse generator or receiver
	other than
	skull mounted, see 61885, 61886)
	► (For revision of cranial neurostimulator pulse generator or receiver
	other than
	skull mounted, use 61888) • (For insertion of skull-mounted cranial neurostimulator pulse
	generator or
	receiver, use 61889)"
	receiver, use 01007)

Page **76** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following codes will be considered investigational when applicable criteria have been met.	
CPT®/HCPCS Code	
0969T	"Removal of epicranial neurostimulator system
	► (For removal of cranial neurostimulator pulse generator or receiver
	other than
	skull mounted, use 61888)
	► (For removal of skull-mounted cranial neurostimulator pulse
	generator or
	receiver, use 61892)"
0970T	"Ablation, benign breast tumor (eg, fibroadenoma), percutaneous,
	laser, including imaging guidance when performed, each tumor
	► (Do not report 0970T in conjunction with 76641, 76642, 76940,
	76942)
	► (Report 0970T only once per tumor)
	► (For cryosurgical ablation of fibroadenoma, use 19105)
	► (For cryoablation of malignant breast tumor[s], use 0581T)
	► (For laser ablation of malignant breast tumor[s], use 0971T)"
0971T	"Ablation, malignant breast tumor(s), percutaneous, laser, including
	imaging guidance when performed, unilateral
	▶ (Do not report 0971T in conjunction with 76641, 76642, 76940,
	76942)
	► (Report 0971T only once per breast)
	► (For cryoablation of breast fibroadenoma[s], use 19105)
	► (For cryosurgical ablation of malignant breast tumor[s], use 0581T)
	► (For laser ablation of benign breast tumor, use 0970T)"
0972T	"Assistive algorithmic classification of burn healing (ie, healing or
	nonhealing) by noninvasive multispectral imaging, including system
	set-up and acquisition,
	selection, and transmission of images, with automated generation of report"
0973T	"Selective enzymatic debridement, partial-thickness and/or full-
09/31	thickness burn eschar, requiring anesthesia (ie, general anesthesia,
	moderate sedation), including
	patient monitoring, trunk, arms, legs; first 100 sq cm"
0974T	"Selective enzymatic debridement, partial-thickness and/or full-
07741	thickness burn eschar, requiring anesthesia (ie, general anesthesia,
	moderate sedation), including
	patient monitoring, trunk, arms, legs; each additional 100 sq cm (List
	separately in addition to code for primary procedure)
	► (Use 0974T in conjunction with 0973T)
	► (Do not report 0973T, 0974T in conjunction with 11042, 11043,
	11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic
	debridement of the same wound during the same session)
	► (For nonselective enzymatic debridement, use 97602)"
0975T	"Selective enzymatic debridement, partial-thickness and/or full-
	thickness burn eschar, requiring anesthesia (ie, general anesthesia,
	moderate sedation), including
	patient monitoring, scalp, neck, hands, feet, and/or multiple digits;
	first 100 sq cm"

Page **77** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following codes will be considered investigational when applicable criteria have been met.	
CPT®/HCPCS Code	
0976T	"Selective enzymatic debridement, partial-thickness and/or full-
	thickness burn eschar, requiring anesthesia (ie, general anesthesia,
	moderate sedation), including
	patient monitoring, scalp, neck, hands, feet, and/or multiple digits;
	each additional 100 sq cm (List separately in addition to code for
	primary procedure)
	► (Use 0976T in conjunction with 0975T)
	► (Do not report 0975T, 0976T in conjunction with 11042, 11043,
	11044, 11045, 11046, 11047, 97597, 97598, for selective enzymatic
	debridement of the same wound during the same session)
0977T	► (For nonselective enzymatic debridement, use 97602)" "Upper gastrointestinal blood detection, sensor capsule, with
09//1	interpretation and
	report"
0978T	Submucosal cryolysis therapy; soft palate, base of tongue, and lingual
67761	tonsil
0979T	Submucosal cryolysis therapy; soft palate only
0980T	Submucosal cryolysis therapy; base of tongue, and lingual tonsil only
	► (Do not report 0979T, 0980T in conjunction with 0978T)
0981T	"Transcatheter implantation of wireless inferior vena cava sensor for
	long-term hemodynamic monitoring, including deployment of the
	sensor, radiological
	supervision and interpretation, right heart catheterization, and
	inferior vena cava venography, when performed ► (Do not report 0981T in conjunction with 36010, 36013, 37252,
	37253, 75825, 76000, 93451, 93453, 93456, 93460, 93461, 93566,
	93593, 93594, 93596, 93597)
	► (For implantation of wireless pulmonary artery sensor, use 33289)
	► (For remote monitoring of an implantable inferior vena cava
	pressure sensor,
	use 0982T)"
0982T	"Remote monitoring of implantable inferior vena cava pressure sensor,
	physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry,
	respiratory flow rate),
	initial set-up and patient education on use of equipment
	(Do not report 0982T more than once per episode of care)
0983T	► (Do not report 0982T for monitoring of less than 16 days)" "Remote monitoring of an implanted inferior vena cava sensor for up
07031	to 30 days, including at least weekly downloads of inferior vena cava
	area recordings,
	interpretation(s), trend analysis, and report(s) by a physician or other
	qualified health care professional ► (Report 0983T only once per 30
	days)"

Page **78** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
0984T	"Intravascular imaging of extracranial cerebral vessels using optical
	coherence tomography (OCT) during diagnostic evaluation and/or
	therapeutic intervention, including all associated radiological
	supervision, interpretation, and report; initial vessel (List separately
	in addition to code for primary procedure)
	► (Use 0984T in conjunction with 36221, 36222, 36225, 36226, 37215,
	37216)
00057	► (Report 0984T once per session)"
0985T	"Intravascular imaging of extracranial cerebral vessels using optical
	coherence tomography (OCT) during diagnostic evaluation and/or
	therapeutic intervention, including all associated radiological supervision, interpretation, and report; each additional vessel (List
	separately in addition to code for primary
	procedure)
	► (Use 0985T in conjunction with 0984T)"
0986T	"Intravascular imaging of intracranial cerebral vessels using optical
	coherence tomography (OCT) during diagnostic evaluation and/or
	therapeutic intervention,
	including all associated radiological supervision, interpretation, and
	report; initial vessel (List separately in addition to code for primary
	procedure) ► (Use 0986T in conjunction with 36223, 36224,
	36225, 36226, 61624, 61630, 61635, 61640, 61645, 61650)
20077	► (Report 0986T once per session)"
0987T	"Intravascular imaging of intracranial cerebral vessels using optical
	coherence tomography (OCT) during diagnostic evaluation and/or therapeutic intervention,
	including all associated radiological supervision, interpretation, and
	report; each additional vessel (List separately in addition to code for
	primary procedure ► (Use 0987T in conjunction with 0986T)"
15011	Harvest of skin for autograft; first
15012	Harvest of skin for autograft; each additional 25 sq cm
15013	Preparation of skin autograft, requiring enzymatic processing,; first 25
	sq cm or less
15014	Preparation of skin autograft, requiring enzymatic processing,; each
	additional 25 sq cm
15015	Application of skin autograft; first 480 sq cm or less
15016	Application of skin autograft; each additional 480 sq cm
15017	Application of skin autograft; first 480 sq cm or less
15018	Application of skin autograft; each additional 480 sq cm
20560	Needle insertion(s) without injection(s); 1 or 2 muscle(s)
20561	Needle insertion(s) without injection(s); 3 or more muscles
22526	Percutaneous intradiscal electrothermal annuloplasty, unilateral or
22527	bilateral including fluoroscopic guidance; single level
22527	Percutaneous intradiscal electrothermal annuloplasty, unilateral or
	bilateral including fluoroscopic guidance; 1 or more additional levels (List separately in addition to code for primary procedure)
22836	Vertebral body tethering; up to 7 vertebral segments
22837	Vertebral body tethering; 8 or more vertebral segments
22037	vertebrat body tetriering, o or more vertebrat segments

Page **79** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
22838	Revision, replacement, or removal of vertebral body
	tethering
22857	Total disc arthroplasty (artificial disc), anterior approach, including
	discectomy to prepare interspace (other than for decompression), single
	interspace, lumbar
22860	Total disc arthroplasty, anterior approach, including discectomy; second lumbar interspace
22862	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, single interspace; lumbar
22867	Insertion of interlaminar/interspinous process stabilization/distraction
	device, without fusion, including image guidance when performed, with
	open decompression, lumbar; single level
22868	Insertion of interlaminar/interspinous process stabilization/distraction
	device, without fusion, including image guidance when performed, with
	open decompression, lumbar; second level (List separately in addition to
	code for primary procedure)
22869	Insertion of interlaminar/interspinous process stabilization/distraction
	device, without open decompression or fusion, including image guidance
22070	when performed, lumbar; single level
22870	Insertion of interlaminar/interspinous process stabilization/distraction
	device, without open decompression or fusion, including image guidance when performed, lumbar; second level (List separately in addition to code
	for primary procedure)
27278	Arthrodesis, sacroiliac joint, percutaneous, with image guidance,
ZIZIO	including placement of intra-articular implant(s) (eg, bone allograft[s],
	synthetic device[s]), without placement of transfixation device
28890	Extracorporeal shock wave, high energy, performed by a physician or
·	other qualified health care professional, requiring anesthesia other than
	local, including ultrasound guidance, involving the plantar fascia
30468	Repair of nasal valve collapse with subcutaneous/submucosal lateral wall implant(s)
30469	Nasal valve collapse repair using low energy, temperature-controlled
	remodeling
31242	Surgical nasal/sinus endoscopy; radiofrequency ablation, posterior
	nasal nerve
31243	Surgical nasal/sinus endoscopy; cryoablation, posterior nasal nerve
31647	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when
	performed; with balloon occlusion, when performed, assessment of air
21212	leak, airway sizing, and insertion of bronchial valve(s), initial lobe
31648	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when
247.40	performed; with removal of bronchial valve(s), initial lobe
31649	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when
	performed; with removal of bronchial valve(s), each additional lobe (List
31651	separately in addition to code for primary procedure) Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when
31031	performed; with balloon occlusion, when performed, assessment of air
	leak, airway sizing, and insertion of bronchial valve(s), each additional
	lobe (List separately in addition to code for primary procedure[s])
	tobe (List separately in addition to code for primary procedure[s])

Page **80** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
31660	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when
	performed; with bronchial thermoplasty, 1 lobe
31661	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when
	performed; with bronchial thermoplasty, 2 or more lobes
33275	Transcatheter removal of permanent leadless pacemaker, right
	ventricular, including imaging guidance (eg, fluoroscopy, venous
	ultrasound, ventriculography, femoral venography), when performed
33276	Phrenic nerve stimulator system placement, initial analysis with
	diagnostic mode activation, when performed
33277	Phrenic nerve stimulator transvenous lead placement (List separately in
22272	addition to code for primary procedure)
33278	Phrenic nerve stimulator removal
33279	Phrenic nerve stimulator removal; transvenous stimulation or sensing
33280	lead(s) only
33281	Phrenic nerve stimulator removal; pulse generator only
33287	Phrenic nerve stimulator transvenous lead repositioning
33288	Phrenic nerve stimulator, removal and replacement; pulse generator
33200	Phrenic nerve stimulator removal and replacement; transvenous stimulation or sensing lead
33289	Transcatheter implantation of wireless pulmonary artery pressure sensor
33207	for long-term hemodynamic monitoring, including deployment and
	calibration of the sensor, right heart catheterization, selective pulmonary
	catheterization, radiological supervision and interpretation, and
	pulmonary artery angiography, when performed
33370	Transcatheter placement and subsequent removal of cerebral embolic
	protection device(s), including arterial access, catheterization, imaging,
	and radiological supervision and interpretation, percutaneous (List
	separately in addition to code for primary procedure)
33548	Surgical ventricular restoration procedure, includes prosthetic patch,
	when performed (eg, ventricular remodeling, SVR, SAVER, Dor
24.772	procedures)
36473	Endovenous ablation therapy of incompetent vein, extremity, inclusive
	of all imaging guidance and monitoring, percutaneous, mechanochemical; first vein treated
26.474	·
36474	Subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)
36836	Upper extremity, single access percutaneous arteriovenous fistula
30030	creation
36837	Upper extremity, separate access percutaneous arteriovenous fistula
	creation
41512	Tongue base suspension, permanent suture technique
43206	Esophagoscopy, flexible, transoral; with optical endomicroscopy
43252	Esophagogastroduodenoscopy, flexible, transoral; with optical
	endomicroscopy
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure,
	placement of sphincter augmentation device (ie, magnetic band),
	including cruroplasty when performed
43285	Removal of esophageal sphincter augmentation device

Page **81** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
43290	Esophagogastroduodenoscopy, with deployment of balloon
43291	Esophagogastroduodenoscopy, with removal of balloon
43497	Lower esophageal myotomy, transoral (ie, peroral endoscopic myotomy
13 177	[POEM])
43647	Laparoscopy, surgical; implantation or replacement of gastric
	neurostimulator electrodes, antrum
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator
	electrodes, antrum
43881	Implantation or replacement of gastric neurostimulator electrodes,
	antrum, open
43882	Revision or removal of gastric neurostimulator electrodes, antrum, open
46707	Repair of anorectal fistula with plug (eg, porcine small intestine submucosa [SIS])
47371	Laparoscopy, surgical, ablation of 1 or more liver tumor(s);
	cryosurgical
47381	Ablation, open, of 1 or more liver tumor(s); cryosurgical
47383	Ablation, 1 or more liver tumor(s), percutaneous, cryoablation
51721	Transurethral ablation transducer insertion for delivery of thermal
	ultrasound for prostate
52284	Cystourethroscopy, with urethral mechanical dilation and drug delivery
	by drug-coated balloon catheter
53451	Periurethral transperineal adjustable balloon continence device;
	bilateral insertion, including cystourethroscopy and imaging guidance
53452	Periurethral transperineal adjustable balloon continence device;
E2.4E2	unilateral insertion, including cystourethroscopy and imaging guidance
53453	Periurethral transperineal adjustable balloon continence device;
F24F4	removal, each balloon
53454	Periurethral transperineal adjustable balloon continence device; percutaneous adjustment of balloon(s) fluid volume
53865	Insertion of temporary device with cystourethroscopy for ischemic
33003	remodeling of bladder neck and prostate
53866	Catheterization with removal of temporary device for ischemic
33000	remodeling of bladder neck and prostate
55880	Ablation of malignant prostate tissue, transrectal, with high intensity-
	focused ultrasound (HIFU), including ultrasound guidance
55881	Transurethral ablation of prostate tissue, using thermal ultrasound
55882	Transurethral ablation of prostate tissue, using thermal ultrasound; with
	insertion of ultrasound transducer
60660	Percutaneous ablation of 1 or more thyroid nodule(s)
60661	Percutaneous ablation of additional lobe of thyroid nodule(s)
61715	MRI guided focused ultrasound high intensity stereotactic intracranial
	ablation
61736	Laser interstitial thermal therapy (LITT) of lesion, intracranial, including
	burr hole(s), with magnetic resonance imaging guidance, when
	performed; single trajectory for 1 simple lesion
61737	Laser interstitial thermal therapy (LITT) of lesion, intracranial, including
	burr hole(s), with magnetic resonance imaging guidance, when
	performed; multiple trajectories for multiple or complex lesion(s)

Page **82** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
62263	Percutaneous lysis of epidural adhesions using solution injection (eg,
	hypertonic saline, enzyme) or mechanical means (eg, catheter) including
	radiologic localization (includes contrast when administered), multiple
	adhesiolysis sessions; 2 or more days
62264	Percutaneous lysis of epidural adhesions using solution injection (eg,
	hypertonic saline, enzyme) or mechanical means (eg, catheter) including
	radiologic localization (includes contrast when administered), multiple
62287	adhesiolysis sessions; 1 day
02207	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, any method utilizing needle based technique to
	remove disc material under fluoroscopic imaging or other form of indirect
	visualization, with discography and/or epidural injection(s) at the treated
	level(s), when performed, single or multiple levels, lumbar
62380	Endoscopic decompression of spinal cord, nerve root(s), including
02000	laminotomy, partial facetectomy, foraminotomy, discectomy and/or
	excision of herniated intervertebral disc, 1 interspace, lumbar
64454	Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches,
	including imaging guidance, when performed
64505	Injection, anesthetic agent; sphenopalatine ganglion
64575	Open implantation of neurostimulator electrode array; peripheral
	nerve (excludes sacral nerve)
64624	Destruction by neurolytic agent, genicular nerve branches including
(4/25	imaging guidance, when performed
64625	Radiofrequency ablation, nerves innervating the sacroiliac joint, with
64628	image guidance (ie, fluoroscopy or computed tomography) Thermal destruction of intraosseous basivertebral nerve, including all
04020	imaging guidance; first 2 vertebral bodies, lumbar or sacral
64629	Thermal destruction of intraosseous basivertebral nerve, including all
	imaging guidance; each additional vertebral body, lumbar or sacral (List
	separately in addition to code for primary procedure)
66683	Iris prosthesis Implantation
76120	Cineradiography/videoradiography, except where specifically included
76125	Cineradiography/videoradiography to complement routine examination
	(List separately in addition to code for primary procedure)
77085	Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more
	sites; axial skeleton (eg, hips, pelvis, spine), including vertebral fracture
77007	assessment
77086	Vertebral fracture assessment via dual-energy X-ray absorptiometry
77089	(DXA) Trabecular bone score (TBS), structural condition of the bone
77009	microarchitecture; using dual X-ray absorptiometry (DXA) or other
	imaging data on gray-scale variogram, calculation, with interpretation
	and report on fracture-risk
77090	Trabecular bone score (TBS), structural condition of the bone
	microarchitecture; technical preparation and transmission of data for
	analysis to be performed elsewhere
77091	Trabecular bone score (TBS), structural condition of the bone
	microarchitecture; technical calculation only

Page **83** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
77092	Trabecular bone score (TBS), structural condition of the bone
77072	microarchitecture; interpretation and report on fracture-risk only by
	other qualified health care professional
78835	Radiopharmaceutical quantification measurement(s) single area (List
	separately in addition to code for primary procedure)
81195	Cytogenomic analysis, optical genome mapping
81277	Cytogenomic neoplasia (genome-wide) microarray analysis,
	interrogation of genomic regions for copy number and loss-of-
0.1.1.0	heterozygosity variants for chromosomal abnormalities
81418	Drug metabolism genomic sequence panel, must include testing of at
	least 6 genes, including CYP2C19, CYP2D6, and CYP2D6 duplications
81449	and deletions Targeted genomic sequence analysis panel, solid organ neoplasm, 5-50
01449	genes RNA analysis
81451	Hematolymphoid neoplasm or disorder, genomic sequence analysis
01101	panel, 5-50 genes, interrogation for sequence variants, and copy
	number variants or rearrangements, or isoform expression or mRNA
	expression levels, if performed; RNA analysis
81456	Solid organ or hematolymphoid neoplasm or disorder, 51 or greater
	genes, genomic sequence analysis panel, interrogation for sequence
	variants and copy number variants or rearrangements, or isoform
	expression or mRNA expression levels, if performed; RNA analysis
81539	Oncology (high-grade prostate cancer), biochemical assay of four proteins
	(Total PSA, Free PSA, Intact PSA, and human kallikrein-2 [hK2]), utilizing
04550	plasma or serum, prognostic algorithm reported as a probability score
81558	Transplantation medicine (allograft rejection, kidney), mRNA, gene expression profiling
81560	Transplantation medicine (allograft rejection, pediatric liver and small
01300	bowel), measurement of donor and third party-induced CD154+T-cytotoxic
	memory cells, utilizing whole peripheral blood, algorithm reported as a
	rejection risk score
82107	Alpha-fetoprotein (AFP); AFP-L3 fraction isoform and total AFP (including
	ratio)
82172	Apolipoprotein, each
82233	Beta-amyloid; 1-40
82234	Beta-amyloid; 1-42
82523	Collagen cross links, any method
82664	Electrophoretic technique, not elsewhere specified
83006	Growth stimulation expressed gene 2 (ST2, Interleukin 1 receptor like-1)
83695	Lipoprotein (a)
83722	Lipoprotein, direct measurement; small dense LDL cholesterol
83884	Neurofilament light chain (NfL)
83937 83987	Osteocalcin (bone g1a protein) pH; exhaled breath condensate
84080	Phosphatase, alkaline; isoenzymes
84393	Tau, phosphorylated
84394	Tau, total
86305	Human epididymis protein 4 (HE4)
00303	Human epidicymis protein 4 (HL4)

Page **84** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
88375	Optical endomicroscopic image(s), interpretation and report, real- time or referred, each endoscopic session
90382	Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use
90584	Dengue vaccine, quadrivalent, live, 2 dose schedule, for subcutaneous use
90612	Influenza virus vaccine, trivalent, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 31.7 mcg/0.32 mL dosage, for intramuscular use
90613	Influenza virus vaccine, quadrivalent, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 40 mcg/0.4 mL dosage, for intramuscular use
90624	Meningococcal pentavalent vaccine, Men B-4C recombinant proteins and outer membrane vesicle and conjugated Men A, C, W, Y-diphtheria toxoid carrier, for intramuscular use
90631	Influenza virus vaccine (IIV), H5, pandemic formulation, split virus, adjuvanted, for intramuscular use
91111	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), esophagus with interpretation and report
91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use
91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use
91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use
91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use
91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, trissucrose formulation, for intramuscular use
91308	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, trissucrose formulation, for intramuscular use
91309	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use

Page **85** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
91311	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
	(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein,
	preservative free, 25 mcg/0.25 mL dosage, for intramuscular use
91323	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)
	(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 10 mcg/0.2 mL
	dosage, for intramuscular use
92145	Corneal hysteresis determination, by air impulse stimulation,
	unilateral or bilateral, with interpretation and report
92548	Computerized dynamic posturography sensory organization test (CDP-
	SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform
	sway, eyes closed platform sway, platform and visual sway), including
207.12	interpretation and report;
92549	Computerized dynamic posturography sensory organization test (CDP-
	SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform
	sway, eyes closed platform sway, platform and visual sway), including
	interpretation and report; with motor control test (MCT) and
92572	adaptation test (ADT) Staggered spondaic word test
92576	Synthetic sentence identification test
92972	Coronary transluminal lithotripsy
93050	Arterial pressure waveform analysis for assessment of central arterial
93030	pressures, includes obtaining waveform(s), digitization and application of
	nonlinear mathematical transformations to determine central arterial
	pressures and augmentation index, with interpretation and report, upper
	extremity artery, non-invasive
93150	Therapy activation of phrenic nerve stimulator system
93151	Interrogation and programming of phrenic nerve stimulator system
93152	Interrogation and programming of phrenic nerve stimulator system done
	at the same time as a polysomnography
93153	Interrogation without programming of phrenic nerve stimulator system
93264	Remote monitoring of a wireless pulmonary artery pressure sensor for up
	to 30 days, including at least weekly downloads of pulmonary artery
	pressure recordings, interpretation(s), trend analysis, and report(s) by a
	physician or other qualified health care professional
93356	Myocardial strain imaging using speckle tracking-derived assessment of
	myocardial mechanics (List separately in addition to codes for
	echocardiography imaging)
93701	Bioimpedance-derived physiologic cardiovascular analysis
95012	Nitric oxide expired gas determination
95803	Actigraphy testing, recording, analysis, interpretation, and report
05005	(minimum of 72 hours to 14 consecutive days of recording)
95905	Motor and/or sensory nerve conduction, using preconfigured electrode
	array(s), amplitude and latency/velocity study, each limb, includes F-
05057	wave study when performed, with interpretation and report
95957	Digital analysis of electroencephalogram (EEG) (eg, for epileptic spike
94000	analysis) Comprehensive computer-based motion analysis by videotaping and 3D
96000	kinematics;
	NITICHIALICS,

Page **86** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
96001	Comprehensive computer-based motion analysis by videotaping and 3D kinematics; with dynamic plantar pressure measurements during walking
96002	Dynamic surface electromyography, during walking or other functional activities, 1-12 muscles
96004	Review and interpretation by physician or other qualified health care professional of comprehensive computer-based motion analysis, dynamic plantar pressure measurements, dynamic surface electromyography during walking or other functional activities, and dynamic fine wire electromyography, with written report
97033	Application of a modality to 1 or more areas; iontophoresis, each 15 minutes
97533	Sensory integrative techniques to enhance sensory processing and promote adaptive responses to environmental demands, direct (one-on-one) patient contact, each 15 minutes
97610	Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day
97799	Unlisted physical medicine/rehabilitation service or procedure
98978	Remote therapeutic monitoring; device supply, recording, transmission to monitor cognitive behavioral therapy, each 30 days
A2001	InnovaMatrix AC, per sq cm
A2002	Mirragen Advanced Wound Matrix, per sq cm
A2004	XCelliStem, per sq cm
A2005	Microlyte Matrix, per sq cm
A2006	NovoSorb SynPath dermal matrix, per sq cm
A2007	Restrata, per sq cm
A2008	TheraGenesis, per sq cm
A2009	Symphony, per sq cm
A2010	Apis, per sq cm
A2013	Innovamatrix FS, per sq cm
A2014	Omeza collagen matrix, per 100 mg
A2015	Phoenix wound matrix, per square centimeter
A2016	Permeaderm b, per square centimeter
A2017	Permeaderm glove, each
A2018	Permeaderm c, per square centimeter
A2019	Kerecis omega3 marigen shield, per square centimeter
A2020	Ac5 advanced wound system (ac5)
A2021	Neomatrix, per square centimeter
A2022	Innovaburn or innovamatrix xl, per square centimeter
A2023	Innovamatrix pd, 1 mg
A2024	Resolve matrix or xenopatch, per square centimeter
A2025	Miro3d, per cubic centimeter
A2026	Restrata minimatrix, 5 mg
A2027	Matriderm, per square centimeter
A2028	Micromatrix flex, per mg
A2029	Mirotract wound matrix sheet, per cubic centimeter
A2030	Miro3d fibers, per milligram
A2031	Miro3d fibers, per milligram

Page **87** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following codes will be considered investigational when applicable criteria have been met.	
CPT®/HCPCS Code	CPT®/HCPCS Code Description
A2032	Myriad matrix, per square centimeter
A2033	Myriad morcells, 4 milligrams
A2034	Foundation drs solo, per square centimeter
A2035	Corplex p or theracor p or allacor p, per milligram
A2036	Cohealyx collagen dermal matrix, per
	square centimeter
A2037	G4derm plus, per milliliter
A2038	Marigen pacto, per square centimeter
A2039	Innovamatrix fd, per square centimeter
A4341	Indwelling intraurethral drainage device with valve, patient inserted,
	replacement only, each
A4342	Accessories for patient inserted indwelling intraurethral drainage device
	with valve, replacement only, each
A4438	Adhesive clip applied to the skin to secure external electrical nerve
	stimulator controller, each
A4540	Distal transcutaneous electrical nerve stimulator, stimulates peripheral
	nerves of the upper arm
A4541	Monthly supplies for use of device coded at E0733
A4542	Supplies and accessories for external upper limb tremor stimulator of the
	peripheral nerves of the wrist
A4543	Supplies for transcutaneous electrical nerve stimulator, for nerves in the
	auricular region, per month
A4544	Electrode for external lower extremity nerve stimulator for restless legs
	syndrome
A4545	Supplies and accessories for external tibial nerve stimulator (e.g., socks,
4.45.40	gel pads, electrodes, etc.), needed for one month
A4560	Neuromuscular electrical stimulator (nmes), disposable, replacement only
A4563	Rectal control system for vaginal insertion, for long term use, includes
A 45.75	pump and all supplies and accessories, any type each
A4575	Topical hyperbaric oxygen chamber, disposable
A4593	Neuromodulation stimulator system, adjunct to rehabilitation therapy
A4594	regime
A4374	Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece each
A4596	Cranial electrotherapy stimulation (ces) system supplies and
A4396	accessories, per month
A6566	Gradient compression garment, neck/head, each
A6567	Gradient compression garment, neck/head, custom, each
A6590	External urinary catheters; disposable, with wicking material, for use
A0370	with suction pump, per month
A6591	External urinary catheter; non-disposable, for use with suction pump,
A0371	per month
A7021	Supplies and accessories for lung expansion airway clearance,
	continuous high frequency oscillation, and nebulization device (e.g.,
	handset, nebulizer kit, biofilter)
A7023	Mechanical allergen particle barrier/inhalation filter, cream, nasal,
	topical
A7049	Expiratory positive airway pressure intranasal resistance valve

Page **88** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have
	been met.
CPT®/HCPCS Code	
A9268	Programmer for transient, orally ingested capsule
A9269	Programable, transient, orally ingested capsule, for use with external programmer, per month
A9291	Prescription digital behavioral therapy, FDA-cleared, per course of treatment
A9292	Prescription digital visual therapy, software-only, fda cleared, per course of treatment
A9507	Indium In-111 capromab pendetide, diagnostic, per study dose, up to 10 millicuries
A9573	Injection, gadopiclenol, 1 ml
A9584	Iodine I-123 ioflupane, diagnostic, per study dose, up to 5 mCi
A9603	Injection, pafolacianine, 0.1 mg
A9609	Gradient compression bandaging supply, not otherwise specified
A9610	Xenon xe-129 hyperpolarized gas, diagnostic, per study dose
A9611	Gradient compression wrap with adjustable straps, above knee, each, custom
C1600	Catheter, transluminal intravascular lesion preparation device, bladed, sheathed (insertable)
C1734	Orthopedic/device/drug matrix for opposing bone-to-bone or soft tissue-to bone (implantable)
C1735	Catheter(s), intravascular for renal denervation, radiofrequency, including all single use system components
C1736	Catheter(s), intravascular for renal denervation, ultrasound, including all single use system components
C1737	Joint fusion and fixation device(s), sacroiliac and pelvis, including all system components (implantable)
C1738	Powered, single-use (i.e. disposable) endoscopic ultrasound-guided biopsy device
C1761	Catheter, transluminal intravascular lithotripsy, coronary
C1821	Interspinous process distraction device (implantable)
C1823	Generator, neurostimulator (implantable), nonrechargeable, with transvenous sensing and stimulation leads
C1825	Generator, neurostimulator (implantable), nonrechargeable with carotid sinus baroreceptor stimulation lead(s)
C1826	Generator, neurostimulator (implantable), includes closed feedback loop leads and all implantable components, with rechargeable battery and charging system
C1827	Generator, neurostimulator (implantable), non-rechargeable, with implantable stimulation lead and external paired stimulation controller
C1831	Personalized, anterior and lateral interbody cage (implantable)
C1832	Autograft suspension, including cell processing and application, and all system components
C1833	Monitor, cardiac, including intracardiac lead and all system components (implantable)
C2614	Probe, percutaneous lumbar discectomy

Page **89** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	CPT®/HCPCS Code Description
C7501	Percutaneous breast biopsies using stereotactic guidance, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, all lesions unilateral and bilateral (for single lesion biopsy, use appropriate code)
C7502	Percutaneous breast biopsies using magnetic resonance guidance, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, all lesions unilateral or bilateral (for single lesion biopsy, use appropriate code)
C8000	Support device, extravascular, for arteriovenous fistula (implantable)
C8001	3d anatomical segmentation imaging for preoperative planning, data preparation and transmission, obtained from previous diagnostic computed tomographic or magnetic resonance examination of the same anatomy
C8002	Preparation of skin cell suspension autograft, automated, including all enzymatic processing and device components (do not report with manual suspension preparation)
C8003	Implantation of medial knee extraarticular implantable shock absorber spanning the knee joint from distal femur to proximal tibia, open, includes measurements, positioning and adjustments, with imaging guidance (eg, fluoroscopy)
C8004	Simulation angiogram with use of a pressure-generating catheter (e.g., one-way valve, intermittently occluding), inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the angiogram, for subsequent therapeutic radioembolization of tumors
C8005	Bronchoscopy, rigid or flexible, non-thermal transbronchial ablation of lesion(s) by pulsed electric field (pef) energy, including fluoroscopic and/or ultrasound guidance, when performed, with computed tomography acquisition(s) and 3d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (e.g., aspiration[s]/biopsy[ies]) of all mediastinal and/or hilar lymph node stations or structures, and therapeutic intervention(s)
C8937	Computer-aided detection, including computer algorithm analysis of breast MRI image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)
C9300	Injection, indigotindisulfonate sodium, 1 mg
C9354	Acellular pericardial tissue matrix of nonhuman origin (Veritas), per sq
C9356	Tendon, porous matrix of cross-linked collagen and glycosaminoglycan matrix (TenoGlide Tendon Protector Sheet), per sq cm
C9358	Dermal substitute, native, nondenatured collagen, fetal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm
C9360	Dermal substitute, native, nondenatured collagen, neonatal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm

Page **90** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

PT®/HCPCS Code	been met. CPT®/HCPCS Code Description
C9362	Porous purified collagen matrix bone void filler (Integra Mozaik
C/302	Osteoconductive Scaffold Strip), per 0.5 cc
C9363	Skin substitute (Integra Meshed Bilayer Wound Matrix), per sq cm
C9364	Porcine implant, Permacol, per sq cm
C9751	Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by
C7751	microwave energy, including fluoroscopic guidance, when performed,
	with computed tomography acquisition(s) and 3D rendering,
	computer-assisted, image-guided navigation, and endobronchial
	ultrasound (EBUS) guided transtracheal and/or transbronchial
	sampling (e.g., aspiration[s]/biopsy[ies]) and all mediastinal and/or
	hilar lymph node stations or structures and therapeutic intervention(s)
C9758	Blind procedure for NYHA Class III/IV heart failure; transcatheter
	implantation of interatrial shunt including right heart catheterization,
	transesophageal echocardiography (TEE)/intracardiac
	echocardiography (ICE), and all imaging with or without guidance
	(e.g., ultrasound, fluoroscopy), performed in an approved
	investigational device exemption (IDE) study
C9759	Transcatheter intraoperative blood vessel microinfusion(s) (e.g.,
	intraluminal, vascular wall and/or perivascular) therapy, any vessel,
	including radiological supervision and interpretation, when performed
C9760	Nonrandomized, nonblinded procedure for NYHA Class II, III, IV heart
	failure; transcatheter implantation of interatrial shunt, including right
	and left heart catheterization, transeptal puncture, transesophageal
	echocardiography (TEE)/intracardiac echocardiography (ICE), and all
	imaging with or without guidance (e.g., ultrasound, fluoroscopy),
	performed in an approved investigational device exemption (IDE)
607/0	study
C9762	Cardiac magnetic resonance imaging for morphology and function,
607/3	quantification of segmental dysfunction; with strain imaging
C9763	Cardiac magnetic resonance imaging for morphology and function,
C07/ 4	quantification of segmental dysfunction; with stress imaging
C9764	Revascularization, endovascular, open or percutaneous, lower
	extremity artery(ies), except tibial/peroneal; with intravascular
	lithotripsy, includes angioplasty within the same vessel(s), when performed
C9765	Revascularization, endovascular, open or percutaneous, lower
C9703	extremity artery(ies), except tibial/peroneal; with intravascular
	lithotripsy, and transluminal stent placement(s), includes angioplasty
	within the same vessel(s), when performed
C9766	Revascularization, endovascular, open or percutaneous, lower
C7700	extremity artery(ies), except tibial/peroneal; with intravascular
	lithotripsy and atherectomy, includes angioplasty within the same
	vessel(s), when performed
C9767	Revascularization, endovascular, open or percutaneous, lower
C77	extremity artery(ies), except tibial/peroneal; with intravascular
	lithotripsy and transluminal stent placement(s), and atherectomy,
	includes angioplasty within the same vessel(s), when performed

Page **91** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
C9772	Revascularization, endovascular, open or percutaneous,
	tibial/peroneal artery(ies), with intravascular lithotripsy, includes
	angioplasty within the same vessel(s), when performed
C9773	Revascularization, endovascular, open or percutaneous,
	tibial/peroneal artery(ies); with intravascular lithotripsy, and
	transluminal stent placement(s), includes angioplasty within the same
	vessel(s), when performed
C9774	Revascularization, endovascular, open or percutaneous,
	tibial/peroneal artery(ies); with intravascular lithotripsy and
	atherectomy, includes angioplasty within the same vessel(s), when
	performed
C9775	Revascularization, endovascular, open or percutaneous,
	tibial/peroneal artery(ies); with intravascular lithotripsy and
	transluminal stent placement(s), and atherectomy, includes
	angioplasty within the same vessel(s), when performed
C9777	Esophageal mucosal integrity testing by electrical impedance,
	transoral, includes esophagoscopy or esophagogastroduodenoscopy
C9780	Insertion of central venous catheter through central venous occlusion
	via inferior and superior approaches (e.g., inside-out technique),
	including imaging guidance
C9781	Arthroscopy, shoulder, surgical; with implantation of subacromial
	spacer (e.g., balloon), includes debridement (e.g., limited or
	extensive), subacromial decompression, acromioplasty, and biceps
	tenodesis when performed
C9784	Gastric restrictive procedure, endoscopic sleeve gastroplasty, with
	esophagogastroduodenoscopy and intraluminal tube insertion, if
	performed, including all system and tissue anchoring components
C9785	Endoscopic outlet reduction, gastric pouch application, with
	endoscopy and intraluminal tube insertion, if performed, including all
	system and tissue anchoring components
C9791	Magnetic resonance imaging with inhaled hyperpolarized xenon-129
	contrast agent, chest, including preparation and administration of
	agent
C9792	Blinded or nonblinded procedure for symptomatic new york heart
	association (nyha) class ii, iii, iva heart failure; transcatheter
	implantation of left atrial to coronary sinus shunt using jugular vein
	access, including all imaging necessary to intra procedurally map the
	coronary sinus for optimal shunt placement (e.g., tee or ice
	ultrasound, fluoroscopy), performed under general anesthesia in an
	approved investigational device exemption (ide) study)
C9796	Repair of enterocutaneous fistula small intestine or colon (excluding
	anorectal fistula) with plug (e.g., porcine small intestine submucosa
	[sis])
C9797	Vascular embolization or occlusion procedure with use of a pressure-
	generating catheter (e.g., one-way valve, intermittently occluding),
	inclusive of all radiological supervision and interpretation,
	intraprocedural roadmapping, and imaging guidance necessary to
	complete the intervention; for tumors, organ ischemia, or infarction
E0201	Penile contracture device, manual, greater than 3 lbs traction force

Page **92** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following codes will be considered investigational when applicable criteria have been met.	
CPT®/HCPCS Code	
E0218	Fluid circulating cold pad with pump, any type
E0236	Pump for water circulating pad
E0468	Home ventilator, dual-function respiratory device, also performs
	additional function of cough stimulation, includes all accessories,
	components and supplies for all functions
E0469	Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device
E0490	Power source and control electronics unit for oral device/appliance
	for neuromuscular electrical stimulation of the tongue muscle, controlled by hardware remote
E0491	Oral device/appliance for neuromuscular electrical stimulation of the
L0471	tongue muscle, used in conjunction with the power source and control electronics unit, controlled by hardware remote, 90-day supply
E0492	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle,
50.400	controlled by phone application
E0493	Oral device/appliance for neuromuscular electrical stimulation of the
	tongue muscle, used in conjunction with the power source and control
E0530	electronics unit, controlled by phone application, 90-day supply Electronic positional obstructive sleep apnea treatment, with sensor,
E0330	includes all components and accessories, any type
E0658	Segmental pneumatic appliance for use with pneumatic compressor,
20050	integrated, 2 full arms and chest
E0659	Segmental pneumatic appliance for
	use with pneumatic compressor, integrated, head, neck and chest
E0677	Non-pneumatic sequential compression garment, trunk
E0683	Non-pneumatic, non-sequential, peristaltic wave compression pump
E0711	Upper extremity medical tubing/lines enclosure or covering device,
	restricts elbow range of motion
E0715	Intravaginal device intended to strengthen pelvic floor muscles during kegel exercises
E0716	Supplies and accessories for intravaginal device intended to
20/10	strengthen pelvic floor muscles during Kegel exercises
E0721	Transcutaneous electrical nerve stimulatory, stimulates nerves in the
	auricular region
E0732	Cranial electrotherapy stimulation (ces) system, any type
E0733	Transcutaneous electrical nerve stimulator for electrical stimulation
	of the trigeminal nerve
E0734	External upper limb tremor stimulator of the peripheral nerves of the wrist
E0736	Transcutaneous tibial nerve stimulator
E0737	Transcutaneous tibial nerve stimulator, controlled by phone application
E0738	Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, include microprocessor, all components and accessories

Page **93** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
E0739	Rehabilitation system with interactive interface providing active
	assistance in rehabilitation therapy, includes all components and
	accessories, motors, microprocessors, sensors
E0740	Nonimplanted pelvic floor electrical stimulator, complete system
E0743	External lower extremity nerve stimulator for restless legs syndrome,
	each
E0746	Electromyography (EMG), biofeedback device
E0761	Nonthermal pulsed high frequency radiowaves, high peak power electromagnetic energy treatment device
E0762	Transcutaneous electrical joint stimulation device system, includes all accessories
E0764	Functional neuromuscular stimulation, transcutaneous stimulation of sequential muscle groups of ambulation with computer control, used for walking by spinal cord injured, entire system, after completion of training program
E0767	External lower extremity nerve stimulator for restless legs syndrome, each
E0769	Electrical stimulation or electromagnetic wound treatment device, not otherwise classified
E0770	Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified
E0936	Continuous passive motion exercise device for use other than knee
E1700	Jaw motion rehabilitation system
E1701	Replacement cushions for jaw motion rehabilitation system, package of 6
E1702	Replacement measuring scales for jaw motion rehabilitation system, package of 200
E1801	Static progressive stretch/patient actualized serial stretch elbow device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories
E1806	Static progressive stretch wrist device, flexion and/or extension, with or without range of motion adjustment, includes all components and accessories
E1811	Static progressive stretch/patient actualized serial stretch knee device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories
E1816	Static progressive stretch/patient actualized serial stretch ankle device, flexion and/or extension, with or without range of motion adjustment, includes all components and accessories
E1818	Static progressive stretch/patient actualized serial stretch forearm pronation / supination device, with or without range of motion adjustment, includes all components and accessories
E1821	Replacement soft interface material/cuffs for bi-directional static progressive stretch device
E1831	Static progressive stretch toe device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories

Page **94** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	•
E1841	Static progressive stretch/patient actualized serial stretch shoulder
	device, with or without range of motion adjustment, includes all
	components and accessories
E1905	Virtual reality cognitive behavioral therapy device (cbt), including pre-
	programmed therapy software
E2001	Suction pump, home model, portable or stationary, electric, any type, for
	use with external urine/or fecal management system
E3200	Gait modulation system, rhythmic auditory stimulation, including
	restricted therapy software, all components and accessories, prescription
	only
G0166	External counterpulsation, per treatment session
G0183	Quantitative software measurements of cardiac volume, cardiac
	chambers volumes and left ventricular wall mass derived from ct
	scan(s) data of the chest/heart (with or without contrast)
G0255	Current perception threshold/sensory nerve conduction test, (SNCT)
	per limb, any nerve
G0276	Blinded procedure for lumbar stenosis, percutaneous image-guided
	lumbar decompression (PILD) or placebo-control, performed in an
	approved coverage with evidence development (CED) clinical trial
G0295	Electromagnetic therapy, to one or more areas, for wound care other
	than described in G0329 or for other uses
G0327	Colorectal cancer screening; blood-based biomarker
G0329	Electromagnetic therapy, to one or more areas for chronic Stage III
	and Stage IV pressure ulcers, arterial ulcers, diabetic ulcers and
	venous stasis ulcers not demonstrating measurable signs of healing
	after 30 days of conventional care as part of a therapy plan of care
G0465	Autologous platelet rich plasma (PRP) for diabetic chronic
	wounds/ulcers, using an FDA-cleared device (includes administration,
	dressings, phlebotomy, centrifugation, and all other preparatory
	procedures, per treatment)
G0555	Provision of replacement patient electronics system (e.g., system
	pillow, handheld reader) for home pulmonary artery pressure
	monitoring
G0566	3d radiodensity-value bone imaging, algorithm derived, from previous
	magnetic resonance examination of the same anatomy
G2000	Blinded administration of convulsive therapy procedure, either
	electroconvulsive therapy (ECT, current covered gold standard) or
	magnetic seizure therapy (MST, noncovered experimental therapy),
	performed in an approved IDE-based clinical trial, per treatment
G9143	session Warfarin responsiveness testing by genetic technique using any
U7 143	method, any number of specimen(s)
G9147	Outpatient Intravenous Insulin Treatment (OIVIT) either pulsatile or
U714/	continuous, by any means, guided by the results of measurements for:
	respiratory quotient; and/or, urine urea nitrogen (UUN); and/or,
	arterial, venous or capillary glucose; and/or potassium concentration
K1004	Low frequency ultrasonic diathermy treatment device for home use
K 1004	Low requeries attrasome diathermy treatment device for nome use

Page **95** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following co	odes will be considered investigational when applicable criteria have been met.
CPT®/HCPCS Code	
K1007	Bilateral hip, knee, ankle, foot (HKAFO) device, powered, includes
	pelvic component, single or double upright(s), knee joints any type,
	with or without ankle joints any type, includes all components and
	accessories, motors, microprocessors, sensors
K1030	External recharging system for battery (internal) for use with
	implanted cardiac contractility modulation generator, replacement
K1036	only Supplies and accessories (e.g., transducer) for low frequency
K1030	ultrasonic diathermy treatment device, per month
K1037	Docking station for use with oral device/appliance used to reduce
1(103)	upper airway collapsibility
L1007	Scoliosis orthosis, sagittal-coronal control provided by a rigid lateral
	frame, extends from axilla, to trochanter, includes all accessory pads,
	straps, and interface, custom fabricated
L8608	Miscellaneous external component, supply or accessory for use with
	the Argus II Retinal Prosthesis System
L8678	Electrical stimulator supplies (external) for use with implantable
1.0700	neurostimulator, per month
L8720	External lower extremity sensory prosthesis, cutaneous stimulation of
L8721	mechanoreceptors proximal to the ankle, per leg Receptor sole for use with L8720, replacement, each
M0076	Prolotherapy
M0248	Intravenous infusion, sotrovimab, includes infusion and post
MOZTO	administration monitoring in the home or residence; this includes a
	beneficiary's home that has been made provider-based to the hospital
	during the COVID-19 public health emergency
P2031	Hair analysis (excluding arsenic)
P9020	Platelet rich plasma, each unit
P9027	Red blood cells, leukocytes reduced, oxygen/ carbon dioxide reduced,
	each unit
Q1005	New technology, intraocular lens, category 5 as defined in Federal
0.4402	Register notice
Q4103 Q4104	Oasis burn matrix, per sq cm Integra bilayer matrix wound dressing (BMWD), per sq cm
Q4104 Q4110	PriMatrix, per sq cm
Q4111 Q4111	GammaGraft, per sq cm
Q4112	Cymetra, injectable, 1 cc
Q4113	GRAFTJACKET XPRESS, injectable, 1 cc
Q4115 Q4115	AlloSkin, per sq cm
Q4117	HYALOMATRIX, per sq cm
Q4118	MatriStem micromatrix, 1 mg
Q4123	AlloSkin RT, per sq cm
Q4124	OASIS ultra tri-layer wound matrix, per sq cm
Q4125	ArthroFlex, per sq cm
Q4126	MemoDerm, DermaSpan, TranZgraft or InteguPly, per sq cm
Q4127	Talymed, per sq cm
Q4130	Strattice TM, per sq cm

Page **96** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following codes will be considered investigational when applicable criteria have been met.		
CPT®/HCPCS Code	CPT®/HCPCS Code Description	
Q4134	HMatrix, per sq cm	
Q4135	Mediskin, per sq cm	
Q4136	E-Z Derm, per sq cm	
Q4141	AlloSkin AC, per sq cm	
Q4142	XCM biologic tissue matrix, per sq cm	
Q4143	Repriza, per sq cm	
Q4146	Tensix, per sq cm	
Q4147	Architect, Architect PX, or Architect FX, extracellular matrix, per sq cm	
Q4149	Excellagen, 0.1 cc	
Q4152	DermaPure, per sq cm	
Q4158	Kerecis Omega3, per sq cm	
Q4161	bio-ConneKt wound matrix, per sq cm	
Q4164	Helicoll, per sq cm	
Q4165	Keramatrix or Kerasorb, per sq cm	
Q4166	Cytal, per sq cm	
Q4167	Truskin, per sq cm	
Q4179	FlowerDerm, per sq cm	
Q4182	Transcyte, per sq cm	
Q4193	Coll-e-Derm, per sq cm	
Q4196	PuraPly AM, per sq cm	
Q4199	Cygnus matrix, per sq cm	
Q4200	SkinTE, per sq cm	
Q4202	Keroxx (2.5 g/cc), 1 cc	
Q4203	Derma-Gide, per sq cm	
Q4222	ProgenaMatrix, per sq cm	
Q4236	carePATCH, per sq cm	
Q4251	Vim, per sq cm	
Q4252	Vendaje, per sq cm	
Q4253	Zenith Amniotic Membrane, per sq cm	
Q4259	Celera dual layer or celera dual membrane, per square centimeter	
Q4260	Signature apatch, per square centimeter	
Q4261	Tag, per square centimeter	
Q4262	Dual layer impax membrane, per square centimeter	
Q4263	Surgraft tl, per square centimeter	
Q4264	Cocoon membrane, per square centimeter	
Q4265	Neostim tl, per square centimeter	
Q4266	Neostim membrane, per square centimeter	
Q4267	Neostim dl, per square centimeter	
Q4268	Surgraft ft, per square centimeter	
Q4269	Surgraft xt, per square centimeter	
Q4270	Complete sl, per square centimeter	
Q4271	Complete ft, per square centimeter	
Q4272	Esano a, per square centimeter	
Q4273	Esano aaa, per square centimeter	
Q4274	Esano ac, per square centimeter	

Page **97** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following codes will be considered investigational when applicable criteria have been met.		
CPT®/HCPCS Code		
Q4275	Esano aca, per square centimeter	
Q4276	Orion, per square centimeter	
Q4278	Epieffect, per square centimeter	
Q4279	Vendaje ac, per square centimeter	
Q4280	Xcell amnio matrix, per square centimeter	
Q4281	Barrera sl or barrera dl, per square centimeter	
Q4282	Cygnus dual, per square centimeter	
Q4283	Biovance tri-layer or biovance 31, per square centimeter	
Q4284	Dermabind sl, per square centimeter	
Q4285	Nudyn dl or nudyn dl mesh, per square centimeter	
Q4286	Nudyn sl or nudyn slw, per square centimeter	
Q4287	Dermabind dl, per square centimeter	
Q4288	Dermabind ch, per square centimeter	
Q4289	Revoshield + amniotic barrier, per square centimeter	
Q4290	Membrane wrap-hydro, per square centimeter	
Q4291	Lamellas xt, per square centimeter	
Q4292	Lamellas, per square centimeter	
Q4294	Amnio quad-core, per square centimeter	
Q4295	Amnio tri-core amniotic, per square centimeter	
Q4296	Rebound matrix, per square centimeter	
Q4297	Emerge matrix, per square centimeter	
Q4298	Amniocore pro, per square centimeter centimeter	
Q4299	Amnicore pro+, per square centimeter	
Q4300	Acesso tl, per square centimeter	
Q4301	Activate matrix, per square centimeter	
Q4302	Complete aca, per square centimeter	
Q4303	Complete aa, per square centimeter	
Q4304	Grafix plus, per square centimeter	
Q4305	American amnion ac tri-layer, per square centimeter"	
Q4306	American amnion ac, per square centimeter	
Q4307	American amnion, per square centimeter	
Q4308	Sanopellis, per square centimeter	
Q4309	Via matrix, per square centimeter	
Q4310	Procenta, per 100 mg	
Q4311	Acesso, per square centimeter	
Q4312	Acesso ac, per square centimeter	
Q4313	Dermabind fm, per square centimeter	
Q4314	Reeva ft, per square cenitmeter	
Q4315	Regenelink amniotic membrane allograft, per square centimeter	
Q4316	Amchoplast, per square centimeter	
Q4317	Vitograft, per square centimeter	
Q4318	E-graft, per square centimeter	
Q4319	Sanograft, per square centimeter	
Q4320	Pellograft, per square centimeter	
Q4321	Renograft, per square centimeter	

Page **98** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following codes will be considered investigational when applicable criteria have been met.		
CPT®/HCPCS Code	CPT®/HCPCS Code Description	
Q4322	Caregraft, per square centimeter	
Q4323	Alloply, per square centimeter	
Q4324	Amniotx, per square centimeter	
Q4325	Acapatch, per square centimeter	
Q4326	Woundplus, per square centimeter	
Q4327	Duoamnion, per square centimeter	
Q4328	Most, per square centimeter	
Q4329	Singlay, per square centimeter	
Q4330	Total, per square centimeter	
Q4331	Axolotl graft, per square centimeter	
Q4332	Axolotl dualgraft, per square centimeter	
Q4333	Ardeograft, per square centimeter	
Q4334	Amnioplast 1, per square centimeter	
Q4335	Amnioplast 2, per square centimeter	
Q4336	Artacent c, per square centimeter	
Q4337	Artacent trident, per square centimeter	
Q4338	Artacent velos, per square centimeter	
Q4339	Artacent vericlen, per square centimeter	
Q4340	Simpligraft, per square centimeter	
Q4341	Simplimax, per square centimeter	
Q4342	Theramend, per square centimeter	
Q4343	Dermacyte ac matrix amniotic membrane allograft, per square centimeter	
Q4344	Tri-membrane wrap, per square centimeter	
Q4345	Matrix hd allograft dermis, per square centimeter	
Q4346	Shelter dm matrix, per square centimeter	
Q4347	Rampart dl matrix, per square centimeter	
Q4348	Sentry sl matrix, per square centimeter	
Q4349	Mantle dl matrix, per square centimeter	
Q4350	Palisade dm matrix, per square centimeter	
Q4351	Enclose tl matrix, per square centimeter	
Q4352	Overlay sl matrix, per square centimeter	
Q4353	Xceed tl matrix, per square centimeter	
Q4354	Palingen dual-layer membrane, per square centimeter	
Q4355	Abiomend xplus membrane and abiomend xplus hydromembrane, per square centimeter	
Q4356	Abiomend membrane and abiomend hydromembrane, per square centimeter	
Q4357	Xwrap dual, per square centimeter	
Q4358	Xwrap dual, per square centimeter	
Q4359	Choriply, per square centimeter	
Q4360	Amchoplast fd, per square centimeter	
Q4361	Epixpress, per square centimeter	
Q4362	Cygnus disk, per square centimeter	
Q4363	Amnio burgeon membrane and hydromembrane, per square centimeter	

Page **99** of **101** Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following codes will be considered investigational when applicable criteria have been met.		
CPT®/HCPCS Code		
Q4364	Amnio burgeon xplus membrane and xplus hydromembrane, per square centimeter	
Q4365	Amnio burgeon dual-layer membrane, per square centimeter	
Q4366	Dual layer amnio burgeon x-membrane, per square centimeter	
Q4367	Amniocore sl, per square centimeter	
Q4368	Amchothick, per square centimeter	
Q4369	Amnioplast 3, per square centimeter	
Q4370	Aeroguard, per square centimeter	
Q4371	Neoguard, per square centimeter	
Q4372	Amchoplast excel, per square centimeter	
Q4373	Membrane wrap-lite, per square centimeter	
Q4375	Duograft ac, per square centimeter	
Q4376	Duograft aa, per square centimeter	
Q4377	Trigraft ft, per square centimeter	
Q4378	Renew ft matrix, per square centimeter	
Q4379	Amniodefend ft matrix, per square centimeter	
Q4380	Advograft one, per square centimeter	
Q4382	Advograft dual, per square centimeter	
Q4383	Axolotl graft ultra, per square centimeter	
Q4384	Axolotl dualgraft ultra, per square centimeter	
Q4385	Apollo ft, per square centimeter	
Q4386	Acesso trifaca, per square centimeter	
Q4387	Neothelium ft, per square centimeter	
Q4388	Neothelium 41, per square centimeter	
Q4389	Neothelium 4l+, per square centimeter	
Q4390	Ascendion, per square centimeter	
Q4391	Amnioplast double, per square centimeter	
Q4392	Grafix duo, per square centimeter	
Q4393	Acesso dl, per square centimeter	
Q4393	Surgraft ac, per square centimeter	
Q4394	Surgraft aca, per square centimeter	
Q4395	Acelagraft, per square centimeter	
Q4396	Natalin, per square centimeter	
Q4397	Summit aaa, per square centimeter	
S0596	Phakic intraocular lens for correction of refractive error	
S1091	Stent, noncoronary, temporary, with delivery system (Propel)	
S2117	Arthroereisis, subtalar	
S2230	Implantation of magnetic component of semi-implantable hearing device on ossicles in middle ear	
S2348	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar	
S3722	Dose optimization by area under the curve (AUC) analysis, for infusional 5-fluorouracil	
S4024	Air polymer-type a intrauterine foam, per study dose	
\$4988	Penile contracture device, manual, greater than 3 lbs traction force	
\$8040	Topographic brain mapping	

Page 100 of 101 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026

The following codes will be considered investigational when applicable criteria have		
been met.		
CPT®/HCPCS Code	CPT®/HCPCS Code Description	
S8130	Interferential current stimulator, 2 channel	
S8131	Interferential current stimulator, 4 channel	
S8930	Electrical stimulation of auricular acupuncture points; each 15	
	minutes of personal one-on-one contact with patient	
S9002	Intra-vaginal motion sensor system, provides biofeedback for pelvic	
	floor muscle rehabilitation device	
S9090	Vertebral axial decompression, per session	
V2787	Astigmatism correcting function of intraocular lens	
V2788	Presbyopia correcting function of intraocular lens	
V2799	Vision item or service, miscellaneous	

Page 101 of 101 Medical Policy Number: 10.01.VT204 Effective Date: 01/01/2026